Page last updated: 2024-10-27

fluorouracil and Nausea

fluorouracil has been researched along with Nausea in 367 studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.

Research Excerpts

ExcerptRelevanceReference
"To evaluate whether adding aprepitant to palonosetron and dexamethasone can further prevent the incidence and severity of nausea and vomiting caused by FOLFIRI (fluorouracil, leucovorin, and irinotecan) or FOLFOX (fluorouracil, leucovorin, and oxaliplatin) chemotherapy regimens among women with gastrointestinal cancer at higher risk."9.41Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial. ( Fong, WP; Hu, MT; Jin, Y; Li, YH; Luo, HY; Peng, JW; Qiu, MZ; Ren, C; Tan, Q; Wang, DS; Wang, FH; Wang, SB; Wang, ZQ; Zou, QF, 2021)
"To investigate whether palonosetron is better than granisetron in preventing chemotherapy-induced nausea and vomiting (CINV) in a three-drug combination with dexamethasone and fosaprepitant (Fos) in patients with breast cancer who are placed on anthracycline and cyclophosphamide (AC-based regimen)."9.34A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophospham ( Aogi, K; Baba, M; Chiba, Y; Fujiwara, K; Hirano, G; Imamura, CK; Imoto, S; Matsumoto, K; Matsuura, K; Miyazaki, C; Naito, Y; Osaki, A; Saeki, T; Sato, K; Takahashi, M; Takano, T; Tamura, K; Tokunaga, S; Yanagihara, K, 2020)
"Chemotherapy-induced nausea and vomiting (CINV) causes significant morbidity among colorectal cancer patients, receiving fluorouracil, oxaliplatin, and leucovorin (FOLFOX) chemotherapy even with standard antiemetic prophylaxis."9.27Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer. ( Blanke, C; Bubalo, JS; Chen, E; Edwards, MS; Fisher, A; Herrington, JD; Lopez, CD; Palumbo, A; Takemoto, M; Williams, C; Willman, P, 2018)
"The granisetron transdermal system (GTS) showed non-inferior efficacy to oral granisetron to control chemotherapy-induced nausea and vomiting (CINV) during multiday chemotherapy."9.20A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients. ( Ahn, JS; Hong, YS; Kim, JE; Kim, KP; Kim, TW; Lee, J; Lee, JL; Park, SJ; Park, YS; Shin, DB; Sym, SJ, 2015)
"The aprepitant therapy was more effective than the control therapy for prevention of CINV in colorectal cancer patients receiving an oxaliplatin-based regimen."9.20Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. ( Doki, Y; Fukunaga, M; Fukuzaki, T; Hata, T; Ide, Y; Kudo, T; Miyake, Y; Mizushima, T; Mori, M; Morita, S; Nakata, K; Nezu, R; Nishimura, J; Ohno, Y; Sakai, D; Satoh, T; Sekimoto, M; Takemasa, I; Takemoto, H; Uemura, M; Yamamoto, H; Yasui, M, 2015)
"The present study aimed to evaluate efficacy and adverse effects of Nimotuzumab combined with docetaxel-cisplatin-fluorouracil regimen in the treatment of advanced oral carcinoma."9.19Efficacy of nimotuzumab combined with docetaxel-cisplatin-fluorouracil regimen in treatment of advanced oral carcinoma. ( Gu, QP; Guo, W; Li, ZP; Meng, J; Meng, QF; Si, YM; Zhang, J; Zhuang, QW, 2014)
"Adverse events associated with 5-fluorouracil (5FU) based adjuvant therapy in colorectal cancer (CRC) patients may predict survival."9.19Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity? ( André, T; Bono, P; de Gramont, A; Hermunen, K; Österlund, P; Poussa, T; Quinaux, E; Soveri, LM, 2014)
"We report the long-term results of a randomised trial comparing tamoxifen with tamoxifen plus cyclophosphamide, methotrexate and fluorouracil (CMF) in postmenopausal high-risk breast cancer patients."9.17One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer. ( Andersen, J; Andersson, M; Cold, S; Ejlertsen, B; Elversang, J; Jensen, MB; Mouridsen, HT; Nielsen, DL; Rasmussen, BB, 2013)
"The safety and efficacy of neratinib monotherapy were compared with that of lapatinib plus capecitabine in patients with human epidermal growth factor receptor-2-positive (HER2+), locally advanced/metastatic breast cancer and prior trastuzumab treatment."9.17A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. ( Awada, A; Bonneterre, J; Germa, C; Geyer, CE; Ito, Y; Kim, SB; Lang, I; Martin, M; Ro, J; Vermette, J; Wang, K, 2013)
"Phase II studies have shown that the combination of capecitabine and irinotecan (the XELIRI regimen) is active in metastatic colorectal cancer (MCRC)."9.14Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. ( Hlebanja, Z; Ocvirk, J; Rebersek, M; Skof, E, 2009)
"Gastric cancer patients with cytologically confirmed malignant ascites were treated with cycles of oxaliplatin at 85 mg/m(2) plus leucovorin 20 mg/m(2) on the first day of treatment, followed by 5-fluorouracil (5-FU) via a 400 mg/m(2) bolus and a 22 h continuous infusion of 600 mg/m(2) 5-FU on Days 1-2 at 2-week intervals."9.12A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites. ( Jang, JS; Jeong, JS; Kim, HJ; Kim, MC; Kim, SH; Kwon, HC; Lee, DM; Lee, S; Oh, SY; Yoo, HS, 2007)
"The purpose is to determine the plasma pharmacokinetics, the maximum-tolerable dose and to preliminary evaluate the antitumor activity of irinotecan administered as a 7-day continuous infusion every 21 days in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed."9.11A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. ( Allegrini, G; Barbara, C; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Masi, G, 2004)
"This multicentre phase I/II study was designed to determine the maximum tolerated dose of irinotecan when combined with 5-fluorouracil and folinic acid according to the Mayo Clinic schedule and to evaluate the activity of this combination as first-line therapy in patients with advanced colorectal cancer."9.11Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. ( Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J, 2004)
"Combination therapy of irinotecan, folinic acid (FA) and 5-fluorouracil (5-FU) has been proven to be highly effective for the treatment of metastatic colorectal cancer."9.11Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. ( Adami, B; Galle, PR; Heike, M; Hohl, H; Höhler, T; Klein, O; Moehler, M; Schroeder, M; Siebler, J; Steinmann, S; Teufel, A; Zanke, C, 2004)
"To verify the effectiveness of oral 1-hexylcarbamoyl-5-fluorouracil (HCFU) in improving the surgical cure rate in advanced colorectal cancer, a multicenter randomized comparative study was conducted."9.11A multicenter randomized study comparing 5-fluorouracil continuous infusion (ci) plus 1-hexylcarbamoyl-5-fluorouracil and 5-FU ci alone in colorectal cancer. ( Kodaira, S; Kotake, K; Koyama, Y; Ohashi, Y, 2005)
"To assess the feasibility and activity of a combination schedule with irinotecan (CPT-11), oxaliplatin (L-OHP), brief infusional fluorouracil (5-FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer (MCC) patients."9.11An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial. ( Amoroso, V; Ferrari, V; Grisanti, S; Marini, G; Marpicati, P; Pasinetti, N; Rangoni, G; Simoncini, E; Valcamonico, F; Vassalli, L, 2005)
"To assess the activity and safety of combined folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC) in metastatic breast cancer patients previously treated with at least two chemotherapy regimens."9.10Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens. ( Correale, P; Fiaschi, AI; Francini, G; Marsili, S; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M, 2002)
"To evaluate the feasibility and a possible activity range of combination irinotecan (CPT-11), oxaliplatin, and 5-FU in advanced colorectal cancer (ACC)."9.10Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study. ( Aramendía, JM; Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Fernández-Hidalgo, O; González-Cao, M; Martín-Algarra, S; Martínez-Monge, R; Rodríguez, J; Salgado, JE, 2002)
"The inhibitory effect of ramosetron hydrochloride (Ram), a 5-HT3 receptor antagonist, on nausea and vomiting occurring in CMF or CEF therapy as a pre- or postoperative adjuvant chemotherapy or chemotherapy for recurrent cancer was evaluated in 34 patients with breast cancer."9.09[Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer]. ( Hojo, S; Noguchi, S; Shiba, E; Taguchi, T; Takamura, Y; Tsukamoto, F; Watanabe, T; Yoneda, K, 1999)
"To compare the response rate, efficacy parameters, and toxicity profile of oral capecitabine with bolus intravenous (IV) fluorouracil plus leucovorin (5-FU/LV) as first-line treatment in patients with metastatic colorectal cancer."9.09Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. ( Ansari, R; Batist, G; Burger, HU; Cox, J; Harrison, E; Hoff, PM; Kocha, W; Kuperminc, M; Maroun, J; Osterwalder, B; Walde, D; Weaver, C; Wong, AO; Wong, R, 2001)
"We have reported that an alternating regimen of bolus and continuous infusion 5-fluorouracil (FU) was superior to bolus FU in terms of response rate and progression-free survival in advanced colorectal cancer."9.095-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer. ( Aschele, C; Caroti, C; Cirillo, M; Cortesi, E; Frassineti, GL; Gallo, L; Grossi, F; Guglielmi, A; Labianca, R; Pessi, MA; Ravaioli, A; Recaldin, E; Sobrero, A; Testore, P; Turci, D, 2001)
"The purpose of this study was to evaluate the activity and safety of oxaliplatin and protracted venous infusion of 5-fluorouracil (PVI 5-FU) in patients with advanced or relapsed 5-FU pretreated colorectal cancer."9.09Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. ( Chau, I; Cunningham, D; Hill, M; Massey, A; Norman, A; Waters, JS; Webb, A, 2001)
"The comparative study among granisetron alone and granisetron combined with hydroxyzine hydrochloride or dexamethasone was undertaken for the prevention of nausea and vomiting during chemotherapy including cisplatin in patients with advanced head and neck carcinomas."9.08[Comparison of granisetron alone and granisetron plus dexamethasone or hydroxyzine hydrochloride for the prevention of nausea and vomiting during chemotherapy including cisplatin]. ( Enomoto, H; Furukawa, M; Ikema, Y; Kawai, S; Kohno, H; Kubota, A; Makino, Y; Matsuda, H; Tsukuda, M; Yago, T, 1995)
"A multicentral cooperative study was conducted to evaluate the clinical efficacy and toxicity of l-Leucovorin (l-LV) and 5-fluorouracil (5-FU) in advanced colorectal cancer."9.08[A late phase II trial of l-leucovorin and 5-fluorouracil in advanced colorectal cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)]. ( Abe, T; Kikkawa, N; Konishi, K; Maehara, Y; Ota, J; Sowa, M; Taguchi, T; Takashima, S; Yabushita, K; Yasutomi, M, 1995)
"The direct effect and safety of carmofur (Mifurol) in cases of advanced and recurrent breast cancer were evaluated as a cooperative study at twenty-two facilities nationwide."9.08[Clinical effects of carmofur (Mifurol) on advanced and recurrent breast cancer in a cooperative study. Research association for re-evaluation of direct effects of Mifurol on breast cancer]. ( Abe, R; Enomoto, K; Koyama, H; Kusama, M; Nishi, T; Sonoo, H; Takashima, S; Tominaga, T; Yamaguchi, S; Yoshida, M, 1995)
"To determine whether a combination chemotherapy regimen that contains epirubicin (fluorouracil, epirubicin, and cyclophosphamide [FEC]) is superior to the standard cyclophosphamide, methotrexate, and fluorouracil (CMF) combination in premenopausal women with axillary node-positive operable breast cancer."9.08Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collab ( Aapro, M; Amadori, D; Bliss, JM; Chilvers, CE; Coombes, G; Coombes, RC; Espié, M; Ferreira, EP; Gambrosier, P; Marty, M; McArdle, C; Morvan, F; Pérez-López, FR; Richards, M; Vassilopoulos, P; Villar-Grimalt, A; Wils, J; Woods, EM, 1996)
"Both the biochemical modulation and the continuous administration of 5-fluorouracil (5-FU) have achieved promising results in patients with gastric carcinoma."9.08Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group. ( Belón, J; Blanco, E; Espinosa, E; Feliu, J; García-Alfonso, P; García-Girón, C; Garrido, P; Gómez-Navarro, J; González Barón, M; Ordónez, A; Zamora, P, 1996)
"A crossover clinical trial between granisetron alone and granisetron combined with methylprednisolone (MPL) was undertaken for the prevention of nausea and vomiting during chemotherapy, including cisplatin, in 12 patients with advanced primary and metastatic lung cancer."9.08[Comparative trial of granisetron alone and granisetron plus methylprednisolone for prevention of nausea and vomiting during cancer chemotherapy]. ( Fujishima, H; Hisano, C; Masumoto, N; Nakamura, M; Nakano, S; Niho, Y; Okuma, K, 1996)
"The aim of this open, nonrandomized, monocentric study was to evaluate the efficacy of a single daily dose of 8 mg oral ondansetron in the prophylaxis of acute nausea and vomiting in chemotherapy-naive breast cancer patients receiving their first cycle of chemotherapy with 5-fluorouracil, doxorubicin and cyclophosphamide (FAC)."9.08Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting. ( Bosnjak, SM; Jovanovic-Micic, DJ; Mitrovic, LB; Neskovic-Konstantinovic, ZB; Radulovic, SS, 1996)
"Azasetron, a selective 5-HT3 receptor antagonist, has been previously shown to be highly effective in the prophylaxis of nausea and vomiting induced by anticancer drugs, and is widely used in the clinical setting in Japan."9.08[Clinical effect of two azasetron treatment methods against nausea and vomiting induced by anticancer drugs including CDDP]. ( Kimura, E; Niimi, S; Tanaka, T; Watanabe, A, 1997)
"Efficacy of combination of ondansetron injection and tablet on CAF (cyclophosphamide, adriamycin, 5-fluorouracil) induced emesis were investigated in 10 breast cancer patients (33 courses)."9.08[Efficacy of combination of ondansetron injection and tablet in CAF-induced emesis in breast cancer patients]. ( Furukawa, T; Kurihara, N; Machimura, T; Nemoto, Y; Nishihori, H; Shinohara, H; Urakami, H; Yonekawa, H, 1998)
"A total of 50 patients were treated weekly with 5-fluorouracil (FU), leucovorin (LV), and 4'-O-tetrahydropyranyl-doxorubicin (THP) as first-line chemotherapy for advanced breast cancer (ABC)."9.07A phase I/II study of 4'-O-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose leucovorin as first-line therapy in advanced breast cancer patients. ( Bauernhofer, T; Derstvenscheg, E; Kuss, I; Moser, R; Ploner, F; Samonigg, H; Schmid, M; Steindorfer, P; Stöger, H; Wilders-Truschnig, M, 1994)
" A sample of 43 patients with breast cancer was accrued from September to November 1992 in a phase II study to assess the efficacy of granisetron in patients receiving FEC (5-FU, epirubicin, cyclophosphamide)."9.07Control of emesis by intravenous granisetron in breast cancer patients treated with 5-FU, epirubicin and cyclophosphamide. ( Ang, PT; Khoo, KS; Tan, EH, 1994)
"The combination of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) is a widely used chemotherapy regimen in breast cancer patients."9.07Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study. ( Aapro, MS; Bauer, J; Brunner, KW; Buser, KS; Cavalli, F; Haefliger, JM; Joss, RA; Jungi, WF; Obrist, R; Piquet, D, 1993)
" To address its use with a widely used but less emetogenic regimen, we performed a double-blind, randomized clinical trial comparing ondansetron with dexamethasone and metoclopramide in patients with breast cancer receiving chemotherapy with cyclophosphamide, methotrexate, and fluorouracil."9.07Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. ( Latreille, J; Levitt, M; Lofters, WS; Perrault, DJ; Potvin, M; Rayner, HL; Warner, E; Warr, D; Wilson, KS; Yelle, L, 1993)
" 97 female breast cancer patients who received their first two FEC courses (epirubicin 50-75 mg/m2, 5-fluorouracil 500 mg/m2, cyclophosphamide 500 mg/m2) entered this randomised crossover study (76 had previously received an adjuvant treatment); tetracosactrin was administered intramuscularly and methylprednisolone intravenously immediately before chemotherapy administration."9.07Tetracosactrin vs. methylprednisolone in the prevention of emesis in patients receiving FEC regimen for breast cancer. ( Bastit, P; Bonneterre, J; Cappelaere, P; Chevrier, A; Fargeot, P; Geyer, G; Kerbrat, P; Metz, R; Roche, H; Tubiana-Hulin, M, 1991)
"The French Epirubicin Study Group carried out a randomized trial comparing epirubicin alone 75 mg/m2 with fluorouracil (5FU) 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 50 mg/m2 (FEC 50) and 5FU 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 75 mg/m2 (FEC 75) as first treatment for advanced breast cancer patients."9.07A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group. ( , 1991)
"Seventy-five breast cancer patients scheduled to receive a first course (in a new cycle) of cyclophosphamide, fluorouracil, and doxorubicin (FAC) or epirubicin (FEC) participated in a double-blind crossover study to compare the antiemetic efficacy and safety of ondansetron (GR38032), a 5-hydroxytryptamine3 (5-HT3) receptor antagonist, and metoclopramide."9.06A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. ( Bonneterre, J; Bons, J; Chevallier, B; Fargeot, P; Metz, R; Paes, D; Pujade-Lauraine, E; Spielmann, M; Tubiana-Hulin, M, 1990)
"Thirty patients with a diagnosis of metastatic adenocarcinoma of the lung were entered on a trial to evaluate the antitumor efficacy of 5-fluorouracil 370 mg/m2 daily for 5 days every four weeks in combination with folinic acid 200 mg/m2, 60 min prior to 5FU."9.065-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung. ( Aitken, SE; Evans, WK; Ezzat, A; Maroun, JA; Rusthoven, J; Shepherd, FA; Stewart, DJ; Wierzbicki, R, 1990)
"The antiemetic effectiveness of haloperidol plus dexamethasone was compared with that of prochlorperazine plus dexamethasone in a prospective study of patients receiving chemotherapy for breast cancer."9.06A randomized comparison of haloperidol plus dexamethasone versus prochlorperazine plus dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for breast cancer. ( Carpenter, JT; Conolley, C; Lee, J; Silvey, L; Wheeler, RH, 1988)
" CMF were included in a double-blind comparative study aimed at evaluating the efficacy of 3 different drugs (methylprednisolone (MP), metoclopramide (MTC), and domperidone (DMP) in preventing chemotherapy-induced nausea and vomiting."9.06Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF. ( Ballatori, E; Basurto, C; del Favero, A; Minotti, V; Roila, F; Tonato, M, 1987)
"The antiemetic efficacy and toxicity of methylprednisolone (MP) and metoclopramide (MTC) in prevention of nausea and vomiting in breast cancer patients receiving intravenous cyclophosphamide methotrexate 5-fluorouracil (CMF) chemotherapy has been evaluated in a double-blind trial."9.06Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide methotrexate 5-fluorouracil: a double-blind randomized study. ( Ballatori, E; Basurto, C; Del Favero, A; Minotti, V; Roila, F; Tonato, M, 1988)
"Patients with visceral patterns of metastatic breast cancer were stratified according to dominant metastatic site and performance status and then randomized to therapy with cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) or CAF alternating with a "cell-cycle active" regimen including cytosine arabinoside, methotrexate with leucovorin rescue, and oncovin ( CAMELEON )."9.05Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a "cycle active" non-cross-resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project. ( Carpenter, J; Fishkin, E; Krauss, S; Moore, MR; Raab, S; Raney, M; Smalley, RV; Stagg, M; Velez-Garcia, E; Vogel, CL, 1984)
"To determine the incidence of anticipatory vomiting (AV) and postchemotherapy nausea and vomiting (PCNV) in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma, we studied 52 women randomized to two regimens (standard-dose and low-dose) of CMF."9.05Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma. ( Abeloff, MD; Fetting, JH; Nettesheim, KM; Wilcox, PM, 1982)
"As of August 1984, 115 women with advanced breast cancer have been randomized to receive a combination of either cyclophosphamide, Novantrone (mitoxantrone) and 5-fluorouracil (CNF) or cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF)."9.05A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Bennett, JM; Byrne, P; DeConti, R; Desai, A; Doroshow, J; Krementz, E; Muggia, F; Plotkin, D; Vogel, C; White, C, 1985)
"One hundred and sixteen patients with advanced and metastatic adenocarcinoma of the pancreas were randomized to treatment with combined Streptozotocin and 5-fluorouracil or combined Streptozotocin and cyclophosphamide."9.04Treatment of advanced adenocarcinoma of the pancreas with combinations of streptozotocin plus 5-fluorouracil and streptozotocin plus cyclophosphamide. ( Carbone, PP; Douglas, HO; Hanley, J; Moertel, CG, 1977)
"An electronic search was undertaken to identify randomized controlled trials comparing raltitrexed-based regimen to 5-fluorouracil-based regimen in patients with advanced colorectal cancer."8.90Raltitrexed-based chemotherapy for advanced colorectal cancer. ( Hong, W; Huang, Q; Liu, Y; Sun, X; Wu, J; Wu, W, 2014)
" A phase III randomized trial, Xeloda in Adjuvant Colorectal Cancer Treatment, demonstrated that treatment with single-agent capecitabine was equivalent to bolus 5-fluorouracil with leucovorin with respect to disease-free survival and overall survival, with significantly less diarrhea, stomatitis, neutropenia, nausea and vomiting, and alopecia."8.83Capecitabine: a new adjuvant option for colorectal cancer. ( Berg, DT, 2006)
"Fluorouracil (5-FU) continuous infusion is superior to 5-FU bolus in patients with advanced colorectal cancer, but the survival difference between the two treatments is small and, therefore, the difference in toxicity profile is crucial in choosing a treatment for individual patients."8.80Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. ( Benedetti, J; Brufman, G; Buyse, M; Fryer, J; Hansen, R; Isacson, R; Laplanche, A; Leichman, C; Lévy, E; Lokich, J; Macdonald, J; Pater, J; Piedbois, P; Pignon, JP; Quinaux, E; Rougier, P; Ryan, L; Thirion, P; Weinerman, B; Zee, B, 1998)
" This study evaluated the percentages of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) undergoing second-line therapy with 5-fluorouracil (5-FU)-based regimens that experienced AEs during treatment and received medication to manage those AEs."8.12Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma. ( Cockrum, P; Kim, G; Surinach, A; Wainberg, Z; Wang, S, 2022)
" We describe a strongly suspected elderly cancer patient's DDI between aprepitant and opium powder in the context of an irinotecan-based regimen manifested by nightmares and visual hallucinations."7.91Nightmares and hallucinations with aprepitant and opium powder: a suspected drug-drug interaction. ( Azzouz, B; Bouché, O; Clarenne, J; Narjoux, G; Slimano, F; Zeller, PS, 2019)
"The objective of this study was to determine the effect of aprepitant(from days 1 to 3, po)and fosaprepitant(day 1, iv) for nausea in patients with oral cancer receiving combination chemotherapy with docetaxel, nedaplatin, or cisplatin(divided doses for 5 days), and 5-fluorouracil(TPF)."7.85[Determination of the Effect of Aprepitant and Fosaprepitant for Nausea in Patients with Oral Cancer Receiving Combination Chemotherapy with TPF]. ( Asoda, S; Iwabuchi, H; Kasazaki, S; Shiiba, Y; Suga, K; Uchiyama, K; Uehara, K; Yamada, M, 2017)
"Although efficacy of aprepitant for suppressing emesis associated with single-dose cisplatin has been demonstrated, there are limited data on the antiemetic effect of this oral neurokinin-1 receptor antagonist during daily administration of cisplatin."7.80Efficacy of aprepitant for nausea in patients with head and neck cancer receiving daily cisplatin therapy. ( Ishimaru, K; Kaneko, K; Katsura, M; Takahashi, H; Takano, A; Yamaguchi, N, 2014)
"To evaluate the efficacy of reduction of dexamethasone with a single-dose of palonosetron in preventing acute and delayed nausea and vomiting in patients receiving highly emetogenic chemotherapy (HEC) for early breast cancer."7.79Single-dose palonosetron and dose-reduced regimen of dexamethasone in preventing nausea and vomiting by anthracycline-including chemotherapy in patients with early breast cancer. ( Cardillo, FD; Cognetti, F; Evangelista, S; Fabi, A; Fattoruso, SI; Pacetti, U; Veltri, E, 2013)
"Gemcitabine plus cisplatin (GP) is a standard chemotherapy option for patients with advanced biliary tract cancer (BTC)."7.79Gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective cohort study. ( Han, SS; Hong, EK; Kim, DH; Kim, JH; Kim, TH; Koh, YH; Lee, JH; Lee, WJ; Park, SJ; Woo, SM, 2013)
" In this retrospective study, we assessed the efficacy of palonosetron versus granisetron for the incidence of CINV induced by mFOLFOX6 and FOLFIRI in patients with advanced colorectal cancer."7.78[Antiemetic effect of palonosetron in advanced colorectal cancer patients receiving mFOLFOX6 and FOLFIRI: a retrospective survey]. ( Hayakawa, Y; Muro, K; Noma, H; Okamoto, H; Sato, Y; Tatematsu, M, 2012)
"We retrospectively analyzed the efficacy and safety of aprepitant in breast cancer patients who were treated with FEC(5- fluorouracil, epirubicin, cyclophosphamide)or EC(epirubicin, cyclophosphamide)."7.77[Efficacy and safety of aprepitant in patients with breast cancer]. ( Aogi, K; Eguchi, H; Hara, F; Kiyoto, S; Matsuhisa, T; Osumi, S; Oze, I; Tagashira, H; Takabatake, D; Takahashi, M; Takashima, S, 2011)
"The aim of the study was to evaluate the role of ramosetron for the prevention of chemoradiotherapy-induced nausea and vomiting (CRINV) in patients receiving upper abdominal irradiation with concurrent 5-fluorouracil chemotherapy."7.75Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer. ( Bang, YJ; Chie, EK; Ha, SW; Im, SA; Jang, JY; Kim, K; Kim, SW; Kim, TY; Oh, DY, 2009)
"We encountered a case of peritoneal dissemination of hepatocellular carcinoma, successfully treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil."7.74Peritoneal dissemination of hepatocellular carcinoma treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil. ( Iwasaki, Y; Miyake, Y; Sakaguchi, K; Shiraha, H; Shiratori, Y, 2007)
"Short-term infusion of 5-fluorouracil with leucovorin in combination with irinotecan or oxaliplatin has been considered as standard treatment for metastatic colorectal cancer."7.74Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan. ( Boku, N; Fukutomi, A; Hasuike, N; Hironaka, S; Machida, N; Ono, H; Onozawa, Y; Yamaguchi, Y; Yamazaki, K; Yoshino, T, 2007)
"The incidence of nausea and vomiting was investigated for a maximum of 7 days in 32 breast cancer patients receiving CAF (cyclophosphamide, adriamycin, 5-fluorouracil) and CMF (cyclophosphamide, methotrexate, 5-fluorouracil) therapies."7.71[Incidence of emesis in outpatients on chemotherapy for breast cancer and the clinical efficacy of ondansetron hydrochloride tablets]. ( Hayakawa, H; Ishida, T; Kusaba, T, 2002)
"The purpose of this study was to investigate the side-effects experienced by patients with colorectal cancer receiving 5-fluorouracil + folinic acid chemotherapy."7.70Patients' experiences of chemotherapy: side-effects associated with 5-fluorouracil + folinic acid in the treatment of colorectal cancer. ( Dikken, C; Sitzia, J, 1998)
"The incidence of nausea and vomiting or anorexia was investigated in 16 outpatients receiving oral antimetabolites such as 5-FU (fluorouracil) as chemotherapy, during a maximum observation period of 28 days."7.70[Chronological observation of nausea and vomiting in outpatients given oral antimetabolites as chemotherapy--two patients receiving ondansetron hydrochloride tablets]. ( Ishikawa, H; Ohya, M; Sasaki, K; Yanagida, T, 2000)
"The antiemetic efficacy of granisetron in repeated CAF chemotherapy after breast cancer operation was investigated."7.69[Antiemetic efficacy of granisetron in repeated CAF chemotherapy after breast cancer operation]. ( Hatano, Y; Kato, N; Okuyama, N; Park, Y; Sasamoto, S; Yamazaki, S, 1997)
"A total of 60 patients with advanced breast cancer were treated with a combination of prednimustine (P: 110 mg/m2, days 1-5), mitoxantrone (M: 12 mg/m2, day 1) and 5-fluorouracil (F: 500 mg/m2, day 1) (PMF)."7.68Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer. ( Dusleag, J; Kasparek, AK; Lechner, P; Pfeiffer, K; Samonigg, H; Schmid, M; Smola, M; Steindorfer, P; Stöger, H, 1991)
"Twenty-nine patients with metastatic breast cancer were treated with fluorouracil, adriamycin, cyclophosphamide (FAC), and methotrexate (MTX), with or without leukovorin rescue."7.67Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate. ( Aboud, A; Blumenschein, GR; Buzdar, AU; Hortobagyi, GN; Yap, HY, 1984)
"Thirty consecutive patients with metastatic breast cancer previously untreated by chemotherapy were given high-dose cyclophosphamide (Cytoxan) and high-dose 5-fluorouracil (5-FU) as first-line therapy."7.67High-dose cyclophosphamide and high-dose 5-fluorouracil. A new first-line regimen for advanced breast cancer. ( Aguilera, J; Breau, JL; Israel, L, 1984)
"Thirty patients with advanced breast cancer, not pretreated with chemotherapy, received a polychemotherapy regimen containing mitoxantrone, fluorouracil and cyclophosphamide at the dose of 10 mg/m2, 500 mg/m2 and 500 mg/m2 i."7.67Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer. ( Canova, N; Ercolino, L; Martoni, A; Pannuti, F; Rani, P, 1988)
"Forty-six outpatients with breast cancer who had experienced severe emesis as a result of chemotherapy were evaluated for the antiemetic efficacy of high-dose metoclopramide (HD-MCP) and dexamethasone (DXM)."7.67High-dose metoclopramide and dexamethasone as an antiemetic in outpatients receiving chemotherapy for breast cancer. Second study. ( Ben-Baruch, N; Ben-Yosef, R; Biran, S; Brufman, G; Gez, E; Uziely, B; Warner-Efraty, E; Yitzhaki, N, 1987)
"In our wide experience of treating advanced breast carcinoma with chemotherapy, the combination of doxorubicin (DOX), vincristine (VCR), cyclophosphamide (CPM) and fluorouracil (FU) gave a complete plus partial response rate of over 60%, with 100% alopecia and frequent cardiac toxicity depending on total dose."7.67Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer. ( Armand, JP; Cappelaere, P; Delgado, M; Grimbert, J; Keiling, R; Mathe, G; Metz, R; Misset, JL; Prevot, G, 1985)
"Sixty-two patients with metastatic hormonal refractory adenocarcinoma of the prostate received a combination of doxorubicin, mitomycin-C, and 5-fluorouracil (DMF)."7.66Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. ( Grant, C; Johnson, DE; Logothetis, CJ; Ogden, S; Samuels, ML; Trindade, A; von Eschenbach, AC, 1983)
"A four-drug combination of intermittent high-dose cyclophosphamide with 5-fluorouracil, hexamethylmelamine, and prednisone was given to 19 patients with advanced breast cancer."7.66Phase I--II evaluation of combination cyclophosphamide, 5-fluorouracil, hexamethylmelamine, and prednisone in advanced breast cancer. ( Chang, YC; Crowley, J; Falkson, G; Tormey, DC, 1981)
"In mouse models of pancreatic cancer, IPI-926, an oral Hedgehog inhibitor, increases chemotherapy delivery by depleting tumor-associated stroma."6.82A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. ( Catenacci, DV; Chang, WC; Kantoff, E; Kate Kelley, R; Kindler, HL; Ko, AH; Lewis, S; LoConte, N; Tempero, MA; Vannier, MW; Venook, AP; Walker, EJ, 2016)
"Survival time for metastatic breast cancer (MBC) can be substantially improved by combination chemotherapy in the adjuvant setting."6.75A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines. ( Alexopoulos, A; Ardavanis, A; Ioannidis, G; Kandylis, C; Malliou, S; Orphanos, G; Rigatos, G; Stavrakakis, J, 2010)
"2005, 62 patients with stage II-III breast cancer were treated with 2 cycles of either GC regimen or FEC regimen before operation."6.73[Clinical comparison of GC regimen (gemcitabine and cisplatin) versus FEC regimen (fluorouracil, epirubicin, and cyclophosphamide) as neoadjuvant chemotherapy for breast cancer]. ( Cheng, B; Liu, K; Qiu, DB; Wang, GB, 2007)
"3 mg of ramosetron (RAM) combined with 8 mg of dexamethasone (DEX) and 0."6.71[A randomized crossover study of ramosetron plus dexamethasone for the prevention of nausea and vomiting induced by chemotherapy including cisplatin-comparison of ramosetron combined with 8 mg and 12 mg of dexamethasone]. ( Horiuchi, C; Ikeda, Y; Ishitoya, J; Katori, H; Matsuda, H; Mikami, Y; Taguchi, T; Tanigaki, Y; Tsukuda, M; Yoshida, T, 2005)
"Therapy for metastatic breast cancer has not improved significantly in recent years."6.68Metastatic breast cancer: treatment with fluorouracil-based combinations. ( Klaassen, U; Seeber, S, 1997)
" From the above results, THP in combination with cyclophosphamide and 5-Fluorouracil is comparable to ADR in efficacy and can be regarded as having better safety than ADR for the treatment of breast cancer."6.66[A randomized controlled study of (2'' R)-4'-O-tetrahydropyranyladriamycin and adriamycin in combination with cyclophosphamide and 5-fluorouracil in the treatment of advanced and recurrent breast cancer]. ( Abe, O; Abe, R; Enomoto, K; Fujimoto, M; Iino, Y; Koyama, H; Nomura, Y; Tanaka, T; Tominaga, T, 1986)
"To compare the efficacy and safety of two chemotherapeutic regimens, irinotecan monotherapy or irinotecan in combination with fluoropyrimidines, for patients with advanced CRC when administered in the first or second-line settings."6.53Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer. ( Repana, D; Van Hemelrijck, M; Wardhana, A; Watkins, J; Wulaningsih, W; Yoshuantari, N, 2016)
"The outbreak of coronavirus disease 2019 (COVID-19) has affected the treatment of cancer patients, with particular regard to the management of both chemotherapy and side effects."5.62NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri even during the COVID-19 pandemic: a real-life study. ( Caputo, V; Cicero, G; De Luca, R; Ferrera, G; Mistretta, O; Paci, R; Rosati, G; Volpe, C, 2021)
"To evaluate whether adding aprepitant to palonosetron and dexamethasone can further prevent the incidence and severity of nausea and vomiting caused by FOLFIRI (fluorouracil, leucovorin, and irinotecan) or FOLFOX (fluorouracil, leucovorin, and oxaliplatin) chemotherapy regimens among women with gastrointestinal cancer at higher risk."5.41Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial. ( Fong, WP; Hu, MT; Jin, Y; Li, YH; Luo, HY; Peng, JW; Qiu, MZ; Ren, C; Tan, Q; Wang, DS; Wang, FH; Wang, SB; Wang, ZQ; Zou, QF, 2021)
"Irinotecan, a topoisomerase inhibitor, is a common cytotoxic agent prescribed for metastatic colorectal cancer (mCRC) patients."5.41A Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated With First-Line FOLFIRI Plus Bevacizumab. ( Chang, TK; Chen, PJ; Chen, YC; Cheng, TL; Chuang, KH; Huang, CW; Li, CC; Ma, CJ; Su, WC; Tsai, HL; Wang, JY; Yin, TC, 2021)
"Aprepitant is a very active antiemetic drug for the prevention of delayed nausea and vomiting induced by mFOLFOX6 regimen."5.36[Clinical usefulness of oral aprepitant for alleviation of delayed nausea and vomiting induced by mFOLFOX6--report of a case]. ( Abe, T; Hachiro, Y; Kunimoto, M, 2010)
"Biweekly schedule of XELOX-2 (capecitabine plus oxaliplatin) showed interesting results in first-line therapy of patients with metastatic colorectal cancer (mCRC)."5.34Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802). ( Aieta, M; Bordonaro, R; Cinieri, S; Colucci, G; Cordio, S; Di Maggio, G; Di Maio, M; Febbraro, A; Giuliani, F; Latiano, TP; Maiello, E; Pisconti, S; Rinaldi, A; Rizzi, D; Rossi, A, 2020)
"To investigate whether palonosetron is better than granisetron in preventing chemotherapy-induced nausea and vomiting (CINV) in a three-drug combination with dexamethasone and fosaprepitant (Fos) in patients with breast cancer who are placed on anthracycline and cyclophosphamide (AC-based regimen)."5.34A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophospham ( Aogi, K; Baba, M; Chiba, Y; Fujiwara, K; Hirano, G; Imamura, CK; Imoto, S; Matsumoto, K; Matsuura, K; Miyazaki, C; Naito, Y; Osaki, A; Saeki, T; Sato, K; Takahashi, M; Takano, T; Tamura, K; Tokunaga, S; Yanagihara, K, 2020)
"Chemotherapy-induced nausea and vomiting (CINV) causes significant morbidity among colorectal cancer patients, receiving fluorouracil, oxaliplatin, and leucovorin (FOLFOX) chemotherapy even with standard antiemetic prophylaxis."5.27Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer. ( Blanke, C; Bubalo, JS; Chen, E; Edwards, MS; Fisher, A; Herrington, JD; Lopez, CD; Palumbo, A; Takemoto, M; Williams, C; Willman, P, 2018)
"Diphenhydramine was administered intramuscularly 30 minutes before and 5 hours after chemotherapy."5.27[The prevention of CDDP-induced emesis with a combination regimen including metoclopramide, dexamethasone, droperidol and diphenhydramine]. ( Arihiro, T; Dozono, H; Morimoto, O; Ochiai, K; Sasaki, H; Takahashi, S; Terashima, Y; Tsuruoka, M; Yasuda, M; Yokoyama, S, 1987)
"Sixteen patients with advanced colo-rectal cancer were treated with the combination methyl-CCNU, vincristin, 5-fluorouracil and streptozotocin (MOF-Strepto)."5.26[The combination methyl-CCNU, vincristine, 5-fluorouracil and streptozotocin in the treatment of advanced colo-rectal adenocarcinoma]. ( Cavalli, F; Sessa, C; Togni, P; Varini, M, 1982)
"The purpose of this phase II study was to explore the efficacy and safety of an alternating regimen consisting of folinic acid, 5-fluorouracil (5-FU) and oxaliplatin (mFOLFOX6) plus bevacizumab, and folinic acid, 5-FU and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer."5.22Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801). ( Akagi, Y; Emi, Y; Higashi, H; Ishikawa, H; Kusumoto, T; Maehara, Y; Matsuda, H; Miwa, K; Ogata, Y; Oki, E; Saeki, H; Samura, H; Sueyoshi, S; Tanaka, T; Tokunaga, S; Touyama, T, 2016)
"The granisetron transdermal system (GTS) showed non-inferior efficacy to oral granisetron to control chemotherapy-induced nausea and vomiting (CINV) during multiday chemotherapy."5.20A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients. ( Ahn, JS; Hong, YS; Kim, JE; Kim, KP; Kim, TW; Lee, J; Lee, JL; Park, SJ; Park, YS; Shin, DB; Sym, SJ, 2015)
"The aprepitant therapy was more effective than the control therapy for prevention of CINV in colorectal cancer patients receiving an oxaliplatin-based regimen."5.20Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. ( Doki, Y; Fukunaga, M; Fukuzaki, T; Hata, T; Ide, Y; Kudo, T; Miyake, Y; Mizushima, T; Mori, M; Morita, S; Nakata, K; Nezu, R; Nishimura, J; Ohno, Y; Sakai, D; Satoh, T; Sekimoto, M; Takemasa, I; Takemoto, H; Uemura, M; Yamamoto, H; Yasui, M, 2015)
"The present study aimed to evaluate efficacy and adverse effects of Nimotuzumab combined with docetaxel-cisplatin-fluorouracil regimen in the treatment of advanced oral carcinoma."5.19Efficacy of nimotuzumab combined with docetaxel-cisplatin-fluorouracil regimen in treatment of advanced oral carcinoma. ( Gu, QP; Guo, W; Li, ZP; Meng, J; Meng, QF; Si, YM; Zhang, J; Zhuang, QW, 2014)
"The purpose of this phase I study was to determine the safety, toxicity, maximum tolerated dose, and pharmacokinetics of capecitabine when administered concurrently with radiotherapy in patients with localised, inoperable pancreatic adenocarcinoma."5.19A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer. ( Crellin, A; Evans, TR; Harden, S; James, A; Lumsden, GR; McDonald, AC; Morrison, R; Paul, J; Roxburgh, P; Sweeting, L, 2014)
"Adverse events associated with 5-fluorouracil (5FU) based adjuvant therapy in colorectal cancer (CRC) patients may predict survival."5.19Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity? ( André, T; Bono, P; de Gramont, A; Hermunen, K; Österlund, P; Poussa, T; Quinaux, E; Soveri, LM, 2014)
"The incidence of diarrhea during chemotherapy was significantly lower in the S-1 plus lafutidine group than in the group treated with S-1 alone (10% vs."5.19Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer. ( Hanazaki, K; Kitagawa, H; Kobayashi, M; Maeda, H; Munekage, E; Namikawa, T, 2014)
"We report the long-term results of a randomised trial comparing tamoxifen with tamoxifen plus cyclophosphamide, methotrexate and fluorouracil (CMF) in postmenopausal high-risk breast cancer patients."5.17One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer. ( Andersen, J; Andersson, M; Cold, S; Ejlertsen, B; Elversang, J; Jensen, MB; Mouridsen, HT; Nielsen, DL; Rasmussen, BB, 2013)
"The safety and efficacy of neratinib monotherapy were compared with that of lapatinib plus capecitabine in patients with human epidermal growth factor receptor-2-positive (HER2+), locally advanced/metastatic breast cancer and prior trastuzumab treatment."5.17A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. ( Awada, A; Bonneterre, J; Germa, C; Geyer, CE; Ito, Y; Kim, SB; Lang, I; Martin, M; Ro, J; Vermette, J; Wang, K, 2013)
"For moderately emetogenic chemotherapy, palonosetron (PALO) is reported to provide complete control of chemotherapy-induced nausea and vomiting (CINV) in 69% of patients."5.16Antiemetic control with palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen in addition to either irinotecan or oxaliplatin: a retrospective study. ( Bekaii-Saab, T; Blazer, M; Efries, D; Griffith, N; Juergens, K; Phillips, G; Reardon, J; Rose, J; Smith, Y; Weatherby, L, 2012)
"Phase II studies have shown that the combination of capecitabine and irinotecan (the XELIRI regimen) is active in metastatic colorectal cancer (MCRC)."5.14Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. ( Hlebanja, Z; Ocvirk, J; Rebersek, M; Skof, E, 2009)
"A single-institution Phase I clinical trial was conducted to determine the maximum tolerated dose (MTD) and define the safety profile of temozolomide and capecitabine when used in combination to treat brain metastases from breast cancer."5.12Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. ( Arun, B; Broglio, K; Buchholz, T; Francis, D; Groves, M; Hortobagyi, GN; Meyers, C; Rivera, E; Valero, V; Yin, G, 2006)
"Gastric cancer patients with cytologically confirmed malignant ascites were treated with cycles of oxaliplatin at 85 mg/m(2) plus leucovorin 20 mg/m(2) on the first day of treatment, followed by 5-fluorouracil (5-FU) via a 400 mg/m(2) bolus and a 22 h continuous infusion of 600 mg/m(2) 5-FU on Days 1-2 at 2-week intervals."5.12A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites. ( Jang, JS; Jeong, JS; Kim, HJ; Kim, MC; Kim, SH; Kwon, HC; Lee, DM; Lee, S; Oh, SY; Yoo, HS, 2007)
"Ninety patients with breast cancer were included; 70 patients received single agent paclitaxel either weekly or every 3 weeks and 20 received FAC (5-FU, doxorubicin, cyclophosphamide) chemotherapy."5.11Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. ( Arun, B; Booser, D; Bruera, E; Cleeland, CS; Fritsche, HA; Hortobagyi, GN; Ibrahim, N; Lara, J; Martinez, MM; Mendoza, TR; Pusztai, L; Reuben, JM; Rivera, E; Royce, M; Syed, A; Valero, V; Willey, JS, 2004)
"The purpose is to determine the plasma pharmacokinetics, the maximum-tolerable dose and to preliminary evaluate the antitumor activity of irinotecan administered as a 7-day continuous infusion every 21 days in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed."5.11A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. ( Allegrini, G; Barbara, C; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Masi, G, 2004)
"This multicentre phase I/II study was designed to determine the maximum tolerated dose of irinotecan when combined with 5-fluorouracil and folinic acid according to the Mayo Clinic schedule and to evaluate the activity of this combination as first-line therapy in patients with advanced colorectal cancer."5.11Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. ( Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J, 2004)
"Combination therapy of irinotecan, folinic acid (FA) and 5-fluorouracil (5-FU) has been proven to be highly effective for the treatment of metastatic colorectal cancer."5.11Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. ( Adami, B; Galle, PR; Heike, M; Hohl, H; Höhler, T; Klein, O; Moehler, M; Schroeder, M; Siebler, J; Steinmann, S; Teufel, A; Zanke, C, 2004)
"To verify the effectiveness of oral 1-hexylcarbamoyl-5-fluorouracil (HCFU) in improving the surgical cure rate in advanced colorectal cancer, a multicenter randomized comparative study was conducted."5.11A multicenter randomized study comparing 5-fluorouracil continuous infusion (ci) plus 1-hexylcarbamoyl-5-fluorouracil and 5-FU ci alone in colorectal cancer. ( Kodaira, S; Kotake, K; Koyama, Y; Ohashi, Y, 2005)
"Cumulative gastrointestinal toxicities and neutropenia were the DLTs of docetaxel, capecitabine, and carboplatin."5.11Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer. ( Akerman, P; Barnett, JM; Berkenblit, A; Harrington, D; Iannitti, D; Maia, C; Miner, T; Nadeem, A; Rathore, R; Roye, D; Safran, H; Stuart, K; Tsai, JY, 2005)
"To assess the feasibility and activity of a combination schedule with irinotecan (CPT-11), oxaliplatin (L-OHP), brief infusional fluorouracil (5-FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer (MCC) patients."5.11An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial. ( Amoroso, V; Ferrari, V; Grisanti, S; Marini, G; Marpicati, P; Pasinetti, N; Rangoni, G; Simoncini, E; Valcamonico, F; Vassalli, L, 2005)
"To assess the activity and safety of combined folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC) in metastatic breast cancer patients previously treated with at least two chemotherapy regimens."5.10Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens. ( Correale, P; Fiaschi, AI; Francini, G; Marsili, S; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M, 2002)
"To evaluate the feasibility and a possible activity range of combination irinotecan (CPT-11), oxaliplatin, and 5-FU in advanced colorectal cancer (ACC)."5.10Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study. ( Aramendía, JM; Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Fernández-Hidalgo, O; González-Cao, M; Martín-Algarra, S; Martínez-Monge, R; Rodríguez, J; Salgado, JE, 2002)
" Chemotherapy naive women with stage I or II breast cancer scheduled to intravenous cyclophosphamide, fluorouracil and methotrexate or cyclophosphamide, epirubicin and fluorouracil every 3 weeks were included."5.09Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy. ( Andersen, LJ; Dombernowsky, P; Havsteen, H; Herrstedt, J; Kjaer, M; Kjaerbøl, AG; Langer, SW; Lund, H; Sigsgaard, T, 1999)
"The inhibitory effect of ramosetron hydrochloride (Ram), a 5-HT3 receptor antagonist, on nausea and vomiting occurring in CMF or CEF therapy as a pre- or postoperative adjuvant chemotherapy or chemotherapy for recurrent cancer was evaluated in 34 patients with breast cancer."5.09[Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer]. ( Hojo, S; Noguchi, S; Shiba, E; Taguchi, T; Takamura, Y; Tsukamoto, F; Watanabe, T; Yoneda, K, 1999)
"To compare the response rate, efficacy parameters, and toxicity profile of oral capecitabine with bolus intravenous (IV) fluorouracil plus leucovorin (5-FU/LV) as first-line treatment in patients with metastatic colorectal cancer."5.09Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. ( Ansari, R; Batist, G; Burger, HU; Cox, J; Harrison, E; Hoff, PM; Kocha, W; Kuperminc, M; Maroun, J; Osterwalder, B; Walde, D; Weaver, C; Wong, AO; Wong, R, 2001)
"We have reported that an alternating regimen of bolus and continuous infusion 5-fluorouracil (FU) was superior to bolus FU in terms of response rate and progression-free survival in advanced colorectal cancer."5.095-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer. ( Aschele, C; Caroti, C; Cirillo, M; Cortesi, E; Frassineti, GL; Gallo, L; Grossi, F; Guglielmi, A; Labianca, R; Pessi, MA; Ravaioli, A; Recaldin, E; Sobrero, A; Testore, P; Turci, D, 2001)
"The purpose of this study was to evaluate the activity and safety of oxaliplatin and protracted venous infusion of 5-fluorouracil (PVI 5-FU) in patients with advanced or relapsed 5-FU pretreated colorectal cancer."5.09Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. ( Chau, I; Cunningham, D; Hill, M; Massey, A; Norman, A; Waters, JS; Webb, A, 2001)
"The comparative study among granisetron alone and granisetron combined with hydroxyzine hydrochloride or dexamethasone was undertaken for the prevention of nausea and vomiting during chemotherapy including cisplatin in patients with advanced head and neck carcinomas."5.08[Comparison of granisetron alone and granisetron plus dexamethasone or hydroxyzine hydrochloride for the prevention of nausea and vomiting during chemotherapy including cisplatin]. ( Enomoto, H; Furukawa, M; Ikema, Y; Kawai, S; Kohno, H; Kubota, A; Makino, Y; Matsuda, H; Tsukuda, M; Yago, T, 1995)
"A multicentral cooperative study was conducted to evaluate the clinical efficacy and toxicity of l-Leucovorin (l-LV) and 5-fluorouracil (5-FU) in advanced colorectal cancer."5.08[A late phase II trial of l-leucovorin and 5-fluorouracil in advanced colorectal cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)]. ( Abe, T; Kikkawa, N; Konishi, K; Maehara, Y; Ota, J; Sowa, M; Taguchi, T; Takashima, S; Yabushita, K; Yasutomi, M, 1995)
"The direct effect and safety of carmofur (Mifurol) in cases of advanced and recurrent breast cancer were evaluated as a cooperative study at twenty-two facilities nationwide."5.08[Clinical effects of carmofur (Mifurol) on advanced and recurrent breast cancer in a cooperative study. Research association for re-evaluation of direct effects of Mifurol on breast cancer]. ( Abe, R; Enomoto, K; Koyama, H; Kusama, M; Nishi, T; Sonoo, H; Takashima, S; Tominaga, T; Yamaguchi, S; Yoshida, M, 1995)
"To determine whether a combination chemotherapy regimen that contains epirubicin (fluorouracil, epirubicin, and cyclophosphamide [FEC]) is superior to the standard cyclophosphamide, methotrexate, and fluorouracil (CMF) combination in premenopausal women with axillary node-positive operable breast cancer."5.08Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collab ( Aapro, M; Amadori, D; Bliss, JM; Chilvers, CE; Coombes, G; Coombes, RC; Espié, M; Ferreira, EP; Gambrosier, P; Marty, M; McArdle, C; Morvan, F; Pérez-López, FR; Richards, M; Vassilopoulos, P; Villar-Grimalt, A; Wils, J; Woods, EM, 1996)
"Both the biochemical modulation and the continuous administration of 5-fluorouracil (5-FU) have achieved promising results in patients with gastric carcinoma."5.08Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group. ( Belón, J; Blanco, E; Espinosa, E; Feliu, J; García-Alfonso, P; García-Girón, C; Garrido, P; Gómez-Navarro, J; González Barón, M; Ordónez, A; Zamora, P, 1996)
"A crossover clinical trial between granisetron alone and granisetron combined with methylprednisolone (MPL) was undertaken for the prevention of nausea and vomiting during chemotherapy, including cisplatin, in 12 patients with advanced primary and metastatic lung cancer."5.08[Comparative trial of granisetron alone and granisetron plus methylprednisolone for prevention of nausea and vomiting during cancer chemotherapy]. ( Fujishima, H; Hisano, C; Masumoto, N; Nakamura, M; Nakano, S; Niho, Y; Okuma, K, 1996)
"The aim of this open, nonrandomized, monocentric study was to evaluate the efficacy of a single daily dose of 8 mg oral ondansetron in the prophylaxis of acute nausea and vomiting in chemotherapy-naive breast cancer patients receiving their first cycle of chemotherapy with 5-fluorouracil, doxorubicin and cyclophosphamide (FAC)."5.08Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting. ( Bosnjak, SM; Jovanovic-Micic, DJ; Mitrovic, LB; Neskovic-Konstantinovic, ZB; Radulovic, SS, 1996)
"Azasetron, a selective 5-HT3 receptor antagonist, has been previously shown to be highly effective in the prophylaxis of nausea and vomiting induced by anticancer drugs, and is widely used in the clinical setting in Japan."5.08[Clinical effect of two azasetron treatment methods against nausea and vomiting induced by anticancer drugs including CDDP]. ( Kimura, E; Niimi, S; Tanaka, T; Watanabe, A, 1997)
" The combination chemotherapy with CDDP and 5-fluorouracil (5-FU), which has great efficacy for head and neck cancer, induces nausea and vomiting as side effects."5.08[Comparison of effects between single vs five-day injection of granisetron for combination chemotherapy with cisplatin and 5-fluorouracil for head and neck cancer]. ( Fujii, M; Imanishi, Y; Kanke, M; Kanzaki, J; Ohno, Y; Tokumaru, Y, 1997)
"Efficacy of combination of ondansetron injection and tablet on CAF (cyclophosphamide, adriamycin, 5-fluorouracil) induced emesis were investigated in 10 breast cancer patients (33 courses)."5.08[Efficacy of combination of ondansetron injection and tablet in CAF-induced emesis in breast cancer patients]. ( Furukawa, T; Kurihara, N; Machimura, T; Nemoto, Y; Nishihori, H; Shinohara, H; Urakami, H; Yonekawa, H, 1998)
"The antiemetic efficacy of dexamethasone (Dexaven) was examined in patients with breast cancer during chemotherapy CMF (cyclophosphamide, methotrexate and 5-fluorouracil) in comparison with patients treated identically but without dexamethasone."5.07[Use of dexamethasone as an antiemetic in patients with breast cancer treated with the CMF regimen]. ( Domaradzka-Woźniak, A; Dziewulska-Bokiniec, A; Wojtacki, J, 1994)
"A total of 50 patients were treated weekly with 5-fluorouracil (FU), leucovorin (LV), and 4'-O-tetrahydropyranyl-doxorubicin (THP) as first-line chemotherapy for advanced breast cancer (ABC)."5.07A phase I/II study of 4'-O-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose leucovorin as first-line therapy in advanced breast cancer patients. ( Bauernhofer, T; Derstvenscheg, E; Kuss, I; Moser, R; Ploner, F; Samonigg, H; Schmid, M; Steindorfer, P; Stöger, H; Wilders-Truschnig, M, 1994)
" A sample of 43 patients with breast cancer was accrued from September to November 1992 in a phase II study to assess the efficacy of granisetron in patients receiving FEC (5-FU, epirubicin, cyclophosphamide)."5.07Control of emesis by intravenous granisetron in breast cancer patients treated with 5-FU, epirubicin and cyclophosphamide. ( Ang, PT; Khoo, KS; Tan, EH, 1994)
"The combination of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) is a widely used chemotherapy regimen in breast cancer patients."5.07Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study. ( Aapro, MS; Bauer, J; Brunner, KW; Buser, KS; Cavalli, F; Haefliger, JM; Joss, RA; Jungi, WF; Obrist, R; Piquet, D, 1993)
" To address its use with a widely used but less emetogenic regimen, we performed a double-blind, randomized clinical trial comparing ondansetron with dexamethasone and metoclopramide in patients with breast cancer receiving chemotherapy with cyclophosphamide, methotrexate, and fluorouracil."5.07Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. ( Latreille, J; Levitt, M; Lofters, WS; Perrault, DJ; Potvin, M; Rayner, HL; Warner, E; Warr, D; Wilson, KS; Yelle, L, 1993)
"The antiemetic response and side effects resulting from treatment with methylprednisolone (MPA) given on two different dose schedules were evaluated in 20 women with breast cancer who were undergoing chemotherapy consisting of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)."5.07Methylprednisolone as antiemetic treatment in breast-cancer patients receiving cyclophosphamide, methotrexate, and 5-fluorouracil: a prospective, crossover, randomized blind study comparing two different dose schedules. ( Cass, Y; Edelmann, DZ; Gez, E; Strauss, N; Vitzhaki, N, 1992)
" 97 female breast cancer patients who received their first two FEC courses (epirubicin 50-75 mg/m2, 5-fluorouracil 500 mg/m2, cyclophosphamide 500 mg/m2) entered this randomised crossover study (76 had previously received an adjuvant treatment); tetracosactrin was administered intramuscularly and methylprednisolone intravenously immediately before chemotherapy administration."5.07Tetracosactrin vs. methylprednisolone in the prevention of emesis in patients receiving FEC regimen for breast cancer. ( Bastit, P; Bonneterre, J; Cappelaere, P; Chevrier, A; Fargeot, P; Geyer, G; Kerbrat, P; Metz, R; Roche, H; Tubiana-Hulin, M, 1991)
"The French Epirubicin Study Group carried out a randomized trial comparing epirubicin alone 75 mg/m2 with fluorouracil (5FU) 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 50 mg/m2 (FEC 50) and 5FU 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 75 mg/m2 (FEC 75) as first treatment for advanced breast cancer patients."5.07A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group. ( , 1991)
"Seventy-five breast cancer patients scheduled to receive a first course (in a new cycle) of cyclophosphamide, fluorouracil, and doxorubicin (FAC) or epirubicin (FEC) participated in a double-blind crossover study to compare the antiemetic efficacy and safety of ondansetron (GR38032), a 5-hydroxytryptamine3 (5-HT3) receptor antagonist, and metoclopramide."5.06A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. ( Bonneterre, J; Bons, J; Chevallier, B; Fargeot, P; Metz, R; Paes, D; Pujade-Lauraine, E; Spielmann, M; Tubiana-Hulin, M, 1990)
"Thirty patients with a diagnosis of metastatic adenocarcinoma of the lung were entered on a trial to evaluate the antitumor efficacy of 5-fluorouracil 370 mg/m2 daily for 5 days every four weeks in combination with folinic acid 200 mg/m2, 60 min prior to 5FU."5.065-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung. ( Aitken, SE; Evans, WK; Ezzat, A; Maroun, JA; Rusthoven, J; Shepherd, FA; Stewart, DJ; Wierzbicki, R, 1990)
"Two hundred sixty-three patients with advanced breast cancer were randomized to two treatment regimens consisting of fluorouracil, 500 mg/m2; cyclophosphamide, 500 mg/m2; and either epirubicin (Farmorubicin, Farmitalia Carlo Erba SpA, Italy), 50 mg/m2 (FEC); or doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH), 50 mg/m2 (FAC), administered intravenously (IV) every 3 weeks."5.06A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group. ( , 1988)
"The antiemetic effectiveness of haloperidol plus dexamethasone was compared with that of prochlorperazine plus dexamethasone in a prospective study of patients receiving chemotherapy for breast cancer."5.06A randomized comparison of haloperidol plus dexamethasone versus prochlorperazine plus dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for breast cancer. ( Carpenter, JT; Conolley, C; Lee, J; Silvey, L; Wheeler, RH, 1988)
" CMF were included in a double-blind comparative study aimed at evaluating the efficacy of 3 different drugs (methylprednisolone (MP), metoclopramide (MTC), and domperidone (DMP) in preventing chemotherapy-induced nausea and vomiting."5.06Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF. ( Ballatori, E; Basurto, C; del Favero, A; Minotti, V; Roila, F; Tonato, M, 1987)
"The antiemetic efficacy and toxicity of methylprednisolone (MP) and metoclopramide (MTC) in prevention of nausea and vomiting in breast cancer patients receiving intravenous cyclophosphamide methotrexate 5-fluorouracil (CMF) chemotherapy has been evaluated in a double-blind trial."5.06Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide methotrexate 5-fluorouracil: a double-blind randomized study. ( Ballatori, E; Basurto, C; Del Favero, A; Minotti, V; Roila, F; Tonato, M, 1988)
"Patients with visceral patterns of metastatic breast cancer were stratified according to dominant metastatic site and performance status and then randomized to therapy with cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) or CAF alternating with a "cell-cycle active" regimen including cytosine arabinoside, methotrexate with leucovorin rescue, and oncovin ( CAMELEON )."5.05Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a "cycle active" non-cross-resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project. ( Carpenter, J; Fishkin, E; Krauss, S; Moore, MR; Raab, S; Raney, M; Smalley, RV; Stagg, M; Velez-Garcia, E; Vogel, CL, 1984)
"One hundred twenty-one patients with advanced measurable adenocarcinoma of the colon were randomized for treatment with intravenous 5-fluorouracil (IV 5-FU) alone, 15 mg/kg/week vs."5.05Treatment of advanced colon cancer with 5-fluorouracil (NSC19893) versus cyclophosphamide (NSC26271) plus 5-fluorouracil: prognostic aspects of the differential white blood cell count. ( Bateman, JR; Chlebowski, RT; Kardinal, C; Pajak, T; Silverberg, I; Weiner, J, 1980)
"To determine the incidence of anticipatory vomiting (AV) and postchemotherapy nausea and vomiting (PCNV) in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma, we studied 52 women randomized to two regimens (standard-dose and low-dose) of CMF."5.05Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma. ( Abeloff, MD; Fetting, JH; Nettesheim, KM; Wilcox, PM, 1982)
"One-hundred-ninety-four eligible and evaluable patients with histologically confirmed locally unresectable adenocarcinoma of the pancreas were randomly assigned to therapy with high-dose (6000 rads) radiation therapy alone, to moderate-dose (4000 rads) radiation + 5-fluorouracil (5-FU), and to high-dose radiation plus 5-FU."5.05Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. ( Barkin, J; Bateman, J; Brooks, J; Chaffey, J; Childs, DS; Corson, JM; Douglas, HO; Frytak, S; Hahn, RG; Holbrook, MA; Kalser, M; Knowlton, A; Lavin, PT; Lessner, H; Livstone, E; Lokich, J; Mann-Kaplan, R; Moertel, CG; Nave, H; Novak, JW; O'Connell, MJ; Ramming, K; Reitemeier, RJ; Rubin, J; Schutt, AJ; Spiro, H; Thomas, P; Weiland, LH; Zamcheck, N, 1981)
"As of August 1984, 115 women with advanced breast cancer have been randomized to receive a combination of either cyclophosphamide, Novantrone (mitoxantrone) and 5-fluorouracil (CNF) or cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF)."5.05A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Bennett, JM; Byrne, P; DeConti, R; Desai, A; Doroshow, J; Krementz, E; Muggia, F; Plotkin, D; Vogel, C; White, C, 1985)
"One hundred and sixteen patients with advanced and metastatic adenocarcinoma of the pancreas were randomized to treatment with combined Streptozotocin and 5-fluorouracil or combined Streptozotocin and cyclophosphamide."5.04Treatment of advanced adenocarcinoma of the pancreas with combinations of streptozotocin plus 5-fluorouracil and streptozotocin plus cyclophosphamide. ( Carbone, PP; Douglas, HO; Hanley, J; Moertel, CG, 1977)
" The incidence of nausea and vomiting in benzquinamide-treated patients was equal to that in placebo-treated patients and significantly higher than that in patients treated with prochlorperazine, 10 mg 3 times daily."5.04Oral benzquinamide in the treatment of nausea and vomiting. ( Hahn, RG; Moertel, CG; O'Fallon, JR; Schutt, AJ, 1975)
"An electronic search was undertaken to identify randomized controlled trials comparing raltitrexed-based regimen to 5-fluorouracil-based regimen in patients with advanced colorectal cancer."4.90Raltitrexed-based chemotherapy for advanced colorectal cancer. ( Hong, W; Huang, Q; Liu, Y; Sun, X; Wu, J; Wu, W, 2014)
"We analyzed individual data on 6,284 patients from nine phase III trials of advanced colorectal cancer (aCRC) that used fluorouracil-based single-agent and combination chemotherapy."4.87Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials. ( Blanke, CD; Bleyer, A; Bot, BM; de Gramont, A; Goldberg, RM; Kohne, CH; Sargent, DJ; Seymour, MT; Thomas, DM, 2011)
" A phase III randomized trial, Xeloda in Adjuvant Colorectal Cancer Treatment, demonstrated that treatment with single-agent capecitabine was equivalent to bolus 5-fluorouracil with leucovorin with respect to disease-free survival and overall survival, with significantly less diarrhea, stomatitis, neutropenia, nausea and vomiting, and alopecia."4.83Capecitabine: a new adjuvant option for colorectal cancer. ( Berg, DT, 2006)
"Fluorouracil (5-FU) continuous infusion is superior to 5-FU bolus in patients with advanced colorectal cancer, but the survival difference between the two treatments is small and, therefore, the difference in toxicity profile is crucial in choosing a treatment for individual patients."4.80Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. ( Benedetti, J; Brufman, G; Buyse, M; Fryer, J; Hansen, R; Isacson, R; Laplanche, A; Leichman, C; Lévy, E; Lokich, J; Macdonald, J; Pater, J; Piedbois, P; Pignon, JP; Quinaux, E; Rougier, P; Ryan, L; Thirion, P; Weinerman, B; Zee, B, 1998)
" This study evaluated the percentages of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) undergoing second-line therapy with 5-fluorouracil (5-FU)-based regimens that experienced AEs during treatment and received medication to manage those AEs."4.12Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma. ( Cockrum, P; Kim, G; Surinach, A; Wainberg, Z; Wang, S, 2022)
"The use of FOLFIRINOX (a combination of oxaliplatin, irinotecan, fluorouracil, and leucovorin) is one of the therapeutic standards in pancreatic adenocarcinoma."4.02Survival and Predictive Factors of Chemotherapy With FOLFIRINOX as First-Line Therapy in Metastatic Pancreatic Cancer: A Retrospective Multicentric Analysis. ( Ben Abdelghani, M; Caron, B; Duclos, B; Kurtz, JE; Nguimpi-Tambou, M; Noirclerc, M; Reimund, JM; Sondag, D, 2021)
" We describe a strongly suspected elderly cancer patient's DDI between aprepitant and opium powder in the context of an irinotecan-based regimen manifested by nightmares and visual hallucinations."3.91Nightmares and hallucinations with aprepitant and opium powder: a suspected drug-drug interaction. ( Azzouz, B; Bouché, O; Clarenne, J; Narjoux, G; Slimano, F; Zeller, PS, 2019)
"To evaluate the impact of sex on toxicity and efficacy outcomes among patients with metastatic colorectal cancer receiving first-line 5-fluorouracil-based regimens."3.91Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials. ( Abdel-Rahman, O, 2019)
"The objective of this study was to determine the effect of aprepitant(from days 1 to 3, po)and fosaprepitant(day 1, iv) for nausea in patients with oral cancer receiving combination chemotherapy with docetaxel, nedaplatin, or cisplatin(divided doses for 5 days), and 5-fluorouracil(TPF)."3.85[Determination of the Effect of Aprepitant and Fosaprepitant for Nausea in Patients with Oral Cancer Receiving Combination Chemotherapy with TPF]. ( Asoda, S; Iwabuchi, H; Kasazaki, S; Shiiba, Y; Suga, K; Uchiyama, K; Uehara, K; Yamada, M, 2017)
"Although efficacy of aprepitant for suppressing emesis associated with single-dose cisplatin has been demonstrated, there are limited data on the antiemetic effect of this oral neurokinin-1 receptor antagonist during daily administration of cisplatin."3.80Efficacy of aprepitant for nausea in patients with head and neck cancer receiving daily cisplatin therapy. ( Ishimaru, K; Kaneko, K; Katsura, M; Takahashi, H; Takano, A; Yamaguchi, N, 2014)
"To evaluate the efficacy of reduction of dexamethasone with a single-dose of palonosetron in preventing acute and delayed nausea and vomiting in patients receiving highly emetogenic chemotherapy (HEC) for early breast cancer."3.79Single-dose palonosetron and dose-reduced regimen of dexamethasone in preventing nausea and vomiting by anthracycline-including chemotherapy in patients with early breast cancer. ( Cardillo, FD; Cognetti, F; Evangelista, S; Fabi, A; Fattoruso, SI; Pacetti, U; Veltri, E, 2013)
"Gemcitabine plus cisplatin (GP) is a standard chemotherapy option for patients with advanced biliary tract cancer (BTC)."3.79Gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective cohort study. ( Han, SS; Hong, EK; Kim, DH; Kim, JH; Kim, TH; Koh, YH; Lee, JH; Lee, WJ; Park, SJ; Woo, SM, 2013)
", drug-adverse event pairs, found in 1,644,220 AERs from 2004 to 2009, it was suggested that leukopenia, neutropenia, and thrombocytopenia were more frequently accompanied by the use of 5-FU than capecitabine, whereas diarrhea, nausea, vomiting, and hand-foot syndrome were more frequently associated with capecitabine."3.78Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations. ( Brown, JB; Kadoyama, K; Miki, I; Okuno, Y; Sakaeda, T; Tamura, T, 2012)
" In this retrospective study, we assessed the efficacy of palonosetron versus granisetron for the incidence of CINV induced by mFOLFOX6 and FOLFIRI in patients with advanced colorectal cancer."3.78[Antiemetic effect of palonosetron in advanced colorectal cancer patients receiving mFOLFOX6 and FOLFIRI: a retrospective survey]. ( Hayakawa, Y; Muro, K; Noma, H; Okamoto, H; Sato, Y; Tatematsu, M, 2012)
" The aim of the present report was to evaluate real-life drug adherence in a prospective cohort analysis of patients with gastrointestinal or breast cancer treated with capecitabine-based chemotherapy."3.77Self-reported compliance with capecitabine: findings from a prospective cohort analysis. ( Bressoud, A; Delmore, G; Hermann, F; Hoesli, P; Pederiva, S; von Moos, R; Winterhalder, R, 2011)
"We retrospectively analyzed the efficacy and safety of aprepitant in breast cancer patients who were treated with FEC(5- fluorouracil, epirubicin, cyclophosphamide)or EC(epirubicin, cyclophosphamide)."3.77[Efficacy and safety of aprepitant in patients with breast cancer]. ( Aogi, K; Eguchi, H; Hara, F; Kiyoto, S; Matsuhisa, T; Osumi, S; Oze, I; Tagashira, H; Takabatake, D; Takahashi, M; Takashima, S, 2011)
"The aim of the study was to evaluate the role of ramosetron for the prevention of chemoradiotherapy-induced nausea and vomiting (CRINV) in patients receiving upper abdominal irradiation with concurrent 5-fluorouracil chemotherapy."3.75Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer. ( Bang, YJ; Chie, EK; Ha, SW; Im, SA; Jang, JY; Kim, K; Kim, SW; Kim, TY; Oh, DY, 2009)
"We encountered a case of peritoneal dissemination of hepatocellular carcinoma, successfully treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil."3.74Peritoneal dissemination of hepatocellular carcinoma treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil. ( Iwasaki, Y; Miyake, Y; Sakaguchi, K; Shiraha, H; Shiratori, Y, 2007)
"Short-term infusion of 5-fluorouracil with leucovorin in combination with irinotecan or oxaliplatin has been considered as standard treatment for metastatic colorectal cancer."3.74Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan. ( Boku, N; Fukutomi, A; Hasuike, N; Hironaka, S; Machida, N; Ono, H; Onozawa, Y; Yamaguchi, Y; Yamazaki, K; Yoshino, T, 2007)
" We evaluated the toxicity and efficacy of a Hypofractionated and intensively Accelerated RT regimen supported with amifostine Cytoprotection (HypoARC) in a cohort of 72 high-risk breast cancer patients treated with modified mastectomy or conservative surgery and FEC (5-fluorouracil/epirubicin/cyclophosphamide) chemotherapy."3.71Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients. ( Frangiadaki, C; Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Koukourakis, MI; Kouroussis, C; Retalis, G; Sivridis, E, 2002)
"The incidence of nausea and vomiting was investigated for a maximum of 7 days in 32 breast cancer patients receiving CAF (cyclophosphamide, adriamycin, 5-fluorouracil) and CMF (cyclophosphamide, methotrexate, 5-fluorouracil) therapies."3.71[Incidence of emesis in outpatients on chemotherapy for breast cancer and the clinical efficacy of ondansetron hydrochloride tablets]. ( Hayakawa, H; Ishida, T; Kusaba, T, 2002)
"The purpose of this study was to investigate the side-effects experienced by patients with colorectal cancer receiving 5-fluorouracil + folinic acid chemotherapy."3.70Patients' experiences of chemotherapy: side-effects associated with 5-fluorouracil + folinic acid in the treatment of colorectal cancer. ( Dikken, C; Sitzia, J, 1998)
"The incidence of nausea and vomiting or anorexia was investigated in 16 outpatients receiving oral antimetabolites such as 5-FU (fluorouracil) as chemotherapy, during a maximum observation period of 28 days."3.70[Chronological observation of nausea and vomiting in outpatients given oral antimetabolites as chemotherapy--two patients receiving ondansetron hydrochloride tablets]. ( Ishikawa, H; Ohya, M; Sasaki, K; Yanagida, T, 2000)
"The antiemetic efficacy of granisetron in repeated CAF chemotherapy after breast cancer operation was investigated."3.69[Antiemetic efficacy of granisetron in repeated CAF chemotherapy after breast cancer operation]. ( Hatano, Y; Kato, N; Okuyama, N; Park, Y; Sasamoto, S; Yamazaki, S, 1997)
"Multiple studies have shown that leucovorin-fluorouracil regimens are modestly superior to fluorouracil alone in the treatment of advanced colorectal cancer."3.69Biochemical modulation in the treatment of advanced cancer: a study of combined leucovorin, fluorouracil, and iododeoxyuridine. ( DeLap, RJ; Marshall, JL; Richmond, E, 1996)
"Seventy-five female patients suffering from advanced breast cancer were treated with toilet mastectomy, radiotherapy and oophorectomy (if premenopausal) or tamoxifen therapy (if postmenopausal) as well as chemotherapy with cyclophosphamide, methotrexate, 5-fluorouracil and prednisone."3.68Toxicity and side-effects of combination chemohormonal therapy of advanced breast cancer. ( Dandapat, MC; Mohapatro, SK; Padhi, NC, 1992)
"A total of 60 patients with advanced breast cancer were treated with a combination of prednimustine (P: 110 mg/m2, days 1-5), mitoxantrone (M: 12 mg/m2, day 1) and 5-fluorouracil (F: 500 mg/m2, day 1) (PMF)."3.68Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer. ( Dusleag, J; Kasparek, AK; Lechner, P; Pfeiffer, K; Samonigg, H; Schmid, M; Smola, M; Steindorfer, P; Stöger, H, 1991)
"Twenty-nine patients with metastatic breast cancer were treated with fluorouracil, adriamycin, cyclophosphamide (FAC), and methotrexate (MTX), with or without leukovorin rescue."3.67Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate. ( Aboud, A; Blumenschein, GR; Buzdar, AU; Hortobagyi, GN; Yap, HY, 1984)
"Thirty consecutive patients with metastatic breast cancer previously untreated by chemotherapy were given high-dose cyclophosphamide (Cytoxan) and high-dose 5-fluorouracil (5-FU) as first-line therapy."3.67High-dose cyclophosphamide and high-dose 5-fluorouracil. A new first-line regimen for advanced breast cancer. ( Aguilera, J; Breau, JL; Israel, L, 1984)
"As adverse reactions to the combination treatment by the digestive system, we observed the occurrence of nausea and vomiting in 15% of the cases who received FTP treatment consisting of 5-FU, toyomicin and prednisone, 25% of the cases who received MFU treatment consisting of MMC, 5-FU and ACNU, and in 64% of the cases who received PPQ treatment consisting of CDDP, Carboquone (CQ) and prednisone."3.67[Adverse reactions to carcinostatics and countermeasures]. ( Nakao, I, 1989)
"Thirty patients with advanced breast cancer, not pretreated with chemotherapy, received a polychemotherapy regimen containing mitoxantrone, fluorouracil and cyclophosphamide at the dose of 10 mg/m2, 500 mg/m2 and 500 mg/m2 i."3.67Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer. ( Canova, N; Ercolino, L; Martoni, A; Pannuti, F; Rani, P, 1988)
"Forty-six outpatients with breast cancer who had experienced severe emesis as a result of chemotherapy were evaluated for the antiemetic efficacy of high-dose metoclopramide (HD-MCP) and dexamethasone (DXM)."3.67High-dose metoclopramide and dexamethasone as an antiemetic in outpatients receiving chemotherapy for breast cancer. Second study. ( Ben-Baruch, N; Ben-Yosef, R; Biran, S; Brufman, G; Gez, E; Uziely, B; Warner-Efraty, E; Yitzhaki, N, 1987)
"We employed a structured interview to retrospectively study tastes and vomiting associated with the parenteral components of cyclophosphamide, methotrexate, and 5-FU in 45 patients with stage II-IV breast cancer."3.67Tastes associated with parenteral chemotherapy for breast cancer. ( Donehower, RC; Enterline, JP; Fetting, JH; Grochow, LB; Sheidler, VR; Wilcox, PM, 1985)
"In our wide experience of treating advanced breast carcinoma with chemotherapy, the combination of doxorubicin (DOX), vincristine (VCR), cyclophosphamide (CPM) and fluorouracil (FU) gave a complete plus partial response rate of over 60%, with 100% alopecia and frequent cardiac toxicity depending on total dose."3.67Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer. ( Armand, JP; Cappelaere, P; Delgado, M; Grimbert, J; Keiling, R; Mathe, G; Metz, R; Misset, JL; Prevot, G, 1985)
"A total of 65 patients with advanced colorectal or breast cancer were given oral tegafur in the phase I study."3.66Phase I-II studies of oral tegafur (ftorafur). ( Ansfield, FJ; Kallas, GJ; Singson, JP, 1983)
"Sixty-two patients with metastatic hormonal refractory adenocarcinoma of the prostate received a combination of doxorubicin, mitomycin-C, and 5-fluorouracil (DMF)."3.66Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. ( Grant, C; Johnson, DE; Logothetis, CJ; Ogden, S; Samuels, ML; Trindade, A; von Eschenbach, AC, 1983)
"A four-drug combination of intermittent high-dose cyclophosphamide with 5-fluorouracil, hexamethylmelamine, and prednisone was given to 19 patients with advanced breast cancer."3.66Phase I--II evaluation of combination cyclophosphamide, 5-fluorouracil, hexamethylmelamine, and prednisone in advanced breast cancer. ( Chang, YC; Crowley, J; Falkson, G; Tormey, DC, 1981)
"A group of 47 patients with advanced breast cancer were treated with a combination of prednimustine, methotrexate, 5-FU, and tamoxifen."3.66Prednimustine in combination with methotrexate and 5-FU (PMF): a pilot study. ( Boesen, E; Mouridsen, HT, 1982)
"Overall, nausea was reported by 86% (n=129) of the patients during the ten-day period from the start of cancer treatment."3.30Single Nucleotide Polymorphism Directed Antiemetic Treatment in Women With Breast Cancer Treated With Neo- or Adjuvant Chemotherapy: A Randomised Multicentre Phase II Study. (EudraCT: 2015-000658-39). ( Andersson, BÅ; Åsenlund, U; Elinder, E; Fust, L; Lewin, F; Lewin, N; Nilsson, MP; Oliva, D; Schildt, EB; Sellerstam, G; Shamoun, L; Sharp, L, 2023)
" The studies demonstrated a significant benefit from the triplet at the price of an increased incidence of chemotherapy-related adverse events (AEs)."2.90Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies. ( Allegrini, G; Aprile, G; Bergamo, F; Boccaccino, A; Boni, L; Borelli, B; Buonadonna, A; Cordio, S; Cremolini, C; Dell'Aquila, E; Falcone, A; Latiano, TP; Libertini, M; Lonardi, S; Marmorino, F; Masi, G; Moretto, R; Passardi, A; Pella, N; Randon, G; Ratti, M; Ricci, V; Ronzoni, M; Rossini, D; Tamburini, E; Urbano, F; Zucchelli, G, 2019)
" Treatment-emergent adverse events (TEAEs) were evaluated, and HRQL was assessed at baseline, cycle 3, and every other cycle using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, EORTC QLQ-CR29, and EuroQol 5-Dimensions 3-Levels questionnaires (NCT01571284)."2.90Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP). ( Aparicio, J; Bordonaro, R; Bury, D; Chau, I; Cicin, I; Di Bartolomeo, M; Drea, E; Fedyanin, MY; García-Alfonso, P; Heinemann, V; Karthaus, M; Kavan, P; Ko, YJ; Maiello, E; Martos, CF; Peeters, M; Picard, P; Riechelmann, RP; Sobrero, A; Srimuninnimit, V; Ter-Ovanesov, M; Yalcin, S, 2019)
"vomiting, anorexia and infection) were recorded, and short-term effect of chemotherapy was evaluated regularly."2.84Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms. ( Deng, B; Jia, L; Li, X; Li, Y; Lou, Y; Tan, H; Yu, L, 2017)
"In mouse models of pancreatic cancer, IPI-926, an oral Hedgehog inhibitor, increases chemotherapy delivery by depleting tumor-associated stroma."2.82A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. ( Catenacci, DV; Chang, WC; Kantoff, E; Kate Kelley, R; Kindler, HL; Ko, AH; Lewis, S; LoConte, N; Tempero, MA; Vannier, MW; Venook, AP; Walker, EJ, 2016)
"7% of patients experienced grade 3 and 4 adverse events, respectively."2.80Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. ( Campone, M; Citron, ML; Dang, CT; Dirix, L; Gianni, L; Krop, IE; Romieu, G; Smitt, M; Suter, TM; Xu, N; Zamagni, C, 2015)
"Patients with advanced solid tumors received oral BKM120 daily combined with standard doses of mFOLFOX6 every 2 weeks of a 28 day cycle."2.80A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors. ( Carlson, C; Ivanova, A; McRee, AJ; O'Neil, BH; Sanoff, HK, 2015)
"Twenty-one Japanese colorectal cancer patients received intravenous FOLFIRI (bolus irinotecan, folinic acid, and fluorouracil followed by 46-hour fluorouracil infusion) followed by bevacizumab (5 mg/kg) in Cycle 1."2.79Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms. ( Doi, T; Fuse, N; Hamamoto, Y; Hatake, K; Iwasaki, J; Matsumoto, H; Mizunuma, N; Motomura, S; Ohtsu, A; Suenaga, M; Yamaguchi, T; Yamanaka, Y, 2014)
"In 2594 patients with complete adverse event (AE) data, the incidence of grade 3 or greater 5FU-AEs in DPYD*2A, I560S, and D949V carriers were 22/25 (88."2.79DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). ( Alberts, SR; Berenberg, JL; Diasio, RB; Goldberg, RM; Lee, AM; Pavey, E; Sargent, DJ; Shi, Q; Sinicrope, FA, 2014)
" The experimental arm's dosage schedule was paclitaxel 60 mg/m2 (intravenous infusion) on days 1, 8 and 15 and S-1 80-120 mg/d (oral administration) on days 1-14."2.78A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer. ( Ba, Y; Deng, T; Guo, Z; Hu, C; Huang, D; Meng, J; Wan, H; Wang, M; Xiong, J; Xu, N; Yan, Z; Yao, Y; Yu, Z; Zhang, Y; Zheng, R; Zhuang, Z, 2013)
"To evaluate the efficacy and safety of trastuzumab in combination with chemotherapy versus chemotherapy alone in the first-line treatment of HER-2-positive advanced gastric or gastro-oesophageal junction cancer."2.78[Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport]. ( Feng, FY; Guan, ZZ; Jiao, SC; Jin, YN; Li, J; Pan, LX; Qin, SK; Shen, L; Tao, M; Wang, JJ; Wang, LW; Wang, YJ; Xu, JM; Yu, SY; Zheng, LZ, 2013)
"Patients with stage II and III esophageal cancer were enrolled."2.77Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer. ( Chak, A; Chang, KJ; Hanna, N; Pinto, H; Reid, T; Senzer, N; Soetikno, R; Swisher, S, 2012)
" We designed a pilot study in order to explore the optimal dosing period for indisetron during modified FOLFOX6 (mFOLFOX6)."2.77Optimal dose period for indisetron tablets for preventing chemotherapy-induced nausea and vomiting with modified FOLFOX6: a randomized pilot study. ( Asaka, M; Kato, K; Komatsu, Y; Kudo, M; Meguro, T; Miyagishima, T; Muto, S; Nakatsumi, H; Oba, K; Sogabe, S; Tateyama, M; Uebayashi, M; Yuki, S, 2012)
"Survival time for metastatic breast cancer (MBC) can be substantially improved by combination chemotherapy in the adjuvant setting."2.75A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines. ( Alexopoulos, A; Ardavanis, A; Ioannidis, G; Kandylis, C; Malliou, S; Orphanos, G; Rigatos, G; Stavrakakis, J, 2010)
"To explore the efficacy, time to disease progression (TTP), overall survival (OS) and toxicity of paclitaxel liposome versus paclitaxel combined with 5-fluorouracil (5-Fu) for patients with advanced gastric cancer."2.75[Comparison of the therapeutic effects of paclitaxel liposome-5-Fu versus paclitaxel-5-Fu on 67 patients with advanced gastric cancer]. ( Chen, SC; Lu, ZH; Wu, F; Xiong, JP, 2010)
"5, or 50 mg) was administered orally once daily on three dosing schedules: 4 weeks on treatment, 2 weeks off treatment (Schedule 4/2); 2 weeks on treatment, 1 week off treatment (Schedule 2/1); and continuous daily dosing (CDD schedule)."2.75A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors. ( Bello, A; Burris, HA; Chao, R; Chiorean, EG; Jones, S; Lee, FC; Liau, KF; Royce, M; Sweeney, CJ; Tye, L; Verschraegen, CF, 2010)
"To evaluate the safety and efficacy of preoperative radiotherapy (RT) in combination with cetuximab, capecitabine, and irinotecan in patients with locally advanced rectal cancer."2.74Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial. ( Barreto-Miranda, M; Dinter, D; Erben, P; Hochhaus, A; Hofheinz, RD; Horisberger, K; Kähler, G; Kienle, P; Mai, S; Post, S; Ströbel, P; Treschl, A; Wenz, F; Willeke, F; Woernle, C, 2009)
"This oxaliplatin combined with ELF regimen shows good efficacy and acceptable safety in advanced gastric cancer patients."2.74[Oxaliplatin combined with ELF regimen in the treatment of patients with advanced gastric cancer]. ( Lou, F; Pan, HM; Zhu, YH, 2009)
"Our results show that the regimen of gemcitabine combined with capecitabine is effective and well tolerated in patients with unresectable relapsed or metastatic carcinoma of the biliary tract."2.73[Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma]. ( Chen, X; Chen, ZS; Li, J; Ouyang, XN; Xie, FW; Yu, ZY, 2008)
" The dosage of chemotherapy was as follows: DOC 60 mg/m(2) on day 1 by infusion over 2 hours; CDGP 20-30 mg/m(2)/day on day 1 to 5 by infusion over 1 hour, and 5-FU 600 mg/m(2)/day on day 1 to 5 by 5 days continuous infusion."2.73[Phase I/II clinical trial of induction chemotherapy with nedaplatin (CDGP), docetaxel (DOC) and 5-fluorouracil (5-FU) for squamous cell carcinoma of head and neck]. ( Iwabuchi, H; Nakayama, S; Uchiyama, K, 2007)
" This study was to evaluate the efficacy of FOLFOX6 regimen on Chinese colorectal cancer patients with liver metastasis, and observe the adverse events."2.73[Efficacy and toxicity of FOLFOX6 regimen in treating colorectal cancer patients with liver metastasis]. ( Chen, G; Ding, PR; Fang, YJ; Li, LR; Lu, ZH; Pan, ZZ; Wan, DS; Wang, GQ; Wu, XJ; Zhou, ZW, 2007)
"2005, 62 patients with stage II-III breast cancer were treated with 2 cycles of either GC regimen or FEC regimen before operation."2.73[Clinical comparison of GC regimen (gemcitabine and cisplatin) versus FEC regimen (fluorouracil, epirubicin, and cyclophosphamide) as neoadjuvant chemotherapy for breast cancer]. ( Cheng, B; Liu, K; Qiu, DB; Wang, GB, 2007)
" In conclusion, capecitabine can safely be combined with docetaxel (40 mg m(-2)) and mitomycin C (4 mg m(-2))."2.73Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial. ( Ernst, T; Gnad-Vogt, U; Hochhaus, A; Hofheinz, RD; Kripp, M; Lukan, N; Merx, K; Schultheis, B, 2007)
"There was a significant difference in adverse effect and toxicity such as naupathia,fever, swirl, asthenia observed between two groups (P < 0."2.73[Study on the efficacy and safety of high dose thymopentin combined with trans-artery chemoembolization for primary liver cancer]. ( Li, T; Li, ZW; Wen, HC, 2007)
" The most frequent common adverse events were nausea, Grades 1 - 2 in 13 patients (81."2.72Chronomodulated chemotherapy with oxaliplatin, 5-FU and sodium folinate in metastatic gastrointestinal cancer patients: original analysis of non-hematological toxicity and patient characteristics in a pilot investigation. ( Farker, K; Hippius, M; Höffken, K; Hoffmann, A; Merkel, U; Wedding, U, 2006)
" Thus, the recommended dosing schedule is level 2."2.72A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer. ( Abe, S; Araki, H; Hareyama, M; Iyama, S; Kato, J; Miyanishi, K; Murase, K; Nagakura, H; Niitsu, Y; Okamoto, T; Sagawa, T; Sato, T; Sato, Y; Takayama, T; Takimoto, R, 2006)
" We thus conducted a phase I/II study of gemcitabine and infusional 5-FU in Japanese patients to determine a recommended dosage for this combination and clarify efficacy and toxicity."2.72A phase I/II study of combination chemotherapy with gemcitabine and 5-fluorouracil for advanced pancreatic cancer. ( Funakoshi, A; Furuse, J; Ishii, H; Okusaka, T; Sumii, T; Ueno, H, 2006)
" A phase I, open-label dose-escalating study was performed to determine the maximum tolerated dose (MTD) of BBR 3464 administered in combination with protracted venous infusional (PVI) 5-fluorouracil (5-FU) for up to six courses in patients with locally advanced and/or metastatic cancer."2.71A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer. ( Bisset, D; Boyle, D; Camboni, G; Cassidy, J; Edwards, C; Gourley, C; Jodrell, D; Samuel, L; Young, A, 2004)
"Grade 2/3 neutropenia was observed in 4 (3%) treatment cycles."2.71Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors. ( Agelaki, S; Amarantidis, K; Androulakis, N; Georgoulias, V; Kakolyris, S; Kouroussis, C; Mavroudis, D; Samonis, G; Souglakos, J; Vardakis, N; Xenidis, N, 2004)
"Capecitabine (Xeloda) is a novel, oral, selectively tumor-activated fluoropyrimidine with proven activity in the treatment of advanced colorectal cancer."2.71A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. ( Cho, JY; Choi, SH; Chung, HC; Han, JY; Hong, YS; Kang, JH; Lee, KS; Lee, SI; Noh, SH; Park, JN; Song, SY, 2004)
"Patients with previously untreated esophageal cancer were eligible if they had performance status 0-1, were 75 years or younger and had adequate organ function."2.71Phase I study of the combination of nedaplatin, adriamycin and 5-fluorouracil for treatment of advanced esophageal cancer. ( Fujitani, K; Hirao, M; Tsujinaka, T, 2004)
"Advanced pancreatic cancer has limited treatment options."2.71Phase II clinical trial of 5-fluorouracil, trimetrexate, and leucovorin (NFL) in patients with advanced pancreatic cancer. ( Baranda, J; Garcia, AA; Leichman, CG; Leichman, L; Lenz, HJ; Pandit, L, 2003)
"Capecitabine was administered in twice daily divided doses, and CI-994 was given as a single daily dose."2.71A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. ( Janisch, L; Kimmel, KA; Kindler, HL; Macek, TA; Olson, SC; Ratain, MJ; Schilsky, RL; Undevia, SD; Vogelzang, NJ, 2004)
"Esophageal cancer has a poor prognosis."2.71[Phase I study of the combination of nedaplatin (NED), adriamycin (ADM), and 5-fluorouracil (5-FU) (NAF) for treatment of unresectable advanced esophageal cancer]. ( Fujitani, K; Hirao, M; Tsujinaka, T, 2005)
"3 mg of ramosetron (RAM) combined with 8 mg of dexamethasone (DEX) and 0."2.71[A randomized crossover study of ramosetron plus dexamethasone for the prevention of nausea and vomiting induced by chemotherapy including cisplatin-comparison of ramosetron combined with 8 mg and 12 mg of dexamethasone]. ( Horiuchi, C; Ikeda, Y; Ishitoya, J; Katori, H; Matsuda, H; Mikami, Y; Taguchi, T; Tanigaki, Y; Tsukuda, M; Yoshida, T, 2005)
"The prognosis of patients with hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is extremely poor."2.70Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. ( Ando, E; Fukumori, K; Kuromatsu, R; Okuda, K; Sata, M; Sumie, S; Tanaka, M; Yamashita, F; Yano, Y; Yutani, S, 2002)
" We investigated the therapeutic and adverse drug reaction of intensive chemotherapy using cisplatin (CDDP), 5-FU and dl-leucovorin (LV) (PFL-therapy), which may be producing dual biochemical modulation effect of 5-FU for advanced colorectal carcinoma."2.70Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer. ( Arai, T; Fukahara, T; Ishikawa, T; Iwai, T; Kuwabara, H; Maruyama, S; Murase, N; Okabe, S; Ootsukasa, S; Tanami, H; Udagawa, M; Yamashita, H, 2002)
"Capecitabine is a novel fluoropyrimidine carbamate, orally administered and selectively activated to fluorouracil by a sequential triple-enzyme pathway in liver and tumor cells."2.70Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy. ( Kramer, G; Locker, GJ; Mader, R; Marberger, M; Rauchenwald, M; Schmidinger, M; Steger, GG; Wenzel, C; Zielinski, CC, 2002)
"The subjects were patients with squamous cell carcinoma of the oral cavity who had not received any therapy, comprising 7 patients with carcinoma of the tongue, 2 with buccal carcinoma, 2 with maxillary gingival carcinoma, and 1 with carcinoma of the oral floor."2.70[Combination chemotherapy with nedaplatin (CDGP) and 5-FU for oral cancer]. ( Ando, T; Fukada, K; Hoshino, M; Kuwazawa, T; Maruoka, Y; Nishihara, N; Ogiuchi, H; Ogiuchi, Y; Okamoto, T, 2002)
", Carlsbad, CA) when administered in combination with 5-fluorouracil (5-FU) and leucovorin (LV)."2.70Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. ( Dorr, FA; Geary, RS; Holmlund, JT; Kindler, HL; Kunkel, K; Mani, S; Ratain, MJ; Rudin, CM, 2002)
"For patients with unresectable gastric cancer registered between July 1994 and September 1995, the following dosage regimen was examined: a drip infusion of cisplatin (CDDP) at 7 mg/m2/day for 5 consecutive days and 2-day withdrawal a week for 3 weeks with concomitant sustained drip infusion of 5-FU at 300 mg/m2/day for 21 days."2.69[A cooperative study on concomitant with low-dose divided administration of cisplatin (CDDP) and sustained drip infusion of 5-fluorouracil (5-FU) for unresectable advanced gastric cancer. Osaka Cisplatin Gastric Cancer Study Group]. ( Ishida, T; Iwanaga, T; Katsu, K; Kobayashi, K; Narahara, H; Okajima, K; Okuno, M; Otani, T; Sowa, M; Taguchi, T; Takami, M; Yamamoto, H; Yasutake, K; Yasutomi, M, 1998)
"To improve survival rate in advanced head and neck cancer, we scheduled 90 patients to receive low dose cisplatin plus 5-fluorouracil regimen as neoadjuvant(NAC), concurrent(CC), adjuvant(AC), and second line chemotherapy (SC) setting."2.69The role of low dose cisplatin plus 5-fluorouracil for treatment of recurrent and/or advanced squamous cell carcinoma of the head and neck. ( Kawada, M; Kitahara, S; Kohno, N; Nakanoboh, M; Shirasaka, T; Tamura, E; Tanabe, T, 2000)
"Patients with a squamous cell carcinoma of the oropharynx for whom curative radiotherapy or surgery was considered feasible were entered in a multicentric randomized trial comparing neoadjuvant chemotherapy followed by loco-regional treatment to the same loco-regional treatment without chemotherapy."2.69Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC). ( Coche-Dequeant, B; De Raucourt, D; Domenge, C; Hill, C; Lefebvre, JL; Luboinski, B; Marandas, P; Rhein, B; Sancho-Garnier, H; Stromboni-Luboinski, M; Wibault, P, 2000)
"N&V and leukopenia were the major side effects."2.68Salvage chemotherapy with PEM and long-CF regimen in CDDP refractory advanced head and neck cancer. ( Ichikawa, G; Inuyama, Y; Kawaida, M; Kohno, N; Ohnuma, T; Shirasaka, T, 1995)
" None of the patients could be administered the initially scheduled dosage of 500 mg/m2 of 5FU."2.68[Combination therapy with interferon-alpha and continuous infusion of 5-fluorouracil for advanced renal cell carcinoma]. ( Hosaka, M; Kubota, Y; Masuda, M; Noguchi, S; Shuin, T; Yao, M, 1995)
"Eleven patients with metastatic renal cell carcinoma received combination therapy with 5-fluorouracil (5-FU), Cisplatin (CDDP) and Interferon alpha-2b (IFN alpha-2b)."2.68[Combination therapy with 5-fluorouracil (5-FU), cisplatin (CDDP) and interferon alpha-2B (IFN alpha-2B) for advanced renal cell carcinoma]. ( Fujinami, K; Ikeda, I; Kondo, I; Miura, T, 1996)
"Therapy for metastatic breast cancer has not improved significantly in recent years."2.68Metastatic breast cancer: treatment with fluorouracil-based combinations. ( Klaassen, U; Seeber, S, 1997)
" Intolerance to single dosing was clearly demonstrated, and only the split dosing was advanced to 500 mg/m2/day."2.68Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil. ( Chan, KK; Groshen, S; Jeffers, S; Leichman, CG; Leichman, L; Muggia, FM; Spicer, D; Wu, X, 1996)
"Vomiting was not consistently related to the excretion of either catecholamine."2.67Delayed chemotherapy-induced nausea is augmented by high levels of endogenous noradrenaline. ( Börjesson, S; Fredrikson, M; Fürst, CJ; Hursti, TJ; Peterson, C; Steineck, G, 1994)
"Fifty patients with advanced breast cancer were treated by high dose cisplatin (DDP) combination chemotherapy during the period of August 1984 to June 1991."2.67[High dose cisplatin combination chemotherapy for advanced breast cancer--a report on 50 cases]. ( Zhou, JC, 1993)
" From the above results, THP in combination with cyclophosphamide and 5-Fluorouracil is comparable to ADR in efficacy and can be regarded as having better safety than ADR for the treatment of breast cancer."2.66[A randomized controlled study of (2'' R)-4'-O-tetrahydropyranyladriamycin and adriamycin in combination with cyclophosphamide and 5-fluorouracil in the treatment of advanced and recurrent breast cancer]. ( Abe, O; Abe, R; Enomoto, K; Fujimoto, M; Iino, Y; Koyama, H; Nomura, Y; Tanaka, T; Tominaga, T, 1986)
"Mitoxantrone (Novantrone), is an anthracenedione which in preclinical studies demonstrated a spectrum of antitumor activity similar to the anthracyclines, but with less cardiotoxicity."2.66Mitoxantrone: an overview of safety and toxicity. ( Bernstein, T; Cartwright, K; Dukart, G; Goldberg, J; Posner, LE, 1985)
"Stomatitis was more frequent on the infusion arm but it was mild and reversible."2.66A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. ( Al-Sarraf, M; Cummings, G; Ensley, JF; Jacobs, J; Kish, JA; Weaver, A, 1985)
"Women with breast carcinoma and four or more involved ipsilateral axillary lymph nodes were randomly assigned to receive an induction course and 2 yr of maintenance chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF, 150 patients), CMF plus vincristine and prednisone (CMFVP, 166 patients), or chemoimmunotherapy with CMF plus the methanol extraction residue of BCG (CMF-MER, 85 patients)."2.65A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer. ( Falkson, G; Falkson, HC; Glidewell, OJ; Henry, PH; Holland, JF; Leone, LA; Perloff, M; Tormey, DC; Weinberg, VE; Weiss, RB, 1983)
"Oral tegafur and I."2.65A comparative study of oral tegafur and intravenous 5-fluorouracil in patients with metastatic colorectal cancer. ( Bedikian, AY; Bodey, GP; Karlin, D; Korinek, J; Stroehlein, J, 1983)
" Weekly oral 5-FU results in comparable response and survival to 5-FU given intravenously, consistent with a relatively low dose-response relationship for 5-FU in breast carcinoma."2.65Treatment of advanced breast carcinoma with 5-fluorouracil: a randomized comparison of two routes of delivery. ( Bateman, JR; Chlebowski, RT; Pugh, RP; Weiner, JM, 1981)
" With the dosage and schedule we used, and in our patient population of largely elderly adults, THC therapy resulted in an overall more unpleasant treatment experience than that noted with prochlorperazine or placebo."2.65Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. ( Creagan, ET; Frytak, S; Moertel, CG; O'Connell, MJ; O'Fallon, JR; Rubin, J; Schutt, AJ; Schwartau, NW, 1979)
"FOLFIRINOX has been one of the first-line options for advanced pancreatic cancer, even though it induces significant adverse effects."2.58The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis. ( Fan, Z; Liu, B; Lu, T; Tong, H, 2018)
"To compare the efficacy and safety of two chemotherapeutic regimens, irinotecan monotherapy or irinotecan in combination with fluoropyrimidines, for patients with advanced CRC when administered in the first or second-line settings."2.53Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer. ( Repana, D; Van Hemelrijck, M; Wardhana, A; Watkins, J; Wulaningsih, W; Yoshuantari, N, 2016)
"Colorectal cancer is one of the most common cancers affecting men and women in the United States."2.43Advanced colorectal cancer: current treatment and nursing management with economic considerations. ( Fung, A; Viale, PH; Zitella, L, 2005)
" Hand-foot syndrome (HFS) is the only clinical adverse event occurring more often during capecitabine treatment."2.42Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda). ( Grothey, A; Marsé, H; Valverde, S; Van Cutsem, E, 2004)
"Advanced pancreatic cancer (APC) disproportionately impacts older adults."1.72Treatment Patterns, Toxicity, and Outcomes of Older Adults With Advanced Pancreatic Cancer Receiving First-line Palliative Chemotherapy. ( Dawe, DE; Kim, CA; Lambert, P; McAndrew, EN; Rittberg, R; Zhang, H, 2022)
"Capecitabine is an oral anticancer drug which can cause some adverse reactions and the great challenge for its use is to ensure the medication adherence."1.72Adverse reactions and adherence to capecitabine: A prospective study in patients with gastrointestinal cancer. ( Barbosa, CR; Cobaxo, TS; de Souza, RN; Dias, LP; Duarte, NC; Lima, CS; Lima, TM; Moriel, P; Pincinato, EC; Tavares, MG; Teixeira, JC; Visacri, MB, 2022)
"The outbreak of coronavirus disease 2019 (COVID-19) has affected the treatment of cancer patients, with particular regard to the management of both chemotherapy and side effects."1.62NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri even during the COVID-19 pandemic: a real-life study. ( Caputo, V; Cicero, G; De Luca, R; Ferrera, G; Mistretta, O; Paci, R; Rosati, G; Volpe, C, 2021)
"Among patients with colorectal cancer (CRC) treated with oxaliplatin (L-OHP)-based chemotherapy, delayed chemotherapy-induced nausea and vomiting (CINV) have not been well controlled."1.62Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk. ( Fukunaga, M; Hayashi, T; Kogawa, T; Matsui, R; Mizuki, F; Nishimura, J; Satoh, T; Shimokawa, M; Tsuji, Y, 2021)
" Given the known sex differences in fluoropyrimidine pharmacokinetics, sex-specific dosing of fluoropyrimidines warrants further investigation."1.62Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database. ( Alberts, SR; Allegra, CJ; Andre, T; Blanke, CD; de Gramont, A; Dixon, JG; Francini, E; George, TJ; Goldberg, RM; Grothey, A; Haller, DG; Kerr, R; Marsoni, S; O'Connell, MJ; Saltz, LB; Seitz, JF; Shi, Q; Taieb, J; Twelves, C; VanCutsem, E; Wagner, AD; Wolmark, N; Yothers, G, 2021)
"Patients with newly diagnosed advanced pancreatic cancer in Saskatchewan, Canada, from 2011 to 2016, who received FOLFIRINOX or GnP were assessed."1.51Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel: A Population-Based Cohort Study. ( Ahmed, S; Chalchal, H; Haider, K; Moser, M; Olson, C; Papneja, N; Shaw, J; Tan, K; Zaidi, A, 2019)
" The frequency and severity of these adverse events vary from patient to patient and are partially explained by genetic polymorphism into the dihydropyrimidine dehydrogenase (DPYD) gene."1.46Fluoropyrimidine-Associated Toxicity in Two Gastrointestinal Cancer Patients: Potential Role of Common DPYD Polymorphisms. ( Cergnul, M; Cheli, S; Falvella, FS; Fava, S; Luoni, M, 2017)
"025) in the toxic group (n = 12) compared to the non-toxic group (n = 19)."1.42Pre-therapy mRNA expression of TNF is associated with regimen-related gastrointestinal toxicity in patients with esophageal cancer: a pilot study. ( Bowen, JM; Game, PA; Hussey, DJ; Irvine, T; Karapetis, CS; Keefe, DM; Kristaly, K; Smith, L; Tan, H; Thompson, SK; Tsykin, A; Watson, DI; White, I, 2015)
"Although hyperammonemia is known as one of the adverse side effects of 5-FU, a disturbance of consciousness caused by hyperammonemia is not a usual finding."1.42[A Case of Consciousness Disturbance Caused by Hyperammonemia during a mFOLFOX6 Regimen for Metastatic Colon Cancer]. ( Egawa, C; Kagawa, Y; Kato, T; Katsura, Y; Murakami, K; Naito, A; Ohmura, Y; Okishiro, M; Takeda, Y; Takeno, A; Tamura, S, 2015)
"Capecitabine is a complex chemotherapeutic agent with many side effects that might affect patient adherence to treatment."1.40Adherence to capecitabine treatment and contributing factors among cancer patients in Malaysia. ( Hassan, NB; Norazwany, Y; Norhayati, I; Norsa'adah, B; Roslan, MH; Wan Nazuha, WR; Zahrina, AK, 2014)
" Grade 3/4 adverse events were: neutropenia (54."1.39Safety and efficacy of modified FOLFOX6 plus high-dose bevacizumab in second-line or later treatment of patients with metastatic colorectal cancer. ( Maruyama, S; Takii, Y, 2013)
"All patients scheduled for breast cancer surgery at Danderyd Hospital, Stockholm, Sweden during 1 year (March 2003-March 2004) were asked to participate in this prospective, observational study."1.39Is there an association between PONV and chemotherapy-induced nausea and vomiting? ( Eksborg, S; Lönnqvist, PA; Öbrink, E; Oddby-Muhrbeck, E; Rotstein, S, 2013)
" Gastro-intestinal adverse events graded according to the WHO criteria were recorded after the first cycle."1.38Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity. ( Bocci, G; Ciccolini, J; Danesi, R; Di Paolo, A; Iliadis, A; Lacarelle, B; Marouani, H; Woloch, C, 2012)
"Colorectal carcinomas are among the most common tumor types and are generally treated with palliative chemotherapy in case of metastatic disease."1.37Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin. ( Peters, GJ; Schneiders, FL; van den Berg, HP; van der Vliet, HJ; Verheul, HM, 2011)
"Three patients (20%) had grade 3-4 dysphagia in weeks 3-4 and were continued on intravenous fluids and pain medications."1.37Toxicity data for preoperative concurrent chemoradiotherapy with oxaliplatin and continuous infusion 5-fluorouracil for locally advanced esophageal cancer. ( Ad, VB; Bar-Ad, V; Both, S; Hwang, WT; Metz, J; O'Dwyer, P; Plastaras, J; Thukral, A, 2011)
"Aprepitant is a very active antiemetic drug for the prevention of delayed nausea and vomiting induced by mFOLFOX6 regimen."1.36[Clinical usefulness of oral aprepitant for alleviation of delayed nausea and vomiting induced by mFOLFOX6--report of a case]. ( Abe, T; Hachiro, Y; Kunimoto, M, 2010)
"While hiccups are usually benign, severe attacks may lead to exhaustion, eating difficulties, and affect quality of life."1.35Severe hiccups during chemotherapy: corticosteroids the likely culprit. ( Gilbar, P; McPherson, I, 2009)
" Thus,we devised a new intermittent dosage regimen utilizing the cell cycle difference of normal GI tract, bone marrow cell and pancreatic cancer cell, making use of 5-FU (-->S-1), CDDP and paclitaxel in March 2002."1.34[The first report from Sapporo Tsukisamu Hospital--chemotherapy and chemoradiotherapy for patients with advanced pancreatic cancer]. ( Hirata, K; Hiyama, S; Inui, N; Kimura, H; Kimura, Y; Koito, K; Shirasaka, T; Yamada, Y; Yamamitsu, S, 2007)
" In May 2002, we devised a new regimen by intermittent dosage of 5-FU (-->S-1), CDDP and paclitaxel utilizing the difference of cell cycle between normal and cancer cells, and thirteen patients with advanced colorectal cancer (Stage IV) were treated with this regimen."1.34[The second report from Sapporo Tsukisamu hospital--chemotherapy for patients with advanced colorectal cancer]. ( Hirata, K; Hiyama, S; Inui, N; Kimura, H; Kimura, Y; Shirasaka, T; Yamada, Y; Yamamitsu, S, 2007)
"The data of 114 breast cancer patients treated with adjuvant dose dense chemotherapy was retrospectively analyzed."1.34[Dose dense chemotherapy in the postoperative adjuvant treatment for breast cancer]. ( Guan, JH; Huan, HY; Mao, F; Sun, Q; Zhou, YD, 2007)
"Pretreatment distress and posttreatment nausea, vomiting, and fatigue were assessed at the 1st, 4th, 6th and last cycles of chemotherapy."1.34Chemotherapy-induced nausea, vomiting, and fatigue--the role of individual differences related to sensory perception and autonomic reactivity. ( Jensen, AB; Johansson, A; Mehlsen, M; Paulsen, K; von der Maase, H; Zachariae, R, 2007)
"The side effect of anticancer agents such as nausea and vomiting frequently interrupt chemotherapy."1.33[Effect of steroid on antiemetic for side effect of anticancer chemotherapy]. ( Matsumoto, T; Mikami, T; Momokawa, K; Nakamura, Y; Sakayauchi, T; Sasaki, T; Watanabe, T, 2005)
" This study was to explore relationship of DPD to serum concentration of 5-FU in colorectal cancer patients treated with FOLFOX6 regimen, and their correlation to treatment response and adverse events."1.33[Relationship of serum level of dihydropyrimidine dehydrogenase and serum concentration of 5-fluorouracil to treatment response and adverse events in colorectal cancer patients]. ( Dong, QM; He, YJ; Li, S; Li, YY; Xia, ZJ; Zhang, L; Zhou, ZM; Zhou, ZW, 2005)
" In patients with Grade 3 or more, leukocytopenia was observed in 7 patients and diarrhea in 1 as adverse events."1.33[Clinical examination of safety and effectiveness of primary chemotherapy with CEF followed by docetaxel in preoperative breast cancer]. ( Dohden, K; Hattori, M; Hayashi, H; Hosokawa, O; Kaizaki, Y; Kiya, T; Morishita, M; Morita, M; Ohta, K, 2006)
"Irinotecan (CPT11) has established activity against advanced colorectal cancer without cross-resistance with 5-fluorouracil + leucovorin-based therapy."1.32Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: a pilot study in Taiwan. ( Chen, PM; Chen, WS; Chiou, TJ; Lin, JK; Liu, JH; Tai, CJ; Wang, WS; Yen, CC, 2003)
"Ten patients with recurrent esophageal cancer were treated with the combination of docetaxel 60 mg/m2 (day 1), CDDP 10 mg/body (days 1-5) and 5-FU 500 mg/body (days 1-5) at intervals of 2-3 weeks."1.32[Preliminary evaluation of chemotherapy with docetaxel, 5-FU, CDDP for recurrent esophageal cancer--a pilot study]. ( Fujita, H; Matono, S; Sasahara, H; Shirouzu, K; Sueyoshi, S; Tanaka, T; Yamana, H, 2003)
"Twenty-four patients with advanced gastric cancer who had been treated by multiple chemotherapy regimens presenting poor responses were allotted."1.32[Oxaliplatin plus capecitabine as a second line chemotherapy for patients with advanced gastric cancer]. ( Chen, YX; He, ZM; Mei, JF; Qian, J; Qin, SK; Shao, ZJ, 2004)
"Transient hypotension was the most common side effect occurring in association with amifostine."1.31Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study. ( Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E, 2001)
"Patients with high risk breast carcinoma were conditioned with high dose carmustine, cisplatin, and cyclophosphamide followed by autologous PSCT."1.30Prolonged nausea and vomiting after high dose chemotherapy and autologous peripheral stem cell transplantation in the treatment of high risk breast carcinoma. ( Chap, L; Hecht, JR; Lembo, T, 1997)
"Twenty-two advanced consecutive thyroid cancer patients with varying histologies were treated with the so called BAP regime which consisted of bleomycin (B) 30 mg a day for three days, adriamycin (A) 60 mg/m2 iv in day 5, and cisplatinum (P) 60 to mg/m2 iv in day 5."1.28Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. ( Busnardo, B; Casara, D; De Besi, P; Fiorentino, MV; Girelli, ME; Nacamulli, D; Simioni, N; Toso, S; Zorat, P, 1991)
"Forty-one patients with bladder cancer and 12 patients with prostatic cancer were evaluated."1.28[Phase II study of 5'-DFUR treatment of the bladder and prostatic cancer]. ( Akebi, N; Josen, T; Kobashi, K; Matsumura, Y; Nanba, K; Nasu, Y; Ochi, J; Ohmori, H; Saika, T; Tanahashi, T, 1991)
"Fifty-two non-resectable and recurrent cancer patients with prior treatment, were entered in this study; 1 esophageal, 33 gastric, 1 duodenal, 4 colorectal, 2 pancreatic, 2 bile duct, and 9 breast cancer."1.28[Combination chemotherapy of CPM-MTX-5-FU in non-resectable and recurrent cancer patients]. ( Hattori, T; Jinushi, K; Kim, R; Niimoto, M; Saeki, K; Saeki, T; Toi, M; Yanagawa, E; Yoshinaka, K, 1989)
"Tegafur was administered orally in two or three divided doses."1.27Phase I evaluation of oral tegafur. ( Bedikian, AY; Bodey, GP; Burgess, MA; Valdivieso, M, 1983)
" Pharmacokinetic study after single oral administration of 300 to 1200 mg of UFT-E was carried out in cancer patients measuring tagafur, uracil and 5-FU levels in serum, normal tissue and tumor tissue using HPLC and GC-mass."1.27[Pharmacokinetics and a phase I study of tegafur-uracil enterogranules in cancer patients]. ( Fujii, S; Hoshino, A; Kamiya, O; Kimura, K; Kojima, T; Nagata, K; Ohara, K; Sugihara, T; Suzuki, M; Yamada, M, 1983)
" Reduced clearance of FU by MISO was associated with an earlier onset of the period of nonlinearity of FU pharmacokinetics and an increased half-life of elimination."1.27Pharmacokinetic rationale for the interaction of 5-fluorouracil and misonidazole in humans. ( Martin, WM; McDermott, BJ; Murphy, RF; Van den Berg, HW, 1983)
"Diphenhydramine was administered intramuscularly 30 minutes before and 5 hours after chemotherapy."1.27[The prevention of CDDP-induced emesis with a combination regimen including metoclopramide, dexamethasone, droperidol and diphenhydramine]. ( Arihiro, T; Dozono, H; Morimoto, O; Ochiai, K; Sasaki, H; Takahashi, S; Terashima, Y; Tsuruoka, M; Yasuda, M; Yokoyama, S, 1987)
"Six patients with an upper gastrointestinal hemorrhage or a small bowel obstruction all had local recurrence."1.27Results in the management of locally unresectable pancreatic carcinoma. ( Parker, RG; Selch, MT, 1986)
"Thirty-six patients with advanced colorectal cancer with unequivocal evidence of progression while treated with fluoropyrimidines were treated with a six-day continuous infusion of 500 mg/m2/d of folinic acid initiated 24 hours before a five-day course of 5-FU administered as an intravenous (IV) bolus of 370 mg/m2/d."1.27High-dose continuous infusion folinic acid and bolus 5-fluorouracil in patients with advanced colorectal cancer: a phase II study. ( Bertrand, M; Blayney, DW; Carr, BI; Cecchi, G; Doroshow, JH; Goldberg, D; Leong, L; Margolin, K; Metter, G; Multhauf, P, 1986)
"Thyroid cancer, nasal cancer and paranasal sinus cancer gave the best results."1.27[Chemotherapy with FT-207 suppository (Futraful Supo) in head and neck cancer--cooperative studies by six medical schools in Kanagawa Prefecture]. ( Hattori, Y; Horiuchi, M; Miyake, H; Murakami, T; Otake, H; Sawaki, S; Takahashi, H; Takeyama, I; Tamamushi, N; Yao, K, 1985)
" Susceptibility to motion sickness appears to be a determinant of the side effects of cancer chemotherapy that may prove useful as a clinical marker of those patients who may require more intensive side effect management."1.27The effect of a susceptibility to motion sickness on the side effects of cancer chemotherapy. ( Morrow, GR, 1985)
"Sixteen patients with advanced colo-rectal cancer were treated with the combination methyl-CCNU, vincristin, 5-fluorouracil and streptozotocin (MOF-Strepto)."1.26[The combination methyl-CCNU, vincristine, 5-fluorouracil and streptozotocin in the treatment of advanced colo-rectal adenocarcinoma]. ( Cavalli, F; Sessa, C; Togni, P; Varini, M, 1982)

Research

Studies (367)

TimeframeStudies, this research(%)All Research%
pre-199087 (23.71)18.7374
1990's70 (19.07)18.2507
2000's101 (27.52)29.6817
2010's93 (25.34)24.3611
2020's16 (4.36)2.80

Authors

AuthorsStudies
De Luca, R1
Volpe, C1
Mistretta, O1
Paci, R1
Ferrera, G1
Caputo, V1
Rosati, G1
Cicero, G1
Shimokawa, M1
Hayashi, T2
Nishimura, J2
Satoh, T2
Fukunaga, M2
Matsui, R1
Tsuji, Y1
Mizuki, F1
Kogawa, T1
McAndrew, EN1
Zhang, H1
Lambert, P1
Rittberg, R1
Dawe, DE1
Kim, CA1
De Francia, S1
Berchialla, P1
Armando, T1
Storto, S1
Allegra, S1
Sciannameo, V1
Soave, G1
Sprio, AE1
Racca, S1
Caiaffa, MR1
Ciuffreda, L1
Mussa, MV1
Kim, G1
Cockrum, P1
Surinach, A1
Wang, S1
Wainberg, Z1
Oliva, D1
Andersson, BÅ1
Shamoun, L1
Lewin, N1
Nilsson, MP1
Schildt, EB1
Fust, L1
Åsenlund, U1
Sellerstam, G1
Elinder, E1
Sharp, L1
Lewin, F1
Marmorino, F1
Rossini, D1
Lonardi, S1
Moretto, R1
Zucchelli, G1
Aprile, G1
Dell'Aquila, E1
Ratti, M1
Bergamo, F1
Masi, G2
Urbano, F1
Ronzoni, M1
Libertini, M1
Borelli, B1
Randon, G1
Buonadonna, A1
Allegrini, G2
Pella, N1
Ricci, V1
Boccaccino, A1
Latiano, TP2
Cordio, S2
Passardi, A1
Tamburini, E1
Boni, L1
Falcone, A2
Cremolini, C1
Maiello, E2
Di Maggio, G1
Cinieri, S1
Giuliani, F1
Pisconti, S1
Rinaldi, A1
Febbraro, A1
Aieta, M1
Rossi, A1
Rizzi, D1
Di Maio, M1
Colucci, G1
Bordonaro, R2
Matsumoto, K1
Takahashi, M2
Sato, K1
Osaki, A1
Takano, T1
Naito, Y1
Matsuura, K1
Aogi, K2
Fujiwara, K1
Tamura, K1
Baba, M1
Tokunaga, S3
Hirano, G1
Imoto, S2
Miyazaki, C1
Yanagihara, K1
Imamura, CK1
Chiba, Y1
Saeki, T2
Loi, M1
Magallon-Baro, A1
Suker, M1
Van Eijck, C1
Hoogeman, M1
Nuyttens, JJ1
Park, H1
Jin, RU1
Wang-Gillam, A1
Suresh, R1
Rigden, C1
Amin, M1
Tan, BR1
Pedersen, KS1
Lim, KH1
Trikalinos, NA1
Acharya, A1
Copsey, ML1
Navo, KA1
Morton, AE1
Gao, F1
Lockhart, AC1
Wagner, AD1
Grothey, A2
Andre, T2
Dixon, JG1
Wolmark, N1
Haller, DG1
Allegra, CJ1
de Gramont, A3
VanCutsem, E1
Alberts, SR2
George, TJ1
O'Connell, MJ3
Twelves, C1
Taieb, J1
Saltz, LB1
Blanke, CD2
Francini, E1
Kerr, R1
Yothers, G1
Seitz, JF1
Marsoni, S2
Goldberg, RM3
Shi, Q2
Visacri, MB1
Duarte, NC1
Lima, TM1
de Souza, RN1
Cobaxo, TS1
Teixeira, JC1
Barbosa, CR1
Dias, LP1
Tavares, MG1
Pincinato, EC1
Lima, CS1
Moriel, P1
Wang, DS1
Hu, MT1
Wang, ZQ2
Ren, C1
Qiu, MZ1
Luo, HY2
Jin, Y1
Fong, WP1
Wang, SB1
Peng, JW1
Zou, QF1
Tan, Q1
Wang, FH2
Li, YH4
Mie, T1
Sasaki, T3
Takeda, T1
Fukuda, K1
Furukawa, T2
Yamada, Y5
Kasuga, A1
Matsuyama, M1
Ozaka, M1
Sasahira, N1
Chang, TK1
Yin, TC1
Su, WC1
Tsai, HL1
Huang, CW1
Chen, YC1
Li, CC1
Chen, PJ1
Ma, CJ1
Chuang, KH1
Cheng, TL1
Wang, JY1
Caron, B1
Reimund, JM1
Ben Abdelghani, M1
Sondag, D1
Noirclerc, M1
Duclos, B1
Kurtz, JE1
Nguimpi-Tambou, M1
Fang, M1
Song, T1
Liang, X1
Lv, S1
Li, J7
Xu, H1
Luo, L1
Jia, Y1
Falvella, FS1
Luoni, M1
Cheli, S1
Fava, S1
Cergnul, M1
Uchiyama, K3
Yamada, M3
Shiiba, Y1
Kasazaki, S1
Suga, K1
Iwabuchi, H3
Asoda, S1
Uehara, K1
Chao, YL1
Anders, CK1
Bubalo, JS1
Herrington, JD1
Takemoto, M1
Willman, P1
Edwards, MS1
Williams, C1
Fisher, A1
Palumbo, A1
Chen, E1
Blanke, C1
Lopez, CD1
Liu, GY1
Lv, X1
Wu, YS1
Mao, MJ1
Ye, YF1
Yu, YH1
Liang, H1
Yang, J1
Ke, LR1
Qiu, WZ1
Huang, XJ1
Li, WZ1
Guo, X1
Xiang, YQ1
Xia, WX2
Tong, H1
Fan, Z1
Liu, B1
Lu, T1
Deng, B1
Jia, L1
Tan, H2
Lou, Y1
Li, X1
Li, Y3
Yu, L1
Narjoux, G1
Clarenne, J1
Azzouz, B1
Zeller, PS1
Slimano, F1
Bouché, O1
Abdel-Rahman, O1
Papneja, N1
Zaidi, A1
Chalchal, H1
Moser, M1
Tan, K1
Olson, C1
Haider, K1
Shaw, J1
Ahmed, S1
Riechelmann, RP1
Srimuninnimit, V1
Kavan, P1
Di Bartolomeo, M1
Cicin, I1
García-Alfonso, P2
Chau, I2
Fedyanin, MY1
Martos, CF1
Ter-Ovanesov, M1
Peeters, M1
Ko, YJ1
Yalcin, S1
Karthaus, M1
Aparicio, J1
Heinemann, V1
Picard, P1
Bury, D1
Drea, E1
Sobrero, A2
Neely, D1
Ong, J1
Patterson, J1
Kirkpatrick, D1
Skelly, R1
Pacetti, U1
Veltri, E1
Fattoruso, SI1
Cardillo, FD1
Evangelista, S1
Cognetti, F1
Fabi, A1
Koch, S1
Wein, A2
Siebler, J2
Boxberger, F1
Neurath, MF1
Harich, HD1
Hohenberger, W2
Dörje, F1
Meng, J2
Gu, QP1
Meng, QF1
Zhang, J1
Li, ZP1
Si, YM1
Guo, W2
Zhuang, QW1
Ejlertsen, B1
Jensen, MB1
Elversang, J1
Rasmussen, BB1
Andersson, M1
Andersen, J1
Nielsen, DL1
Cold, S1
Mouridsen, HT2
Huang, D1
Ba, Y1
Xiong, J1
Xu, N4
Yan, Z1
Zhuang, Z1
Yu, Z2
Wan, H1
Zhang, Y2
Deng, T1
Zheng, R1
Guo, Z1
Hu, C1
Wang, M1
Yao, Y2
Takii, Y1
Maruyama, S3
Martin, M2
Bonneterre, J4
Geyer, CE2
Ito, Y1
Ro, J1
Lang, I1
Kim, SB1
Germa, C1
Vermette, J1
Wang, K2
Awada, A2
Silvestris, N1
Brunetti, AE1
Russano, M1
Nardulli, P1
Shen, L2
Xu, JM1
Feng, FY2
Jiao, SC1
Wang, LW1
Guan, ZZ3
Qin, SK2
Wang, JJ1
Yu, SY1
Wang, YJ1
Jin, YN1
Tao, M1
Zheng, LZ1
Pan, LX2
Yamashita, H2
Omori, M1
Okuma, K2
Kobayashi, R1
Igaki, H1
Nakagawa, K1
Likhacheva, A1
Jhingran, A1
Bodurka, DC1
Sun, C1
Sam, M1
Eifel, PJ1
Tomasello, G1
Liguigli, W1
Poli, R1
Lazzarelli, S1
Brighenti, M1
Negri, F1
Curti, A1
Martinotti, M1
Olivetti, L1
Rovatti, M1
Donati, G1
Passalacqua, R1
Kajiura, S1
Hosokawa, A2
Yoshita, H1
Ueda, Y1
Ueda, A1
Mihara, H1
Ando, T3
Fujinami, H1
Nishikawa, J1
Ogawa, K1
Minemura, M1
Sugiyama, T1
Gozzo, Tde O1
Moysés, AM1
da Silva, PR1
de Almeida, AM1
Woo, SM1
Lee, WJ1
Kim, JH3
Kim, DH1
Han, SS1
Park, SJ2
Kim, TH1
Lee, JH2
Koh, YH1
Hong, EK1
Suenaga, M1
Fuse, N1
Yamaguchi, T1
Yamanaka, Y1
Motomura, S1
Matsumoto, H1
Hamamoto, Y2
Mizunuma, N2
Doi, T3
Hatake, K1
Iwasaki, J1
Ohtsu, A2
Liu, Y1
Wu, W2
Hong, W1
Sun, X1
Wu, J1
Huang, Q1
Roxburgh, P1
Lumsden, GR1
Paul, J1
Harden, S1
Sweeting, L1
James, A1
Crellin, A1
Morrison, R1
Evans, TR1
McDonald, AC1
Bayoglu, IV1
Varol, U1
Yildiz, I1
Muslu, U1
Alacacioglu, A1
Kucukzeybek, Y1
Akyol, M1
Demir, L1
Dirican, A1
Cokmert, S1
Yildiz, Y1
Karabulut, B1
Uslu, R1
Tarhan, MO1
Soveri, LM1
Hermunen, K1
Poussa, T1
Quinaux, E2
Bono, P1
Österlund, P1
Lee, AM1
Pavey, E1
Sargent, DJ2
Sinicrope, FA1
Berenberg, JL1
Diasio, RB1
Zahrina, AK1
Norsa'adah, B1
Hassan, NB1
Norazwany, Y1
Norhayati, I1
Roslan, MH1
Wan Nazuha, WR1
Kim, JE2
Hong, YS3
Lee, JL1
Kim, KP2
Sym, SJ1
Shin, DB2
Lee, J3
Park, YS2
Ahn, JS1
Kim, TW2
Namikawa, T1
Munekage, E1
Maeda, H1
Kitagawa, H1
Kobayashi, M1
Hanazaki, K1
Ishimaru, K1
Takano, A1
Katsura, M1
Yamaguchi, N1
Kaneko, K1
Takahashi, H2
Krop, IE1
Suter, TM1
Dang, CT1
Dirix, L1
Romieu, G1
Zamagni, C1
Citron, ML1
Campone, M1
Smitt, M1
Gianni, L1
Bowen, JM1
White, I1
Smith, L1
Tsykin, A1
Kristaly, K1
Thompson, SK1
Karapetis, CS1
Game, PA1
Irvine, T1
Hussey, DJ1
Watson, DI1
Keefe, DM1
Takemoto, H1
Nakata, K1
Ide, Y1
Fukuzaki, T1
Kudo, T1
Miyake, Y2
Yasui, M1
Morita, S2
Sakai, D1
Uemura, M1
Hata, T1
Takemasa, I1
Mizushima, T1
Ohno, Y3
Yamamoto, H3
Sekimoto, M1
Nezu, R1
Doki, Y1
Mori, M2
Miwa, K1
Oki, E2
Emi, Y2
Saeki, H2
Kusumoto, T1
Akagi, Y2
Ogata, Y2
Samura, H1
Ishikawa, H2
Tanaka, T5
Sueyoshi, S2
Higashi, H1
Matsuda, H3
Touyama, T1
Maehara, Y3
Ko, AH1
LoConte, N1
Tempero, MA1
Walker, EJ1
Kate Kelley, R1
Lewis, S1
Chang, WC1
Kantoff, E1
Vannier, MW1
Catenacci, DV1
Venook, AP1
Kindler, HL3
Arslan, M1
Ozdemir, L1
Komatsu, S1
Souma, T1
Onizawa, K1
Yasui, T1
Nakayama, S2
McRee, AJ1
Sanoff, HK1
Carlson, C1
Ivanova, A1
O'Neil, BH1
Kagawa, Y1
Kato, T1
Naito, A1
Murakami, K1
Katsura, Y1
Ohmura, Y1
Okishiro, M1
Takeno, A1
Egawa, C1
Takeda, Y1
Tamura, S1
Bi, T1
Jin, F1
Long, J1
Gong, X1
Luo, X1
Li, Z1
He, Q1
Qu, B1
Tebbutt, NC1
Price, TJ1
Ferraro, DA1
Wong, N1
Veillard, AS1
Hall, M1
Sjoquist, KM1
Pavlakis, N1
Strickland, A1
Varma, SC1
Cooray, P1
Young, R1
Underhill, C1
Shannon, JA1
Ganju, V1
Gebski, V1
Wulaningsih, W1
Wardhana, A1
Watkins, J1
Yoshuantari, N1
Repana, D1
Van Hemelrijck, M1
Zhao, L1
Liu, R1
Zhang, Z1
Li, T2
Li, F1
Liu, H1
Li, G1
Nakata, Y1
Ijichi, K1
Hanai, N1
Nishikawa, D1
Suzuki, H1
Hirakawa, H1
Kodaira, T1
Fujimoto, Y1
Fujii, T1
Miyazaki, T1
Shimizu, T2
Hasegawa, Y1
Kim, JW1
Lee, KW1
Kim, SY1
Park, SR1
Nam, BH1
Cho, SH2
Chung, IJ2
Oh, HS1
Lee, MA1
Kang, HJ1
Park, YI1
Song, EK1
Han, HS1
Lee, KT1
Kang, JH2
Zang, DY1
Nomura, H1
Kawakami, H1
Nagai, S1
Shinohara, T1
Isaka, H1
Yu, ZY1
Ouyang, XN1
Chen, ZS1
Chen, X1
Xie, FW1
Huang, HQ1
Cai, QQ1
Lin, XB1
Wang, AL1
Bu, Q1
Hu, XH2
Pan, ZH1
Shuang, YR1
Kim, K2
Chie, EK1
Jang, JY1
Kim, SW1
Oh, DY1
Im, SA1
Kim, TY1
Bang, YJ1
Ha, SW1
Horisberger, K1
Treschl, A1
Mai, S1
Barreto-Miranda, M1
Kienle, P1
Ströbel, P1
Erben, P1
Woernle, C1
Dinter, D1
Kähler, G1
Hochhaus, A2
Post, S1
Willeke, F1
Wenz, F1
Hofheinz, RD2
Kiba, T1
Oikawa, M1
Hokkoku, K1
Watanabe, Y1
Nakagawa, T1
Shintaku, K1
Yoshimitsu, Y1
Sakuma, H1
Ueda, H1
Nakai, M1
Gilbar, P1
McPherson, I1
Skof, E1
Rebersek, M1
Hlebanja, Z1
Ocvirk, J1
Lou, F1
Zhu, YH1
Pan, HM1
Lorenzen, S1
Schuster, T1
Porschen, R1
Al-Batran, SE1
Hofheinz, R1
Thuss-Patience, P1
Moehler, M2
Grabowski, P1
Arnold, D1
Greten, T1
Müller, L1
Röthling, N1
Peschel, C1
Langer, R1
Lordick, F1
Orphanos, G1
Alexopoulos, A1
Malliou, S1
Ioannidis, G1
Ardavanis, A1
Kandylis, C1
Stavrakakis, J1
Rigatos, G1
Zhang, DS1
Feng, F1
Zhang, L4
Xu, RH3
Jiang, WQ3
He, YJ3
Bae, WK1
Hwang, JE1
Shim, HJ1
Lee, JK1
Lim, SC1
Chung, WK1
Lu, M1
Zhang, XD1
Bao, HY1
Fang, WJ1
Zhang, XC1
Shi, GM1
Huang, S1
Yu, LF1
Chen, J1
Mou, HB1
Deng, J1
Shen, P1
Kong, L1
Zhang, YW1
Hu, CS1
Guo, Y1
Wu, F1
Chen, SC1
Lu, ZH2
Xiong, JP2
Boku, N3
Kato, K2
Komatsu, Y2
Yamaguchi, K1
Muro, K5
Sato, A1
Koizumi, W1
Takiuchi, H1
Schneiders, FL1
van den Berg, HP1
Peters, GJ1
Verheul, HM1
van der Vliet, HJ1
Rades, D1
Kronemann, S1
Meyners, T1
Bohlen, G1
Tribius, S1
Kazic, N1
Schroeder, U1
Hakim, SG1
Schild, SE1
Dunst, J1
Sweeney, CJ1
Chiorean, EG1
Verschraegen, CF1
Lee, FC1
Jones, S1
Royce, M2
Tye, L1
Liau, KF1
Bello, A1
Chao, R1
Burris, HA1
Malik, I1
Bernal, P1
Byrd, J1
Chon, YE1
Seong, J1
Kim, BK1
Cha, J1
Kim, SU1
Park, JY2
Ahn, SH2
Han, KH2
Chon, CY2
Shin, SK1
Kim, DY1
Bastani, P1
Ahmad Kiadaliri, A1
Thukral, A1
Metz, J1
Hwang, WT1
O'Dwyer, P1
Plastaras, J1
Both, S1
Bar-Ad, V1
Ad, VB1
Abe, T2
Hachiro, Y1
Kunimoto, M1
Gallerani, E1
Bauer, J2
Hess, D1
Boehm, S1
Droege, C1
Jeckelmann, S1
Miani, M1
Herrmann, R1
Sperka, S1
Sessa, C2
Hesketh, PJ1
Sanz-Altamira, P1
Bushey, J1
Hesketh, AM1
Cao, KJ1
Zhang, AL1
Ma, WJ1
Huang, PY1
Luo, DH1
Li, JH1
Li, B1
Jiang, HR1
Zhong, MZ1
Winterhalder, R1
Hoesli, P1
Delmore, G1
Pederiva, S1
Bressoud, A1
Hermann, F1
von Moos, R1
Bot, BM1
Thomas, DM1
Bleyer, A1
Kohne, CH2
Seymour, MT1
Tagashira, H1
Matsuhisa, T1
Oze, I1
Kiyoto, S1
Hara, F1
Takabatake, D1
Takashima, S3
Osumi, S1
Eguchi, H1
Sato, Y3
Tatematsu, M2
Ishikawa, K1
Okamoto, H2
Noma, H3
Chakravarty, T1
Crane, CH1
Ajani, JA2
Mansfield, PF1
Briere, TM1
Beddar, AS1
Mok, H1
Reed, VK1
Krishnan, S1
Delclos, ME1
Das, P1
Kim, YJ1
Goh, PG1
Kim, ES1
Lee, SY1
Moon, HS1
Lee, ES1
Sung, JK1
Kim, SH3
Lee, BS1
Jeong, HY1
Kadoyama, K1
Miki, I1
Tamura, T1
Brown, JB1
Sakaeda, T1
Okuno, Y1
Xiang, XJ1
Qiu, F1
Yu, F1
Zhan, ZY1
Feng, M1
Yan, J1
Zhao, JG1
Oshiro, C1
Kamigaki, S1
Nakamura, Y2
Arai, T2
Kanai, Y1
Fujino, M1
Fujii, C1
Hamaguchi, Y1
Iseki, C1
Hachino, Y1
Furukawa, H1
Chang, KJ1
Reid, T1
Senzer, N1
Swisher, S1
Pinto, H1
Hanna, N1
Chak, A1
Soetikno, R1
Blazer, M1
Phillips, G1
Reardon, J1
Efries, D1
Smith, Y1
Weatherby, L1
Juergens, K1
Rose, J1
Griffith, N1
Bekaii-Saab, T1
Qi, WX1
Tang, LN1
He, AN1
Shen, Z1
Hayakawa, Y1
Flaherty, AM1
Woloch, C1
Di Paolo, A2
Marouani, H1
Bocci, G1
Ciccolini, J1
Lacarelle, B1
Danesi, R2
Iliadis, A1
Schwartzman, AD1
Sethi, R1
Smith, R1
Zhong, LP1
Zhang, CP1
Ren, GX1
William, WN1
Sun, J1
Zhu, HG1
Tu, WY1
Cai, YL1
Wang, LZ1
Fan, XD1
Wang, ZH1
Hu, YJ1
Ji, T1
Yang, WJ1
Ye, WM1
He, Y1
Wang, YA1
Xu, LQ1
Wang, BS1
Kies, MS1
Lee, JJ1
Myers, JN1
Zhang, ZY1
Oddby-Muhrbeck, E1
Öbrink, E1
Eksborg, S1
Rotstein, S2
Lönnqvist, PA1
Nakatsumi, H1
Yuki, S1
Sogabe, S1
Tateyama, M1
Muto, S1
Kudo, M1
Miyagishima, T1
Uebayashi, M1
Meguro, T1
Oba, K1
Asaka, M1
Sadanaga, N1
Kakeji, Y1
Baba, H1
Nishimaki, T1
Natsugoe, S1
Shirouzu, K2
Uncu, D1
Aksoy, S1
Çetin, B1
Yetişyiğit, T1
Özdemir, N1
Berk, V1
Dane, F1
Inal, A1
Harputluoğlu, H1
Budakoğlu, B1
Koca, D1
Sevinç, A1
Cihan, S1
Durnalı, AG1
Özkan, M1
Öztürk, MA1
Işıkdoğan, A1
Büyükberber, S1
Benekli, M1
Köş, T1
Alkış, N1
Karaca, H1
Turhal, NS1
Zengin, N1
Ando, E3
Tanaka, M3
Yamashita, F3
Kuromatsu, R1
Yutani, S1
Fukumori, K2
Sumie, S1
Yano, Y2
Okuda, K1
Sata, M2
Francini, G1
Petrioli, R1
Messinese, S1
Pozzessere, D1
Marsili, S1
Correale, P1
Sabatino, M1
Fiaschi, AI1
Carlomagno, C1
Lauria, R1
De Laurentiis, M1
Arpino, G1
Massarelli, E1
Ferrara, C1
Milano, A1
Vernaglia Lombardi, A1
Costanzo, R1
Catalano, G1
Bianco, AR1
De Placido, S1
Calvo, E1
Cortés, J1
González-Cao, M1
Rodríguez, J1
Aramendía, JM1
Fernández-Hidalgo, O1
Martín-Algarra, S1
Salgado, JE1
Martínez-Monge, R1
de Irala, J1
Brugarolas, A1
Liaw, CC1
Chang, HK1
Liau, CT1
Huang, JS1
Lin, YC2
Chen, JS1
Okabe, S1
Ishikawa, T1
Tanami, H1
Kuwabara, H1
Fukahara, T1
Udagawa, M1
Ootsukasa, S1
Murase, N1
Iwai, T1
Shimada, Y2
Matsumura, Y2
Fujita, S1
Akasu, T1
Moriya, Y1
Shirao, K3
Tai, CJ1
Liu, JH1
Chen, WS1
Lin, JK1
Wang, WS1
Yen, CC1
Chiou, TJ1
Chen, PM1
HARTMANN, JR1
ORIGENES, ML1
MURPHY, ML1
SITARZ, A1
ERLANDSON, M1
CUDMORE, JT1
GROESBECK, HP1
SCHELL, HW1
MOERTEL, CG7
REITEMEIER, RJ4
HAHN, RG4
TOURNEUR, R1
GRIVAUX, M1
LAMOTTE-BARRILLON, S1
MCCAFFERY, JF1
Stickel, F1
Jüngert, B1
Brueckl, V1
Schirner, I1
Brueckl, WM1
Männlein, G1
Hegewald, J1
Mühldorfer, S1
Bittorf, B1
Hahn, EG1
Ura, T1
Gourley, C1
Cassidy, J1
Edwards, C1
Samuel, L1
Bisset, D1
Camboni, G1
Young, A1
Boyle, D1
Jodrell, D1
Sasahara, H1
Matono, S1
Yamana, H1
Fujita, H1
Pusztai, L1
Mendoza, TR1
Reuben, JM1
Martinez, MM1
Willey, JS1
Lara, J1
Syed, A1
Fritsche, HA1
Bruera, E1
Booser, D1
Valero, V2
Arun, B2
Ibrahim, N1
Rivera, E2
Cleeland, CS1
Hortobagyi, GN5
Barbara, C1
Cupini, S1
Del Tacca, M1
Schrijvers, D1
Van Herpen, C1
Kerger, J1
Joosens, E1
Van Laer, C1
Van den Weyngaert, D1
Nguyen, H1
Le Bouder, C1
Castelijns, JA1
Kaanders, J1
De Mulder, P1
Vermorken, JB1
Cals, L1
Rixe, O1
François, E1
Favre, R1
Merad, L1
Deplanque, G1
Laadem, A1
Juin, P1
Bereder, JM1
Bernardini, D1
Herait, P1
Kakolyris, S2
Souglakos, J1
Kouroussis, C2
Androulakis, N1
Samonis, G1
Vardakis, N1
Amarantidis, K1
Agelaki, S1
Mavroudis, D1
Xenidis, N1
Georgoulias, V2
Kuehr, T1
Ruff, P1
Rapoport, BL1
Falk, S1
Daniel, F1
Jacobs, C1
Davidson, N1
Thaler, J1
Boussard, B1
Carmichael, J1
Teufel, A1
Steinmann, S1
Zanke, C1
Hohl, H1
Adami, B1
Schroeder, M1
Klein, O1
Höhler, T1
Galle, PR1
Heike, M1
Lu, JW1
Gao, CM1
Wu, JZ1
Sun, XF1
Wang, L1
Feng, JF1
Song, SY1
Lee, SI1
Chung, HC1
Choi, SH1
Noh, SH1
Park, JN1
Han, JY1
Lee, KS1
Cho, JY1
Marsé, H1
Van Cutsem, E1
Valverde, S1
Hirao, M2
Fujitani, K2
Tsujinaka, T2
Garcia, AA1
Leichman, L2
Baranda, J1
Pandit, L1
Lenz, HJ1
Leichman, CG2
Undevia, SD1
Janisch, L1
Olson, SC1
Schilsky, RL1
Vogelzang, NJ1
Kimmel, KA1
Macek, TA1
Ratain, MJ2
Ishida, K1
Ando, N1
Yamamoto, S1
Ide, H1
Shinoda, M1
Schena, M1
Barone, C1
Birocco, N1
Dongiovanni, D1
Numico, G1
Colantonio, I1
Bertetto, O1
Qian, J1
Mei, JF1
Chen, YX1
Shao, ZJ1
He, ZM1
Momokawa, K1
Sakayauchi, T1
Watanabe, T2
Mikami, T1
Matsumoto, T1
Dong, QM1
Li, S1
Zhou, ZM1
Zhou, ZW2
Xia, ZJ1
Li, YY1
Steiner, M1
Seule, M1
Steiner, B1
Bauer, I1
Freund, M1
Schuff-Werner, P1
Kotake, K1
Ohashi, Y1
Kodaira, S1
Koyama, Y1
Suzuki, S1
Harada, N1
Takeo, Y1
Tanaka, S1
Suzuki, M2
Hanyu, F1
Tsai, JY1
Iannitti, D1
Berkenblit, A1
Akerman, P1
Nadeem, A1
Rathore, R1
Harrington, D1
Roye, D1
Miner, T1
Barnett, JM1
Maia, C1
Stuart, K1
Safran, H1
Lee, KE1
Im, YH1
Kang, WK1
Park, K1
Shim, YM1
Ito, T1
Hata, Y1
Matsuoka, S1
Nakajima, N1
Yokoyama, R1
Honda, S1
Sano, F1
Akasaka, Y1
Ohmori, K1
Viale, PH1
Fung, A1
Zitella, L1
Ferrari, V1
Valcamonico, F1
Amoroso, V1
Simoncini, E1
Vassalli, L1
Marpicati, P1
Rangoni, G1
Grisanti, S1
Pasinetti, N1
Marini, G1
Tanigaki, Y1
Mikami, Y1
Horiuchi, C1
Taguchi, T4
Yoshida, T1
Ishitoya, J1
Katori, H1
Ikeda, Y1
Tsukuda, M2
Farker, K1
Merkel, U1
Wedding, U1
Hippius, M1
Höffken, K1
Hoffmann, A1
Takayama, T1
Sagawa, T1
Okamoto, T2
Miyanishi, K1
Sato, T1
Araki, H1
Iyama, S1
Abe, S1
Murase, K1
Takimoto, R1
Nagakura, H1
Hareyama, M1
Kato, J1
Niitsu, Y1
Ohta, K1
Dohden, K1
Morishita, M1
Hayashi, H1
Hattori, M1
Hosokawa, O1
Morita, M1
Kaizaki, Y1
Kiya, T1
Miyata, Y1
Muto, M1
Hamaguchi, T1
Mera, K1
Yano, T1
Tanigawara, Y1
Okusaka, T1
Ishii, H1
Funakoshi, A1
Ueno, H1
Furuse, J1
Sumii, T1
Zhang, P1
Wu, LY1
Hu, Y1
Liu, JW1
Gao, YJ1
Guan, XQ1
Nan, KJ1
Suo, AL1
Wang, XW1
Zhang, MH1
Zhang, WD1
Li, CW1
Zhao, JB1
Meyers, C1
Groves, M1
Francis, D1
Broglio, K1
Yin, G1
Buchholz, T1
Berg, DT1
Jiang, Y1
Qiu, XH1
Yang, YX1
Zhang, SQ1
Chen, ZM1
Shi, YX2
Huang, H1
Ma, ZY1
Wang, JH1
Xie, WM1
Li, XG1
Liu, YL1
Dai, AD1
Zhuang, W1
Zhang, C1
Zhang, W1
Zhao, ZY1
Wu, Q1
Cheng, J1
Wu, CP1
Xu, LG1
Wang, GQ1
Wan, DS1
Pan, ZZ1
Chen, G1
Fang, YJ1
Wu, XJ1
Li, LR1
Ding, PR1
Liu, K1
Wang, GB1
Cheng, B1
Qiu, DB1
Iwasaki, Y1
Shiraha, H1
Sakaguchi, K1
Shiratori, Y1
Maruoka, Y2
Ogiuchi, Y2
Ogiuchi, H2
Yoon, YJ1
Kim, JK1
Lee, HW1
Lee, DY1
Moon, YM1
Yamamitsu, S2
Kimura, H2
Inui, N2
Hiyama, S2
Hirata, K2
Kimura, Y2
Koito, K1
Shirasaka, T5
Wang, F1
Yoshino, T1
Onozawa, Y1
Hironaka, S1
Fukutomi, A1
Yamaguchi, Y2
Hasuike, N1
Yamazaki, K1
Machida, N1
Ono, H2
Zhou, YD1
Sun, Q1
Huan, HY1
Mao, F1
Guan, JH1
Zachariae, R1
Paulsen, K1
Mehlsen, M1
Jensen, AB1
Johansson, A1
von der Maase, H1
Kim, SG1
Oh, SY2
Kwon, HC2
Lee, S2
Kim, HJ2
Ernst, T1
Merx, K1
Gnad-Vogt, U1
Lukan, N1
Kripp, M1
Schultheis, B1
Lee, DM1
Yoo, HS1
Jang, JS1
Kim, MC1
Jeong, JS1
Li, ZW1
Wen, HC1
Benz, C1
Tillis, T1
Tattelman, E1
Cadman, E1
Habeshaw, T1
Adam, JS1
Kirk, J1
Kemeny, NE1
Ahmed, T1
Michaelson, RA1
Harper, HD1
Yip, LC1
Togni, P1
Varini, M1
Cavalli, F2
Legha, SS2
Blumenschein, GR4
Buzdar, AU4
Tormey, DC4
Weinberg, VE1
Holland, JF1
Weiss, RB1
Glidewell, OJ1
Perloff, M1
Falkson, G3
Falkson, HC2
Henry, PH1
Leone, LA1
Vogel, CL1
Smalley, RV1
Raney, M1
Krauss, S1
Carpenter, J1
Velez-Garcia, E1
Fishkin, E1
Raab, S1
Moore, MR1
Stagg, M1
Bedikian, AY2
Stroehlein, J1
Korinek, J1
Karlin, D1
Bodey, GP3
Valdivieso, M2
Burgess, MA1
Kamiya, O1
Hoshino, A1
Ohara, K1
Nagata, K1
Kojima, T1
Sugihara, T1
Kimura, K1
Fujii, S1
Ansfield, FJ2
Kallas, GJ1
Singson, JP1
Logothetis, CJ1
Samuels, ML1
von Eschenbach, AC1
Trindade, A1
Ogden, S1
Grant, C1
Johnson, DE1
Bukowski, RM2
Abderhalden, RT1
Hewlett, JS1
Weick, JK1
Groppe, CW1
Pinnamaneni, K1
Yap, HY3
Distefano, A1
David, M1
Durand, M1
Chauvergne, J1
Mauriac, L1
Bui, BN1
Hoerni, B1
Aboud, A1
Shildt, RA1
Kennedy, PS1
Chen, TT1
Athens, JW1
O'Bryan, RM1
Balcerzak, SP1
McDermott, BJ1
Van den Berg, HW1
Martin, WM2
Murphy, RF1
Windschitl, H1
Scott, M1
Schutt, A1
McCormack, G1
Everson, L1
Cullinan, S1
Gerstner, J1
Krook, J1
Laurie, J1
Shreck, R1
Kotake, T1
Usami, M1
Miki, T1
Kuroda, M1
Obata, K1
Osafune, M1
Fujioka, H1
Takasugi, Y1
Israel, L1
Breau, JL1
Aguilera, J1
Chang, YC1
Crowley, J1
Lee, YT1
Chlebowski, RT2
Silverberg, I1
Pajak, T1
Weiner, J1
Kardinal, C1
Bateman, JR2
Wiseman, CL1
Gutterman, JU1
Hersh, EM1
McCracken, JD1
Ray, P1
Heilbrun, LK1
Vaitkevicius, VK1
Saiki, JH1
Rivkin, SE2
Rossof, AH1
Moore, TN1
Vogl, SE1
Lanham, R1
Kaplan, BH1
Engstrom, PF1
MacIntyre, JM1
Douglass, HO2
Muggia, F2
Mittelman, A2
Wilcox, PM2
Fetting, JH2
Nettesheim, KM1
Abeloff, MD1
Sorbe, B1
Frankendal, B1
Boesen, E1
Pugh, RP1
Weiner, JM1
Frytak, S2
Rubin, J2
Schutt, AJ3
Weiland, LH1
Childs, DS1
Holbrook, MA1
Lavin, PT1
Livstone, E1
Spiro, H1
Knowlton, A1
Kalser, M1
Barkin, J1
Lessner, H1
Mann-Kaplan, R1
Ramming, K1
Douglas, HO2
Thomas, P1
Nave, H1
Bateman, J1
Lokich, J2
Brooks, J1
Chaffey, J1
Corson, JM1
Zamcheck, N1
Novak, JW1
Kohno, N2
Ichikawa, G1
Inuyama, Y1
Kawaida, M1
Ohnuma, T1
Noguchi, S2
Shuin, T1
Kubota, Y1
Masuda, M1
Yao, M1
Hosaka, M1
Kohno, H1
Enomoto, H1
Kawai, S1
Yago, T1
Ikema, Y1
Makino, Y1
Kubota, A1
Furukawa, M1
Hebbar, M1
Hecquet, B1
Vanlemmens, L1
Lecomte, S1
Pion, JM1
Adenis, A1
Konishi, K1
Yabushita, K1
Ota, J1
Kikkawa, N1
Yasutomi, M2
Sowa, M2
Kusama, M1
Tominaga, T3
Enomoto, K2
Yoshida, M1
Koyama, H2
Sonoo, H1
Abe, R2
Nishi, T1
Yamaguchi, S1
Huber, MH1
Shirinian, M1
Lippman, SM1
Dimery, IW1
Frankenthaler, RA1
Hong, WK1
Nakazato, H1
Koike, A1
Saji, S1
Ogawa, N1
Sakamoto, J1
Nakai, Y1
Furuse, K1
Ohta, M1
Fujii, M3
Asakawa, M1
Fukuoka, M1
Yoshida, K1
Niitani, H1
Fredrikson, M2
Hursti, TJ1
Steineck, G1
Fürst, CJ2
Börjesson, S1
Peterson, C1
Domaradzka-Woźniak, A1
Wojtacki, J1
Dziewulska-Bokiniec, A1
Stöger, H2
Bauernhofer, T1
Schmid, M2
Ploner, F1
Moser, R1
Derstvenscheg, E1
Steindorfer, P2
Wilders-Truschnig, M1
Kuss, I1
Samonigg, H2
Tan, EH1
Ang, PT1
Khoo, KS1
Zhou, JC1
Tomio, L1
Zorat, PL1
Paccagnella, A1
Segati, R1
Loreggian, L1
Lora, O1
Friso, ML1
Chiarion-Sileni, V1
Favaretto, A1
Fede, A1
Buser, KS1
Joss, RA1
Piquet, D1
Aapro, MS1
Haefliger, JM1
Jungi, WF1
Obrist, R1
Brunner, KW1
Arai, Y1
Sone, Y1
Inaba, Y1
Mukaijo, T1
Nakatsuka, A1
Nagashima, K1
Kido, C1
Ariyoshi, Y1
Levitt, M1
Warr, D1
Yelle, L1
Rayner, HL1
Lofters, WS1
Perrault, DJ1
Wilson, KS1
Latreille, J1
Potvin, M1
Warner, E1
Lekander, M1
Blomgren, H1
Williamson, SK1
Tangen, CM1
Maddox, AM1
Spiridonidis, CH1
Macdonald, JS2
Singh, G1
Singh, DP1
Gupta, D1
Muralikrishna, BV1
Coombes, RC1
Bliss, JM1
Wils, J1
Morvan, F1
Espié, M1
Amadori, D1
Gambrosier, P1
Richards, M1
Aapro, M1
Villar-Grimalt, A1
McArdle, C1
Pérez-López, FR1
Vassilopoulos, P1
Ferreira, EP1
Chilvers, CE1
Coombes, G1
Woods, EM1
Marty, M1
Feliu, J2
González Barón, M2
García-Girón, C1
Espinosa, E2
Belón, J1
Blanco, E1
Garrido, P1
Ordónez, A2
Gómez-Navarro, J1
Zamora, P1
Wang, R1
Fan, Q1
Wang, Z1
Hisano, C1
Nakano, S1
Masumoto, N1
Fujishima, H1
Nakamura, M1
Niho, Y1
Bosnjak, SM1
Neskovic-Konstantinovic, ZB1
Jovanovic-Micic, DJ1
Mitrovic, LB1
Radulovic, SS1
Fujinami, K1
Ikeda, I1
Miura, T1
Kondo, I1
García Girón, C1
Vicent, JM1
Gómez Navarro, J1
Berrocal, A1
Vilches, Y1
de Castro, J1
Díaz, J1
Park, Y1
Hatano, Y1
Sasamoto, S1
Kato, N1
Okuyama, N1
Yamazaki, S1
Kobayashi, F1
Yamanouchi, T1
Sato, H1
Adachi, I1
Sakamoto, T1
Fujimaki, M1
Horikoshi, I1
Hecht, JR1
Lembo, T1
Chap, L1
Tanikawa, K2
Kimura, E1
Niimi, S1
Watanabe, A1
Tokumaru, Y2
Imanishi, Y2
Kanke, M2
Kanzaki, J2
Iop, A1
Cartei, G1
Vigevani, E1
Clocchiatti, L1
Mansutti, M1
Sibau, AM1
Klaassen, U1
Seeber, S1
Fujii, K1
Nakashima, K1
Ohno, T1
Anai, H1
Hoshino, K1
Ono, K1
Kimura, O1
Kawaguchi, H1
Fukui, H1
Ikeda, M1
Shinohara, H1
Yonekawa, H1
Machimura, T1
Nishihori, H1
Kurihara, N1
Urakami, H1
Nemoto, Y1
Ollivier, S1
Fonck, M1
Bécouarn, Y1
Brunet, R1
Narahara, H1
Otani, T1
Iwanaga, T1
Okajima, K1
Katsu, K1
Kobayashi, K1
Okuno, M1
Takami, M1
Ishida, T2
Yasutake, K1
Kato, O1
Fukuda, H1
Kusaba, T2
Steyn, RS1
Vijeyasingam, R1
Darnton, SJ1
Cullen, MH1
Matthews, HR1
Chiara, S1
Nobile, MT1
Vincenti, M1
Lionetto, R1
Gozza, A1
Barzacchi, MC1
Sanguineti, O1
Repetto, L1
Rosso, R1
Muggia, FM1
Wu, X1
Spicer, D1
Groshen, S1
Jeffers, S1
Chan, KK1
Marshall, JL1
Richmond, E1
DeLap, RJ1
Lévy, E1
Piedbois, P1
Buyse, M1
Pignon, JP1
Rougier, P2
Ryan, L1
Hansen, R1
Zee, B1
Weinerman, B1
Pater, J1
Leichman, C1
Macdonald, J1
Benedetti, J1
Fryer, J1
Brufman, G2
Isacson, R1
Laplanche, A1
Thirion, P1
Dikken, C1
Sitzia, J1
Rothenberg, ML1
Cox, JV1
DeVore, RF1
Hainsworth, JD1
Pazdur, R1
Sandbach, J1
Wolf, DL1
Mohrland, JS1
Elfring, GL1
Miller, LL1
Von Hoff, DD1
Asato, Y1
Yoshimi, F1
Amemiya, R1
Koizumi, S1
Hasegawa, H1
Miya, T1
Goya, T1
Sigsgaard, T1
Herrstedt, J1
Andersen, LJ1
Havsteen, H2
Langer, SW1
Kjaerbøl, AG1
Lund, H1
Kjaer, M3
Dombernowsky, P1
Tsukamoto, F1
Yoneda, K1
Takamura, Y1
Hojo, S1
Shiba, E1
Colevas, AD1
Norris, CM1
Tishler, RB1
Fried, MP1
Gomolin, HI1
Amrein, P1
Nixon, A1
Lamb, C1
Costello, R1
Barton, J1
Read, R1
Adak, S1
Posner, MR1
Miyashita, M1
Onda, M1
Ikeda, K1
Bando, K1
Hagiwara, N1
Tsuchiya, Y1
Yoshiyuki, T1
Kiyama, T1
Saito, T1
Sasajima, K1
Yamashita, K1
Faivre, C1
Ducreux, M1
Mitry, E1
Lusinchi, A1
Lasser, P1
Elias, D1
Eschwege, F1
Sasaki, K1
Yanagida, T1
Ohya, M1
Tsuji, A1
Horimi, T1
Takasaki, M1
Takahashi, I2
Kitahara, S1
Tamura, E1
Tanabe, T1
Nakanoboh, M1
Kawada, M1
Domenge, C1
Hill, C1
Lefebvre, JL1
De Raucourt, D1
Rhein, B1
Wibault, P1
Marandas, P1
Coche-Dequeant, B1
Stromboni-Luboinski, M1
Sancho-Garnier, H1
Luboinski, B1
Santini, D1
Tonini, G1
Salerno, A1
Vincenzi, B1
Patti, G1
Battistoni, F1
Dicuonzo, G1
Labianca, R2
Hoff, PM1
Ansari, R1
Batist, G1
Cox, J1
Kocha, W1
Kuperminc, M1
Maroun, J1
Walde, D1
Weaver, C1
Harrison, E1
Burger, HU1
Osterwalder, B1
Wong, AO1
Wong, R1
Guglielmi, A1
Cirillo, M1
Recaldin, E1
Frassineti, GL1
Aschele, C1
Ravaioli, A1
Testore, P1
Caroti, C1
Gallo, L1
Pessi, MA1
Cortesi, E1
Turci, D1
Grossi, F1
Genvresse, I1
Lange, C1
Schanz, J1
Schweigert, M1
Harder, H1
Possinger, K1
Späth-Schwalbe, E1
Olencki, T1
Peereboom, D1
Wood, L1
Budd, GT1
Novick, A1
Finke, J1
McLain, D1
Elson, P1
Tomita, T1
Patt, YZ1
Hassan, MM1
Lozano, RD1
Waugh, KA1
Hoque, AM1
Frome, AI1
Lahoti, S1
Ellis, L1
Vauthey, JN1
Curley, SA1
Schnirer, II1
Raijman, I1
Webb, A1
Cunningham, D1
Hill, M1
Waters, JS1
Norman, A1
Massey, A1
Wenzel, C1
Locker, GJ1
Schmidinger, M1
Mader, R1
Kramer, G1
Marberger, M1
Rauchenwald, M1
Zielinski, CC1
Steger, GG1
Koukourakis, MI1
Giatromanolaki, A1
Sivridis, E1
Frangiadaki, C1
Retalis, G1
Yang, TS1
Hsu, KC1
Wang, HM1
Hoshino, M1
Nishihara, N1
Fukada, K1
Kuwazawa, T1
Mani, S1
Rudin, CM1
Kunkel, K1
Holmlund, JT1
Geary, RS1
Dorr, FA1
Luoma, ML1
Hakamies-Blomqvist, L1
Sjöström, J1
Mouridsen, H1
Pluzanska, A1
Malmström, P1
Bengtsson, NO1
Hultborn, R1
Ostenstaad, B1
Mjaaland, I1
Valvere, V1
Wist, E1
Baldursson, G1
Ahigren, J1
Blomqvist, C1
Shinchi, H1
Takao, S1
Matsuo, Y1
Mataki, Y1
Mori, S1
Aikou, T1
Hayakawa, H1
Adimi, P1
Hansen, F1
Aabo, K1
Keldsen, N1
Pfeiffer, P1
Sandberg, E1
Jakobsen, A1
Hanley, J1
Carbone, PP1
Jones, KD1
Hughes, LE1
Lundbeck, F1
Christophersen, IS1
Hartman, HA1
Kessinger, A1
Lemon, HM1
Foley, JF1
O'Fallon, JR2
Creagan, ET1
Schwartau, NW1
Cedermark, BJ1
Kaufman, JH1
Amrein, PC1
Fabian, RL1
Mohapatro, SK1
Dandapat, MC1
Padhi, NC1
Diaz-Rubio, E1
Casado, A1
Dominguez, S1
Sastre, J1
Gez, E2
Strauss, N1
Vitzhaki, N1
Cass, Y1
Edelmann, DZ1
Flaherty, L1
Wozniak, A1
Redman, B1
Kraut, M1
Martino, S1
Heilbrun, L1
Tohnai, I1
Kawabe, Y1
Nakashima, T1
Yamagiwa, M1
Suzuki, T1
Mizuno, A1
Mineda, H1
De Besi, P1
Busnardo, B1
Toso, S1
Girelli, ME1
Nacamulli, D1
Simioni, N1
Casara, D1
Zorat, P1
Fiorentino, MV1
Ohmori, H1
Ochi, J1
Kobashi, K1
Akebi, N1
Saika, T1
Nanba, K1
Tanahashi, T1
Josen, T1
Nasu, Y1
Kerbrat, P1
Fargeot, P2
Metz, R3
Roche, H1
Bastit, P1
Chevrier, A1
Tubiana-Hulin, M2
Geyer, G1
Cappelaere, P2
Kasparek, AK1
Dusleag, J1
Pfeiffer, K1
Smola, M1
Lechner, P1
Chevallier, B1
Pujade-Lauraine, E1
Spielmann, M1
Paes, D1
Bons, J1
Evans, WK1
Wierzbicki, R1
Shepherd, FA1
Rusthoven, J1
Stewart, DJ1
Aitken, SE1
Maroun, JA1
Ezzat, A1
Nakao, I1
Ota, K1
Ibayashi, J1
Sakata, Y1
Matsuoka, T1
Ishikawa, M1
Wakui, A1
Ogoshi, K1
Akazawa, S1
Sakai, Y1
Jinushi, K1
Kim, R1
Toi, M1
Saeki, K1
Yoshinaka, K1
Yanagawa, E1
Niimoto, M1
Hattori, T1
Gordon, W1
Stansberry, PK1
Weiss, GB1
Silvey, L1
Carpenter, JT1
Wheeler, RH1
Conolley, C1
Martoni, A1
Rani, P1
Ercolino, L1
Canova, N1
Pannuti, F1
Roila, F2
Tonato, M2
Basurto, C2
Minotti, V2
Ballatori, E2
del Favero, A2
Shiu, W1
Tsang, V1
Lam, YM1
Zacharia, A1
Zhao, TP1
He, GF1
Dozono, H1
Yasuda, M1
Yokoyama, S1
Takahashi, S1
Ochiai, K1
Tsuruoka, M1
Morimoto, O1
Sasaki, H1
Arihiro, T1
Terashima, Y1
Selch, MT1
Parker, RG1
Bertrand, M1
Doroshow, JH1
Multhauf, P1
Blayney, DW1
Carr, BI1
Cecchi, G1
Goldberg, D1
Leong, L1
Margolin, K1
Metter, G1
Greene, PG1
Seime, RJ1
Merlano, M1
Grimaldi, A1
Brunetti, I1
Modenesi, M1
Scala, M1
Margarino, G1
Scasso, F1
Santelli, A1
Castiglia, G1
Pallestrini, E1
Warner-Efraty, E1
Ben-Yosef, R1
Ben-Baruch, N1
Yitzhaki, N1
Uziely, B1
Biran, S1
Abe, O1
Iino, Y1
Fujimoto, M1
Nomura, Y1
Sheidler, VR1
Enterline, JP1
Donehower, RC1
Grochow, LB1
Page, JP1
Levi, JA1
Woods, RL1
Tattersall, MN1
Fox, RM1
Coates, AS1
Posner, LE1
Dukart, G1
Goldberg, J1
Bernstein, T1
Cartwright, K1
Bennett, JM1
Byrne, P1
Desai, A1
White, C1
DeConti, R1
Vogel, C1
Krementz, E1
Doroshow, J1
Plotkin, D1
Kish, JA1
Ensley, JF1
Jacobs, J1
Weaver, A1
Cummings, G1
Al-Sarraf, M1
Kitamura, M1
Hayashi, K1
Kosaki, G1
Sawaki, S1
Tamamushi, N1
Yao, K1
Takeyama, I1
Otake, H1
Miyake, H1
Horiuchi, M1
Hattori, Y1
Murakami, T1
Morrow, GR1
Delgado, M1
Keiling, R1
Armand, JP1
Prevot, G1
Misset, JL1
Grimbert, J1
Mathe, G1
Furue, H1
Byfield, JE1
Frankel, SS1
Hornbeck, CL1
Sharp, TR1
Callipari, FB1
Floyd, RA1
Bounous, G1
Gentile, JM1
Hugon, J1
Gailani, S1
Leone, L1
Stutz, FH1
Blom, J1
van Eden, EB1
Cichy, A1
Jurga, L1
Klvana, M1
Priestman, TJ1
Nadler, SH2
Moore, GE1
Piro, AJ1
Wilson, RE1
Hall, TC1
Aliapoulios, MA1
Nevinny, HB1
Moore, FD1
Hill, GJ1
Grage, TB1
Wilson, W1

Clinical Trials (45)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of Breast Cancer Chemotherapy-induced Nausea and Vomiting: a Single-center, Randomized Controlled Clinical Trial[NCT05841849]Phase 41,028 participants (Anticipated)Interventional2023-07-31Not yet recruiting
Phase II Study of FOLFIRINOX Chemotherapy for Treatment of Advanced Gastric, Gastro-esophageal Junction, and Esophageal Tumors[NCT01928290]Phase 267 participants (Actual)Interventional2013-11-08Completed
Efficacy of Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Nondrinking Women Younger Than 50 Years Who Received Moderately Emetogenic Chemotherapy: A Randomized, Double-blind, Phase Ⅲ Trial[NCT03674294]Phase 3248 participants (Actual)Interventional2015-08-04Completed
A Multicenter Randomized Dble-Blind Placebo Controlled Phase III Study of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin and 5-FU/LV Combination in First-Line Treatment of Patients With Metastatic Colorectal Carcinoma(MCRC)[NCT00272051]Phase 3620 participants Interventional2002-07-31Completed
A Multicenter, Randomized Double-blind Placebo Controlled Phase III Study of the Efficacy of Xaliproden in Preventing the Neurotoxicity of Oxaliplatin in First-line Treatment of Patients With Metastatic Colorectal Cancer Treated With Oxaliplatin / 5-FU/LV[NCT00305188]Phase 3879 participants (Actual)Interventional2005-12-31Completed
PACCE: A Randomized, Open-Label, Controlled, Clinical Trial of Chemotherapy and Bevacizumab With and Without Panitumumab in the First-Line Treatment of Subjects With Metastatic Colorectal Cancer[NCT00115765]Phase 31,053 participants (Actual)Interventional2005-06-01Completed
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Pat[NCT00384176]Phase 2/Phase 31,814 participants (Actual)Interventional2006-08-30Completed
A Randomized, Multicenter, Phase 3 Study to Compare the Efficacy of Panitumumab in Combination With Oxaliplatin/ 5-fluorouracil/ Leucovorin to the Efficacy of Oxaliplatin/ 5-fluorouracil/ Leucovorin Alone in Patients With Previously Untreated Metastatic C[NCT00364013]Phase 31,183 participants (Actual)Interventional2006-08-01Completed
A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen[NCT01571284]Phase 3781 participants (Actual)Interventional2012-05-30Completed
Phase II Study of Paclitaxel Liposome Plus S-1 as Neoadjuvant Chemotherapy for Advanced Gastric Cancer[NCT02163291]Phase 230 participants (Anticipated)Interventional2013-12-31Not yet recruiting
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer[NCT00777101]Phase 2233 participants (Actual)Interventional2009-02-04Completed
An Open Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With HER2+ Breast Cancer Treated With Neratinib With or Without Trastuzumab[NCT03094052]Phase 211 participants (Actual)Interventional2018-10-09Completed
A Phase 2 Study of Low-Dose Fractionated Radiation Therapy to the Whole Liver in Combination With Gemcitabine and Cisplatin in Locally Advanced Mass-Forming Intrahepatic Cholangiocarcinoma[NCT02254681]Phase 26 participants (Actual)Interventional2014-09-30Terminated (stopped due to lack of funding)
Randomized Study of the Efficacy and Safety of Transdermal Granisetron Compared With Intravenous and Oral Agent in the Control of Nausea and Vomiting Induced by Moderately Emetogenic Chemotherapy[NCT01662687]Phase 4276 participants (Anticipated)Interventional2012-02-29Recruiting
A Multicenter, Multinational Phase II Study to Assess the Clinical Safety and Feasibility of Trastuzumab Emtansine Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage HER2-positive Breast Ca[NCT01196052]Phase 2153 participants (Actual)Interventional2010-10-31Completed
Phase III Prospective Randomized Trial Comparing Ramosetron Versus Ondansetron for Radiotherapy Induced Nausea and Vomiting in the Treatment of Gastrointestinal Cancer[NCT00971399]Phase 3172 participants (Anticipated)Interventional2009-09-30Completed
An Open-label, Randomized Phase III Trial of Cisplatin and 5-fluorouracil With or Without Panitumumab for Patients With Nonresectable, Advanced or Metastatic Esophageal Squamous Cell Cancer[NCT01627379]Phase 3300 participants (Anticipated)Interventional2012-05-31Terminated (stopped due to Sponsor decision due to recommendation of the IDMC.)
A Single Arm, Phase II Study of TNFerade™ Biologic Gene Therapy + Radiation + 5-FU and Cisplatin in Locally Advanced, Resectable, Esophageal Cancer[NCT00051480]Phase 20 participants InterventionalCompleted
A Prospective, Single-arm, Phase II Study of Adelbelimab Combined With Carboplatin and Nab-paclitaxel in Neoadjuvant Therapy for Patients With Resectable Locally Advanced Squamous Cell Carcinoma of the Head and Neck[NCT06016413]Phase 230 participants (Anticipated)Interventional2023-09-01Not yet recruiting
Study of TPF (Docetaxel, Cisplatin, 5-fluorouracil) Induction Chemotherapy Followed by Surgery and Radiotherapy in Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma[NCT01542931]Phase 2/Phase 3256 participants (Actual)Interventional2008-01-31Completed
Phase 0 Trial of [F-18]-5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT01479348]Early Phase 15 participants (Actual)Interventional2011-11-01Terminated (stopped due to Slow, insufficient accrual.)
A Phase I/II Study of Vorinostat (Zolinza®) in Combination With Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer[NCT01045538]Phase 1/Phase 245 participants (Actual)Interventional2010-02-28Completed
A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas[NCT00447330]Phase 260 participants (Actual)Interventional2007-02-28Completed
Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320]Phase 2200 participants (Actual)Interventional2015-10-05Active, not recruiting
Phase I Study of Chemoradiation Therapy With Epitope Peptide Vaccine Therapy in Treating Patients With Unresectable, Advanced or Recurrent Esophageal Cancer[NCT00632333]Phase 19 participants (Anticipated)Interventional2008-02-29Recruiting
Two-arm Phase III Trial Comparing Radiotherapy With Differentcycles of Cisplatin-5-fluorouracil for Esophageal Cancer[NCT02607540]Phase 3210 participants (Anticipated)Interventional2014-10-31Recruiting
A Prospective, Phase Ⅱ Study of S-1 Plus Moderately Hypofractionated Conformal Radiation for Esophageal Squamous Cell Carcinoma[NCT03660449]Phase 258 participants (Actual)Interventional2017-10-01Completed
A Prospective, Single-arm Study of Simultaneous Modulated Accelerated Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Carcinoma.[NCT02606916]Phase 242 participants (Actual)Interventional2015-07-31Completed
A Phase II Trial of Gemcitabine, Herceptin, and Radiation for Regionally Confined Adenocarcinoma of the Pancreas[NCT00005926]Phase 250 participants Interventional2000-06-30Completed
09.017 - A Phase I Study of Tolfenamic Acid With Gemcitabine and Radiation in Patients With Locally Advanced or Metastatic Pancreatic Cancer Requiring Definitive or Palliative Radiation Therapy[NCT02159248]Phase 10 participants (Actual)Interventional2014-03-31Withdrawn (stopped due to The study closed prior to enrolling any participants.)
Randomized Multicenter Controlled Phase III Study of Postoperative Adjuvant Therapy for Stage II/IIIA Gastric Cancer Using TS-1 Alone or TS-1+PSK Combined Therapy[NCT00216034]Phase 3255 participants (Actual)Interventional2005-03-31Completed
Phase III Randomized Controlled Study of Postoperative Adjuvant Therapy Using TS-1 or TS-1+PSK for Stage II or III Gastric Cancer Patients[NCT00687843]Phase 3480 participants (Anticipated)Interventional2008-06-30Active, not recruiting
Randomized Phase II Study of TS-1 Therapy and TS-1+PSK Therapy Against Unresectable Advanced Gastric Carcinoma and Recurrent Gastric Carcinoma[NCT00503321]Phase 2/Phase 313 participants (Actual)Interventional2006-10-31Terminated (stopped due to Patients' enrollment was not sufficient.)
A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer[NCT01685489]Phase 10 participants (Actual)Interventional2013-05-31Withdrawn (stopped due to funding sequestered)
Sorafenib Alone Versus Sorafenib Combined With Hepatic Arterial Chemoinfusion for Advanced HCC With Portal Vein Tumor Thrombosis: a Multicentre Randomised Controlled Trial[NCT02774187]Phase 3247 participants (Actual)Interventional2016-05-31Completed
Phase II Trial of Sorafenib Combined With Concurrent Hepatic Arterial Infusion (HAI) of Oxaliplatin, 5-fluorouracil and Leucovorin for Hepatocellular Carcinoma[NCT02981498]Phase 235 participants (Anticipated)Interventional2015-06-30Completed
The Optimisation of 5-Fluorouracil Dose by Pharmacokinetic Monitoring in Asian Patients With Advanced Stage Cancer[NCT00943137]Phase 255 participants (Anticipated)Interventional2009-06-30Active, not recruiting
Phase Ⅱ Clinical Study of RALOX or CAPOX Combined With Bevacizumab in the First-line Treatment of Advanced Colorectal Cancer[NCT03813641]Phase 2100 participants (Anticipated)Interventional2019-01-28Recruiting
Phase I Study of Cabazitaxel - Platinum Fluorouracil Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck[NCT01379339]Phase 140 participants (Actual)Interventional2011-04-30Completed
Phase 1 Study of Postoperative Capecitabine With Concurrent Radiation in Elderly With Stage II/III Rectal Cancer[NCT01268943]Phase 118 participants (Actual)Interventional2010-11-30Completed
A Pilot Study Using Neoadjuvant Proton Beam Radiation Therapy and Chemotherapy for Marginally Resectable Carcinoma of the Pancreas[NCT00763516]8 participants (Actual)Interventional2009-02-28Completed
Randomized Trial to Evaluate Therapeutic Gain by Changing Chemoradiotherapy From Concurrent-adjuvant to Induction-concurrent Sequence, and Radiotherapy From Conventional to Accelerated Fractionation for Advanced Nasopharyngeal Carcinoma[NCT00379262]Phase 3803 participants (Actual)Interventional2006-09-30Completed
A Study Using Photon/Proton Beam Radiation Therapy and Chemotherapy for Unresectable Carcinoma of the Pancreas[NCT00685763]13 participants (Actual)Interventional2008-03-31Completed
A Pilot Study- Prevention of Capecitabine Induced Hand and Foot Syndrome[NCT01291628]10 participants (Anticipated)Interventional2012-01-31Not yet recruiting
Phase I Study of Preoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients[NCT01584544]Phase 124 participants (Actual)Interventional2011-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Clinical Benefit Rate

"Clinical benefit rate is the percentage of combined patients who have achieved complete response (CR), partial response (PR), and stable disease (SD)~CR: Disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm~PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters~SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study." (NCT01928290)
Timeframe: Through completion of treatment (estimated to be 4 months)

InterventionParticipants (Count of Participants)
Arm A: FOLFIRINOX (HER2-negative)33
Arm B: FOLFIRINOX & Trastuzumab (HER2-positive)22

Duration of Response

Time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)

Interventionmonths (Median)
Arm A: FOLFIRINOX (HER2-negative)5.8
Arm B: FOLFIRINOX & Trastuzumab (HER2-positive)10.5

Number of Participants With an Objective Response

"Objective response (defined as complete response (CR) + partial response (PR) by RECIST 1.1 criteria)~CR: Disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.~PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters." (NCT01928290)
Timeframe: Through completion of treatment (estimated to be 4 months)

InterventionParticipants (Count of Participants)
Arm A: FOLFIRINOX (HER2-negative)25
Arm B: FOLFIRINOX & Trastuzumab (HER2-positive)22

Overall Survival (OS)

Overall survival is defined as the time interval from date of diagnosis to date of death from any cause. (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)

Interventionmonths (Median)
Arm A: FOLFIRINOX (HER2-negative)15.5
Arm B: FOLFIRINOX & Trastuzumab (HER2-positive)19.6

Progression Free Survival

Duration of time from start of treatment to time of progression or death, whichever occurs first. (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)

Interventionmonths (Median)
Arm A: FOLFIRINOX (HER2-negative)8.4
Arm B: FOLFIRINOX & Trastuzumab (HER2-positive)13.8

Time to Progression (TTP)

Duration of time from start of treatment to time of progression. Progression is defined as At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)

Interventionmonths (Median)
Arm A: FOLFIRINOX (HER2-negative)8.0
Arm B: FOLFIRINOX & Trastuzumab (HER2-positive)13.9

Toxicity and Tolerability (Arm A and Arm B) as Measured by the Number of Participants With Grade 3 or Higher Adverse Events

(NCT01928290)
Timeframe: 30 days after completion of treatment (estimated to be 5 months)

,
Interventionparticipants (Number)
AnemiaFebrile neutropeniaAnal FistulaDiarrheaHematemesisNauseaPeripheral ischemiaVomitingFatigueLaparoscopy surgeryPainSepsisLung infectionPneumoniaHypernatremiaNeutrophil count decreasedPlatelet count decreasedAnorexiaDehydrationHypokalemiaBack painPeripheral sensory neuropathySyncopeDyspneaPleural embolismSkin infectionThromboembolic eventAbdominal painEnterocolitisHemorrhoidsG-tube infectionNeutropenic entercolitisAlkaline phosphatase increased
Arm A: FOLFIRINOX (HER2-negative)1214121341111111933411211114000000
Arm B: FOLFIRINOX & Trastuzumab (HER2-positive)000502010000000800020010000111111

Objective Tumor Response Rate (Irinotecan)

Best overall response of complete or partial response within irinotecan stratum (NCT00115765)
Timeframe: Overall Study

InterventionParticipant (Number)
Irinotecan and Bevacizumab Plus Panitumumab49
Irinotecan and Bevacizumab Without Panitumumab46

Objective Tumor Response Rate (Mutant KRAS)

Best overall response of complete or partial response in participants treated with irinotecan and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS) (NCT00115765)
Timeframe: Overall Study

InterventionParticipant (Number)
Irinotecan and Bevacizumab Plus Panitumumab14
Irinotecan and Bevacizumab Without Panitumumab15

Objective Tumor Response Rate (Oxaliplatin)

Best overall response of complete or partial response within oxaliplatin stratum (NCT00115765)
Timeframe: Overall study

InterventionParticipant (Number)
Oxaliplatin and Bevacizumab Plus Panitumumab190
Oxaliplatin and Bevacizumab Without Panitumumab196

Objective Tumor Response Rate (Wild-type KRAS)

Best overall response of complete or partial response in participants treated with irinotecan and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS) (NCT00115765)
Timeframe: Overall Study

InterventionParticipant (Number)
Irinotecan and Bevacizumab Plus Panitumumab31
Irinotecan and Bevacizumab Without Panitumumab28

Objective Tumor Response Through Week 12 (Irinotecan)

Objective tumor response (complete or partial) rate through week 12 based on central review in the Irinotecan stratum (NCT00115765)
Timeframe: Overall Study

InterventionParticipant (Number)
Irinotecan and Bevacizumab Plus Panitumumab29
Irinotecan and Bevacizumab Without Panitumumab27

Overall Survival (Irinotecan)

Incidence of mortality from any cause in groups treated with Irinotecan. Incidence is provided in lieu of the median time to death since the median or its measure of dispersion was not estimable for at least one treatment arm. (NCT00115765)
Timeframe: Overall study

InterventionParticipant (Number)
Irinotecan and Bevacizumab Plus Panitumumab26
Irinotecan and Bevacizumab Without Panitumumab18

Overall Survival (Mutant KRAS)

Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS). Since the measure of dispersion could not be estimated for at least one treatment arm, participant incidence is provided in lieu of the median. (NCT00115765)
Timeframe: Overall Study

InterventionParticipant (Number)
Oxaliplatin and Bevacizumab Plus Panitumumab47
Oxaliplatin and Bevacizumab Without Panitumumab45

Overall Survival (Oxaliplatin)

Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin (NCT00115765)
Timeframe: Overall study

InterventionMonth (Median)
Oxaliplatin and Bevacizumab Plus Panitumumab19.4
Oxaliplatin and Bevacizumab Without Panitumumab24.5

Overall Survival (Wild-type KRAS)

Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS). Since the measure of dispersion could not be estimated for at least one treatment arm, participant incidence is provided in lieu of the median (NCT00115765)
Timeframe: Overall Study

InterventionParticipant (Number)
Oxaliplatin and Bevacizumab Plus Panitumumab71
Oxaliplatin and Bevacizumab Without Panitumumab46

Progression-free Survival (Irinotecan)

Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression (NCT00115765)
Timeframe: Overall Study

InterventionMonth (Median)
Irinotecan and Bevacizumab Plus Panitumumab10.1
Irinotecan and Bevacizumab Without Panitumumab11.7

Progression-free Survival (Mutant KRAS)

Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression in groups treated with oxaliplatin and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS) (NCT00115765)
Timeframe: Overall Study

InterventionMonth (Median)
Oxaliplatin and Bevacizumab Plus Panitumumab10.4
Oxaliplatin and Bevacizumab Without Panitumumab11.0

Progression-Free Survival (Oxaliplatin)

Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression (NCT00115765)
Timeframe: Overall study

InterventionMonth (Median)
Oxaliplatin and Bevacizumab Plus Panitumumab10.0
Oxaliplatin and Bevacizumab Without Panitumumab11.4

Progression-free Survival (Wild-type KRAS)

Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression in groups treated with oxaliplatin and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS) (NCT00115765)
Timeframe: Overall Study

InterventionMonth (Median)
Oxaliplatin and Bevacizumab Plus Panitumumab9.8
Oxaliplatin and Bevacizumab Without Panitumumab11.5

Time to Progression (Irinotecan)

Kaplan-Meier estimate of the median time from randomization to disease progression or death due to disease progression within the irinotecan stratum (NCT00115765)
Timeframe: Overall Study

InterventionMonth (Median)
Irinotecan and Bevacizumab Plus Panitumumab11.1
Irinotecan and Bevacizumab Without Panitumumab11.9

Time to Progression (Oxaliplatin)

Kaplan-Meier estimate of the median time from randomization to disease progression or death due to disease progression within the oxaliplatin stratum (NCT00115765)
Timeframe: Overall Study

InterventionMonth (Median)
Oxaliplatin and Bevacizumab Plus Panitumumab10.8
Oxaliplatin and Bevacizumab Without Panitumumab11.4

Time to Treatment Failure (Irinotecan)

Kaplan-Meier estimate of the median time from randomization to the date the decision was made to discontinue treatment for a reason other than a complete response to treatment within the irinotecan stratum (NCT00115765)
Timeframe: Overall Study

InterventionMonth (Median)
Irinotecan and Bevacizumab Plus Panitumumab6.6
Irinotecan and Bevacizumab Without Panitumumab6.0

Time to Treatment Failure (Oxaliplatin)

Kaplan-Meier estimate of the median time from randomization to the date the decision was made to discontinue treatment for a reason other than a complete response to treatment within the oxaliplatin stratum. (NCT00115765)
Timeframe: Overall study

InterventionMonth (Median)
Oxaliplatin and Bevacizumab Plus Panitumumab5.7
Oxaliplatin and Bevacizumab Without Panitumumab5.9

Duration of Response

Duration of Response is calculated as the time from the first recording of CR/PR until the patient progresses, regardless of whether the patient was still taking study medication. Only confirmed responses are included in the calculation. For patients who had not progressed, the end date used in the calculation of duration of response is the data cut-off date of 15th November 2009. (NCT00384176)
Timeframe: Up until data cut-off date of 15/11/2007

InterventionMonths (Median)
Cediranib 20 mg8.6
Bevacizumab 5 mg/kg9.6

Objective Response Rate

"Objective response rate is Complete Response (CR) + Partial Response (PR) as defined below:~CR = Disappearance of all target lesions. PR = At least a 30% decrease in the sum of longest diameters (LDs) of target lesions, taking as reference the baseline sum of LDs." (NCT00384176)
Timeframe: Up until data cut-off

InterventionParticipants (Number)
Cediranib 20 mg328
Bevacizumab 5 mg/kg337

Overall Survival

Number of months from randomisation to the date of death from any cause (NCT00384176)
Timeframe: Randomisation until data cut-off

InterventionMonths (Median)
Cediranib 20 mg22.8
Bevacizumab 5 mg/kg21.3

Percentage Change in Tumour Size

Percentage change in tumour size from baseline to first RECIST assessment (Week 8) ((Week 8 - baseline)/baseline)*100 (NCT00384176)
Timeframe: Baseline to Week 8

InterventionPercentage change in tumour size (Mean)
Cediranib 20 mg-23.2
Bevacizumab 5 mg/kg-22.1

Progression Free Survival

Progression is defined as the number of months from randomisation until progressive disease based on RECIST (progression of target lesions, clear progression of existing non-target lesions or the appearance of one or more new lesions) or death in the absence of progression. (NCT00384176)
Timeframe: Baseline then at Weeks 8, 16, 24 and then every 12 weeks until progression

InterventionMonths (Median)
Cediranib 20 mg9.9
Bevacizumab 5 mg/kg10.3

Time to Worsening of Health Related Quality of Life (QOL) Based on the FACT Colorectal Symptom Index (FCSI)

Time to worsening of symptoms, as measured by the FACT colorectal symptom index (FCSI), will be defined as the time when a sustained clinically important deterioration in the total score from the FCSI has been recorded. (NCT00384176)
Timeframe: Baseline through to data cut-off

InterventionDays (Median)
Cediranib 20 mg170
Bevacizumab 5 mg/kg245

Duration of Response

Duration of response was calculated only for those participants with a confirmed CR or PR, as the time from the first CR or PR (subsequently confirmed within no less than 4 weeks) to first observed disease progression per modified RECIST criteria, based on a blinded central review. (NCT00364013)
Timeframe: Every 8 weeks until disease progression up to the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.

Interventionmonths (Median)
Wild-type KRAS - FOLFOX + Panitumumab11.1
Wild-type KRAS - FOLFOX8.8
Mutant KRAS - FOLFOX + Panitumumab7.4
Mutant KRAS - FOLFOX8.0

Overall Survival

The definition of overall survival is the time from randomization to death; participants who were alive at the analysis data cutoff were censored at their last contact date. (NCT00364013)
Timeframe: From randomization until the data cutoff date of 28 August 2009. Maximum time on follow-up was 153 weeks.

Interventionmonths (Median)
Wild-type KRAS - FOLFOX + Panitumumab23.9
Wild-type KRAS - FOLFOX19.7
Mutant KRAS - FOLFOX + Panitumumab15.5
Mutant KRAS - FOLFOX19.3

Percentage of Participants With an Objective Response

Participants were evaluated for tumor response per the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria every 8 weeks until disease progression. Objective response by central radiological assessment was defined as the incidence of either a confirmed complete or partial response (CR or PR) while on the first-line treatment, as determined by blinded independent central review and confirmed no less than 4-weeks after the criteria for response are first met. CR: Disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions and no progression of non-target or no new lesions, or, disappearance of all target lesions and the persistence of ≥ 1 non-target lesion not qualifying for either CR or progressive disease. Participants without a post-baseline assessment were considered non-responders. (NCT00364013)
Timeframe: Every 8 weeks until disease progression up to the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.

Interventionpercentage of participants (Number)
Wild-type KRAS - FOLFOX + Panitumumab55.21
Wild-type KRAS - FOLFOX47.68
Mutant KRAS - FOLFOX + Panitumumab39.53
Mutant KRAS - FOLFOX40.28

Progression-free Survival

Progression-free survival (PFS), assessed by central radiological assessment, was defined as the time from randomization to disease progression per modified response evaluation criteria in solid tumors (RECIST) criteria or death. Participants who were alive but did not meet criteria for progression by the data cutoff date were censored at their last evaluable disease assessment date. Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions. (NCT00364013)
Timeframe: From randomization until the data cutoff date of 30 September 2008. Maximum follow-up time was 109 weeks.

Interventionmonths (Median)
Wild-type KRAS - FOLFOX + Panitumumab9.6
Wild-type KRAS - FOLFOX8.0
Mutant KRAS - FOLFOX + Panitumumab7.3
Mutant KRAS - FOLFOX8.8

Time to Progression

Time to progression was defined as time from randomization date to date of disease progression per the modified RECIST criteria. (NCT00364013)
Timeframe: From randomization until the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.

Interventionmonths (Median)
Wild-type KRAS - FOLFOX + Panitumumab10.8
Wild-type KRAS - FOLFOX9.2
Mutant KRAS - FOLFOX + Panitumumab7.5
Mutant KRAS - FOLFOX9.0

Number of Participants With Adverse Events (AEs)

"A serious adverse event (SAE) is defined as an AE that • is fatal • is life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. The relationship of the adverse event to the study treatment was assessed by the Investigator by means of the question: Is there a reasonable possibility that the event may have been caused by the study treatment?" (NCT00364013)
Timeframe: From randomization until the data cut-off date of 28 August 2009; Maximum time on follow-up was 153 weeks.

,
Interventionparticipants (Number)
Any adverse eventSerious adverse eventLeading to discontinuation of any study drugTreatment-related adverse event (TRAE)Serious treatment-related adverse eventTRAE leading to discontinuation of any study drug
FOLFOX + Panitumumab583262136581162117
FOLFOX Alone579198845658963

Creatinine Clearance of Aflibercept Plus FOLFIRI

Creatinine clearance is a measure of kidney function. Creatinine clearance rate is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Creatinine clearance can be measured directly or estimated using established formulas. For this study, the creatinine clearance was calculated using the Cockroft-Gault or Modification of Diet in Renal Disease (MDRD). (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

InterventionmL/min (Mean)
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)71.4

Number of Participants With Proteinuria Grade >=2

Proteinuria is defined as the ratio of protein to creatinine. Number of participants with proteinuria grade >=2 (graded as per NCI CTCAE Version 4.03), where Grade>=2 represents moderate to life-threatening/disabling event. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

Interventionparticipants (Number)
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)182

Change From Baseline in HRQL EORTC QLQ-C30 Score: Symptom Scales

EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) & other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health & quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 & 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favorable outcome with a best quality of life for participant. (NCT01571284)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)

Interventionunits on a scale (Mean)
Fatigue - BaselineFatigue - Change at Cycle 3Fatigue - Change at Cycle 5Fatigue - Change at Cycle 7Fatigue - Change at Cycle 9Fatigue - Change at Cycle 11Fatigue - Change at Cycle 13Fatigue - Change at Cycle 15Fatigue - Change at Cycle 17Fatigue - Change at Cycle 19Fatigue - Change at Cycle 21Fatigue - Change at Cycle 23Fatigue - Change at Cycle 25Fatigue - Change at Cycle 27Fatigue - Change at Cycle 29Fatigue - Change at Cycle 31Fatigue - Change at Cycle 33Fatigue - Change at Cycle 35Fatigue - Change at EOTNausea and Vomiting - BaselineNausea and Vomiting - Change at Cycle 3Nausea and Vomiting - Change at Cycle 5Nausea and Vomiting - Change at Cycle 7Nausea and Vomiting - Change at Cycle 9Nausea and Vomiting - Change at Cycle 11Nausea and Vomiting - Change at Cycle 13Nausea and Vomiting - Change at Cycle 15Nausea and Vomiting - Change at Cycle 17Nausea and Vomiting - Change at Cycle 19Nausea and Vomiting - Change at Cycle 21Nausea and Vomiting - Change at Cycle 23Nausea and Vomiting - Change at Cycle 25Nausea and Vomiting - Change at Cycle 27Nausea and Vomiting - Change at Cycle 29Nausea and Vomiting - Change at Cycle 31Nausea and Vomiting - Change at Cycle 33Nausea and Vomiting - Change at Cycle 35Nausea and Vomiting - Change at EOTPain - BaselinePain - Change at Cycle 3Pain - Change at Cycle 5Pain - Change at Cycle 7Pain - Change at Cycle 9Pain - Change at Cycle 11Pain - Change at Cycle 13Pain - Change at Cycle 15Pain - Change at Cycle 17Pain - Change at Cycle 19Pain - Change at Cycle 21Pain - Change at Cycle 23Pain - Change at Cycle 25Pain - Change at Cycle 27Pain - Change at Cycle 29Pain - Change at Cycle 31Pain - Change at Cycle 33Pain - Change at Cycle 35Pain - Change at EOTDyspnoea - BaselineDyspnoea - Change at Cycle 3Dyspnoea - Change at Cycle 5Dyspnoea - Change at Cycle 7Dyspnoea - Change at Cycle 9Dyspnoea - Change at Cycle 11Dyspnoea - Change at Cycle 13Dyspnoea - Change at Cycle 15Dyspnoea - Change at Cycle 17Dyspnoea - Change at Cycle 19Dyspnoea - Change at Cycle 21Dyspnoea - Change at Cycle 23Dyspnoea - Change at Cycle 25Dyspnoea - Change at Cycle 27Dyspnoea - Change at Cycle 29Dyspnoea - Change at Cycle 31Dyspnoea - Change at Cycle 33Dyspnoea - Change at Cycle 35Dyspnoea - Change at EOTInsomnia - BaselineInsomnia - Change at Cycle 3Insomnia - Change at Cycle 5Insomnia - Change at Cycle 7Insomnia - Change at Cycle 9Insomnia - Change at Cycle 11Insomnia - Change at Cycle 13Insomnia - Change at Cycle 15Insomnia - Change at Cycle 17Insomnia - Change at Cycle 19Insomnia - Change at Cycle 21Insomnia - Change at Cycle 23Insomnia - Change at Cycle 25Insomnia - Change at Cycle 27Insomnia - Change at Cycle 29Insomnia - Change at Cycle 31Insomnia - Change at Cycle 33Insomnia - Change at Cycle 35Insomnia - Change at EOTAppetite loss - BaselineAppetite loss - Change at Cycle 3Appetite loss - Change at Cycle 5Appetite loss - Change at Cycle 7Appetite loss - Change at Cycle 9Appetite loss - Change at Cycle 11Appetite loss - Change at Cycle 13Appetite loss - Change at Cycle 15Appetite loss - Change at Cycle 17Appetite loss - Change at Cycle 19Appetite loss - Change at Cycle 21Appetite loss - Change at Cycle 23Appetite loss - Change at Cycle 25Appetite loss - Change at Cycle 27Appetite loss - Change at Cycle 29Appetite loss - Change at Cycle 31Appetite loss - Change at Cycle 33Appetite loss - Change at Cycle 35Appetite loss - Change at EOTConstipation - BaselineConstipation - Change at Cycle 3Constipation - Change at Cycle 5Constipation - Change at Cycle 7Constipation - Change at Cycle 9Constipation - Change at Cycle 11Constipation - Change at Cycle 13Constipation - Change at Cycle 15Constipation - Change at Cycle 17Constipation - Change at Cycle 19Constipation - Change at Cycle 21Constipation - Change at Cycle 23Constipation - Change at Cycle 25Constipation - Change at Cycle 27Constipation - Change at Cycle 29Constipation - Change at Cycle 31Constipation - Change at Cycle 33Constipation - Change at Cycle 35Constipation - Change at EOTDiarrhoea - BaselineDiarrhoea - Change at Cycle 3Diarrhoea - Change at Cycle 5Diarrhoea - Change at Cycle 7Diarrhoea - Change at Cycle 9Diarrhoea - Change at Cycle 11Diarrhoea - Change at Cycle 13Diarrhoea - Change at Cycle 15Diarrhoea - Change at Cycle 17Diarrhoea - Change at Cycle 19Diarrhoea - Change at Cycle 21Diarrhoea - Change at Cycle 23Diarrhoea - Change at Cycle 25Diarrhoea - Change at Cycle 27Diarrhoea - Change at Cycle 29Diarrhoea - Change at Cycle 31Diarrhoea - Change at Cycle 33Diarrhoea - Change at Cycle 35Diarrhoea - Change at EOTFinancial difficulties - BaselineFinancial difficulties - Change at Cycle 3Financial difficulties - Change at Cycle 5Financial difficulties - Change at Cycle 7Financial difficulties - Change at Cycle 9Financial difficulties - Change at Cycle 11Financial difficulties - Change at Cycle 13Financial difficulties - Change at Cycle 15Financial difficulties - Change at Cycle 17Financial difficulties - Change at Cycle 19Financial difficulties - Change at Cycle 21Financial difficulties - Change at Cycle 23Financial difficulties - Change at Cycle 25Financial difficulties - Change at Cycle 27Financial difficulties - Change at Cycle 29Financial difficulties - Change at Cycle 31Financial difficulties - Change at Cycle 33Financial difficulties - Change at Cycle 35Financial difficulties - Change at EOT
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)29.167.358.409.547.8911.308.337.416.708.9310.3910.807.669.6611.6714.0715.1514.4412.315.886.686.986.616.208.976.826.853.456.563.997.874.027.251.6713.333.033.336.6420.472.682.523.002.726.645.167.269.398.747.258.335.755.074.1710.007.586.6710.8513.453.635.756.986.898.196.363.585.166.783.794.041.233.03-1.7516.6716.6716.676.5324.150.37-0.08-2.37-0.242.560.65-2.19-1.921.640.74-0.93-0.00-1.52-3.33-4.44-6.06-3.335.3117.389.109.029.849.9814.5310.6710.748.919.8413.0412.3811.4915.9415.0015.5615.1516.6712.0312.712.423.772.635.354.424.584.925.438.336.069.265.751.456.6722.2212.1210.003.7810.3711.7210.8514.6311.4415.4611.2611.0210.3415.2514.0718.5210.3413.6416.6720.0018.1830.007.3120.12-1.83-1.32-0.99-0.493.301.11-0.270.771.674.442.94-4.60-2.900.00-2.22-3.030.002.97

Change From Baseline in HRQL EQ-5D-3L Quality of Life: Single Index Utility Score

EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and Visual Analogue Scale (VAS). EQ-5D descriptive system comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels (no problem, some problems & severe problems) within a particular EQ-5D dimension. 5 dimensional 3-level system was converted into single index utility score. Possible values for single index utility score ranged from -0.594 (severe problems in all dimensions) to 1.0 (no problem in all dimensions) on scale where 1 represented best possible health state. (NCT01571284)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)

Interventionunits on a scale (Mean)
BaselineChange at Cycle 3Change at Cycle 5Change at Cycle 7Change at Cycle 9Change at Cycle 11Change at Cycle 13Change at Cycle 15Change at Cycle 17Change at Cycle 19Change at Cycle 21Change at Cycle 23Change at Cycle 25Change at Cycle 27Change at Cycle 29Change at Cycle 31Change at Cycle 33Change at Cycle 35Change at EOT
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)0.77-0.02-0.03-0.04-0.05-0.07-0.05-0.06-0.05-0.05-0.09-0.14-0.08-0.08-0.08-0.120.02-0.05-0.11

Change From Baseline in HRQL EQ-5D-3L VAS Score

EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and VAS. EQ-5D descriptive system comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels (no problem, some problems & severe problems) within a particular EQ-5D dimension. 5 dimensional 3-level system was converted into single index utility score. The VAS recorded the respondent's self-rated health on a vertical visual analogue scale. The VAS 'thermometer' has endpoints of 100 (Best imaginable health state) at the top and 0 (Worst imaginable health state) at the bottom. This information can be used as a quantitative measure of health outcome as judged by the individual respondents. (NCT01571284)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)

Interventionunits on a scale (Mean)
BaselineChange at Cycle 3Change at Cycle 5Change at Cycle 7Change at Cycle 9Change at Cycle 11Change at Cycle 13Change at Cycle 15Change at Cycle 17Change at Cycle 19Change at Cycle 21Change at Cycle 23Change at Cycle 25Change at Cycle 27Change at Cycle 29Change at Cycle 31Change at Cycle 33Change at Cycle 35Change at EOT
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)72.81-1.85-2.15-2.20-2.74-3.10-2.36-1.05-1.91-3.06-2.13-5.77-7.28-4.94-8.80-6.69-7.90-8.88-6.67

Mean Change From Baseline in Health Related Quality of Life (HRQL) European Organization for Research and Treatment for Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30 Score): Global Health Status

EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) & other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health & quality of life, coded on 7-point scale (1=very poor to 7=excellent).EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 & 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favourable outcome with a best quality of life for participant. (NCT01571284)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at the end of treatment (EOT) (within 30 days of last treatment) (maximum exposure: 214 weeks)

Interventionunits on a scale (Mean)
BaselineChange at Cycle 3Change at Cycle 5Change at Cycle 7Change at Cycle 9Change at Cycle 11Change at Cycle 13Change at Cycle 15Change at Cycle 17Change at Cycle 19Change at Cycle 21Change at Cycle 23Change at Cycle 25Change at Cycle 27Change at Cycle 29Change at Cycle 31Change at Cycle 33Change at Cycle 35Change at EOT
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)68.61-3.34-4.70-3.63-3.97-5.85-2.26-3.05-1.18-2.36-5.56-6.86-8.05-10.14-8.33-9.44-11.36-5.83-8.82

Mean Change From Baseline in HRQL EORTC QLQ-C30 Score: Functional Scales

EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) & other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health & quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 & 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28).Answers were converted into grading scale, with values between 0 and 100. A high score represented a favourable outcome with a best quality of life for participant. (NCT01571284)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)

Interventionunits on a scale (Mean)
Physical - BaselinePhysical - Change at Cycle 3Physical - Change at Cycle 5Physical - Change at Cycle 7Physical - Change at Cycle 9Physical - Change at Cycle 11Physical - Change at Cycle 13Physical - Change at Cycle 15Physical - Change at Cycle 17Physical - Change at Cycle 19Physical - Change at Cycle 21Physical - Change at Cycle 23Physical - Change at Cycle 25Physical - Change at Cycle 27Physical - Change at Cycle 29Physical - Change at Cycle 31Physical - Change at Cycle 33Physical - Change at Cycle 35Physical - Change at EOTRole - BaselineRole - Change at Cycle 3Role - Change at Cycle 5Role - Change at Cycle 7Role - Change at Cycle 9Role - Change at Cycle 11Role - Change at Cycle 13Role - Change at Cycle 15Role - Change at Cycle 17Role - Change at Cycle 19Role - Change at Cycle 21Role - Change at Cycle 23Role - Change at Cycle 25Role - Change at Cycle 27Role - Change at Cycle 29Role - Change at Cycle 31Role - Change at Cycle 33Role - Change at Cycle 35Role - Change at EOTEmotional - BaselineEmotional - Change at Cycle 3Emotional - Change at Cycle 5Emotional - Change at Cycle 7Emotional - Change at Cycle 9Emotional - Change at Cycle 11Emotional - Change at Cycle 13Emotional - Change at Cycle 15Emotional - Change at Cycle 17Emotional - Change at Cycle 19Emotional - Change at Cycle 21Emotional - Change at Cycle 23Emotional - Change at Cycle 25Emotional - Change at Cycle 27Emotional - Change at Cycle 29Emotional - Change at Cycle 31Emotional - Change at Cycle 33Emotional - Change at Cycle 35Emotional - Change at EOTCognitive - BaselineCognitive - Change at Cycle 3Cognitive - Change at Cycle 5Cognitive - Change at Cycle 7Cognitive - Change at Cycle 9Cognitive - Change at Cycle 11Cognitive - Change at Cycle 13Cognitive - Change at Cycle 15Cognitive - Change at Cycle 17Cognitive - Change at Cycle 19Cognitive - Change at Cycle 21Cognitive - Change at Cycle 23Cognitive - Change at Cycle 25Cognitive - Change at Cycle 27Cognitive - Change at Cycle 29Cognitive - Change at Cycle 31Cognitive - Change at Cycle 33Cognitive - Change at Cycle 35Cognitive- Change at EOTSocial - BaselineSocial - Change at Cycle 3Social - Change at Cycle 5Social - Change at Cycle 7Social - Change at Cycle 9Social - Change at Cycle 11Social - Change at Cycle 13Social - Change at Cycle 15Social - Change at Cycle 17Social - Change at Cycle 19Social - Change at Cycle 21Social - Change at Cycle 23Social - Change at Cycle 25Social - Change at Cycle 27Social - Change at Cycle 29Social - Change at Cycle 31Social - Change at Cycle 33Social - Change at Cycle 35Social - Change at EOT
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)81.79-3.73-3.95-4.62-4.36-6.99-4.99-3.54-5.10-5.68-5.70-7.87-5.75-6.59-7.67-9.33-5.45-10.00-11.1679.91-6.26-5.66-6.68-6.55-8.76-7.36-7.18-9.58-9.84-9.78-10.65-10.92-10.14-10.83-14.44-15.15-15.00-12.1178.961.140.741.581.690.080.932.512.911.390.061.754.981.572.641.300.25-0.00-2.8786.90-1.77-1.87-1.99-2.18-4.27-2.83-2.28-3.45-5.00-5.56-5.71-6.90-5.80-6.67-5.56-10.61-11.67-4.9880.57-2.05-2.86-4.78-4.56-7.09-5.56-6.18-5.56-5.28-5.56-7.62-4.60-2.17-5.00-7.78-1.52-1.67-9.01

Number of Participants With Abnormal Electrolytes Parameters

Abnormal electrolytes parameters included: hyponatremia, hypernatremia, hypocalcemia, hypercalcemia, hypokalemia, and hyperkalemia. Number of participants with each of these parameters were analyzed by grades ( All Grades and Grades 3-4 as per NCI CTCAE Version 4.03, where Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

InterventionParticipants (Count of Participants)
Hyponatremia: All GradesHyponatremia: Grades 3-4Hypernatremia: All GradesHypernatremia: Grades 3-4Hypocalcemia: All GradesHypocalcemia: Grades 3-4Hypercalcemia: All GradesHypercalcemia: Grades 3-4Hypokalemia: All GradesHypokalemia: Grades 3-4Hyperkalemia: All GradesHyperkalemia: Grades 3-4
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)1813275121355221211616610

Number of Participants With Abnormal Hematological Parameters

Abnormal hematological parameters included: anaemia, thrombocytopenia, leukopenia and neutropenia. Number of participants with each of these parameters were analyzed by grades (All Grades and Grades 3-4 as per NCI CTCAE (Version 4.03), where Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

InterventionParticipants (Count of Participants)
Anaemia: All GradesAnaemia: Grades 3-4Thrombocytopenia: All GradesThrombocytopenia: Grades 3-4Leukopenia: All GradesLeukopenia: Grades 3-4Neutropenia: All GradesNeutropenia: Grades 3-4
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)535142931353272450227

Number of Participants With Abnormal Non-Gradable Biochemistry Parameters

Non-gradeable biochemistry parameters included; chloride, urea, total protein, blood urea nitrogen (BUN) and lactate dehydrogenase (LDH). Number of participants with upper limit of normal ranges (ULN) for each of these parameters were reported. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

InterventionParticipants (Count of Participants)
ChlorideChloride>ULNBUNBUN>ULNUREAUREA>ULNLDHLDH>ULNTotal proteinsTotal proteins>ULN
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)1352174183602507942316277

Number of Participants With Abnormal Renal and Liver Function Parameters

Renal and liver function parameters included: creatinine, hyperbilirubinemia, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase. Number of participants with each of these parameters were analyzed by grades (All Grades and Grades 3-4) as per NCI CTCAE version 4.03, where Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

InterventionParticipants (Count of Participants)
Creatinine: All GradesCreatinine: Grades 3-4Hyperbilirubinemia: All GradesHyperbilirubinemia: Grades 3-4AST: All GradesAST: Grades 3-4ALT: All GradesALT: Grades 3-4Alkaline phosphatase: All GradesAlkaline phosphatase: Grades 3-4
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)16121309342122701046523

Number of Participants With Cycle Delay and/or Dose Modification

A theoretical cycle is a 2 week period i.e. 14 days. A cycle is delayed if duration of previous cycle is greater than 14+2 days ; dose modification includes dose reduction and dose omission. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

InterventionParticipants (Count of Participants)
No delay and no dose modificationAny delay and/or dose modificationDelay onlyDelay and Aflibercept modifiedDelay and FOLFIRI modifiedDelay and Aflibercept and Folfiri modifiedOnly Aflibercept modifiedOnly FOLFIRI modifiedBoth Aflibercept and FOLFIRI modified
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)11966016339308975435

Number of Participants With International Normalized Ratio (INR)

The INR is a derived measure of the prothrombin time. The INR is the ratio of a participant's prothrombin time to a normal control sample. Normal range (without anti coagulation therapy): 0.8-1.2; Targeted range (with anti coagulation therapy) 2.0-3.0. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

InterventionParticipants (Count of Participants)
INR<1.5INR>=1.5 to <3INR>=3 to <5INR>=5
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)106022

Number of Participants With Other Abnormal Biochemistry Parameters

Other abnormal biochemistry parameters included: hypoglycemia, hyperglycemia and hypoalbuminemia. Number of participants with each of these parameters were analyzed by grades (All Grades and Grades 3-4) as per NCI CTCAE Version 4.03, where Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

InterventionParticipants (Count of Participants)
Hypoglycemia: All GradesHypoglycemia: Grades 3-4Hyperglycemia: All GradesHyperglycemia: Grades 3-4Hypoalbuminemia: All GradesHypoalbuminemia: Grades 3-4
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)906403302416

Number of Participants With Proteinuria (Grade>=2) Concomitant With Hematuria and /or Hypertension

Proteinuria is defined as the presence of excess proteins in the urine (assessed either by spot sample, dipstick/ urine protein or 24 hour urine collection). Hematuria is defined as the presence of blood in urine (positive dipstick for RBC or reported AE). Number of participants with proteinuria grade >=2 (graded as per NCI CTCAE Version 4.03), where Grade>=2 represents moderate to life-threatening/disabling event. Hypertension (high blood pressure) is defined as having a blood pressure reading of more than 140/90 mmHg over a number of weeks. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

InterventionParticipants (Count of Participants)
Proteinuria with hematuriaProteinuria with hypertensionProteinuria with hematuria and hypertension
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)7243

Number of Participants With Proteinuria Events

Proteinuria is defined as the ratio of protein to creatinine. Number of participants with proteinuria were analyzed by grades (Grades 1, 2, 3 ,4) as per NCI CTCAE Version 4.03 where Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

InterventionParticipants (Count of Participants)
Grade 1Grade 2Grade 3Grade 4
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)286123545

Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an adverse event (AE) without regard to possibility of causal relationship with this treatment. A serious AE (SAE): Any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. National Cancer Institute Common Terminology Criteria (NCI-CTCAE) Version 4.03 was used to assess severity (Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling) of AEs. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

InterventionParticipants (Count of Participants)
Any TEAE (All Grades)Any TEAEs (Grades 3-4)Any serious TEAEAny serious related TEAEAny TEAE leading to deathAny TEAE (permanent treatment discontinuation)Any TEAE (premature treatment discontinuation)
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)76960927215947208104

Number of Participants With Urinary Protein-Creatinine Ratio (UPCR)

Urinary protein creatinine ratio (UPCR) corresponds to the ratio of the urinary protein and urinary creatinine concentration (expressed in mg/dL). This ratio provides an accurate quantification of 24-hours urinary protein excretion. There is a high correlation between morning UPCR and 24-hour proteinuria in participants with normal or reduced renal functions. Normal ratio is < or = 1. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

InterventionParticipants (Count of Participants)
UPCR<=1UPCR>=1 to <=2UPCR>=2 to <=3UPCR>3
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)265512427

Clinical Benefit Rate

"Clinical benefit rate (CR, PR, or SD = 24 weeks) for women For ErbB2 Positive Advanced Breast Cancer. Clinical benefit rate was the percentage of subjects who achieved overall tumor response per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.~Clinical Benefit (CB) = CR + PR + SD >= 24 weeks." (NCT00777101)
Timeframe: From randomization date to progression or last tumor assessment, assessed up to 69 months

Interventionpercentage of participants (Median)
Neratinib44.4
Lapatinib+Capecitabine63.8

Duration of Response

Duration of response was measured from the time at which response criteria were met for complete response (CR) or partial response (PR) (whichever status was recorded first) until the first date of recurrence or progressive disease (PD) or death. For subjects without death or progression, censorship was at the last valid tumor assessment per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions. (NCT00777101)
Timeframe: From start date of response to first PD, assessed up to 69 months after the first subject was randomized.

Interventionmonths (Median)
Neratinib12.48
Lapatinib+Capecitabine7.98

Frequency of CNS Metastases (Frequency)

The percent of patients with symptomatic or progressive CNS lesions was the proportion of subjects who had PD considering CNS lesions only, according to RECIST criteria. (NCT00777101)
Timeframe: From randomization date to first CNS symptom or lesions

Interventionpercentage of participants (Number)
Neratinib9.4
Lapatinib+Capecitabine12.9

Objective Response Rate (ORR).

Objective Response Rate, investigator assessment. The ORR was defined as the percentage of participants demonstrating a confirmed objective response, either Complete Response (CR) or Partial Response (PR) during the study per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v.1.0: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; and Non-PD for non-target lesions, and no new lesions. (NCT00777101)
Timeframe: From randomization date to progression or last tumor assessment, assessed up to 69 months

Interventionpercentage of participants (Number)
Neratinib29.1
Lapatinib+Capecitabine40.5

Overall Survival (OS)

Overall Survival (OS) was defined as the time from randomization to death due to any cause. Subjects last known to be alive were censored at the last date of last contact or the data cutoff employed for the analysis, whichever was earlier. (NCT00777101)
Timeframe: From randomization date to death, assessed up to 69 months

Interventionmonths (Median)
Neratinib19.74
Lapatinib+Capecitabine23.62

Progression Free Survival

Progression Free Survival, Measured in Months, for Subjects Randomized. Investigator assessment. The time interval from the date of randomization until the earliest date of progression per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) or death due to any cause. For subjects without death or progression, censorship was at the last valid tumor assessment. (NCT00777101)
Timeframe: From randomization date to progression or death, assessed up to 69 months

Interventionmonths (Median)
Neratinib4.53
Lapatinib+Capecitabine6.83

Time to CNS Metastases

Time to symptomatic or progressive Central nervous system (CNS) lesions. Time to symptomatic or progressive CNS lesions was the time from the date of randomization until the date of progressive disease (PD) considering CNS lesions only (ie, appearance of newly diagnosed CNS lesions or progressive CNS lesions). (NCT00777101)
Timeframe: From randomization date to first CNS symptom or lesions

Interventionmonths (Median)
Neratinib19.68
Lapatinib+CapecitabineNA

Number of Participants Who Discontinued Neratinib Early

The number of participants who discontinued neratinib earlier than expected during the course of study therapy will be reported (NCT03094052)
Timeframe: Up to 55 weeks

InterventionParticipants (Count of Participants)
Treatment (Neratinib)1

Number of Participants With Neratinib Dose Holds

The number of participants who experienced a dose hold of neratinib during the course of study therapy will be reported (NCT03094052)
Timeframe: Up to 55 weeks

InterventionParticipants (Count of Participants)
Treatment (Neratinib)0

Number of Participants With Neratinib Dose-reductions

The number of participants whose dose was reduced at any time during the course of therapy will be reported (NCT03094052)
Timeframe: Up to 55 weeks

InterventionParticipants (Count of Participants)
Treatment (Neratinib)5

Percentage of Participants With Grade 3 or Greater Diarrhea

Percentage of participants with clinically assessed grade 3 or greater diarrhea reported within the first 2 cycles (each cycle is 21 days) of neratinib while using anti-diarrheal strategies. Reports of diarrhea will be graded according to NCI CTCAE version 4.0. (NCT03094052)
Timeframe: Up to 6 weeks

Interventionpercentage of participants (Number)
Treatment (Neratinib)36.3

Percentage of Participants With Multiple Anti-diarrheal Medications

Percentage of patients requiring multiple anti-diarrheal medications will be reported (NCT03094052)
Timeframe: Up to 55 weeks

InterventionParticipants (Count of Participants)
Treatment (Neratinib)7

Percentage of Participants With Treatment-related Adverse Events

Percentage of participants with reported serious adverse events and adverse events of interest of any grade that have been determined to be related to the anti-diarrhea treatment will be reported by worst grade and associated toxicity. (NCT03094052)
Timeframe: Up to 55 weeks

Interventionparticipants (Number)
Treatment (Neratinib)100

Number of Participants With Intrahepatic Disease Progression After Treatment With Combination Low-dose Radiotherapy and Gemcitabine-cisplatin.

To determine the number of participants with Intrahepatic disease progression assessed by MRI of the abdomen with intravenous gadolinium contrast using RECIST criteria. (NCT02254681)
Timeframe: From date of first treatment until date of first documented progression or date of death from any cause, which ever comes first, assessed up to 24 months.

InterventionParticipants (Count of Participants)
Treatment6

Number of Participants With Intrahepatic Recurrence After Partial Hepatectomy With Antecedent Combination Low-dose Radiotherapy and Gemcitabine-cisplatin.

To determine the number of participants with Intrahepatic recurrence assessed by RECIST criteria using MRI of the abdomen with intravenous gadolinium contrast. (NCT02254681)
Timeframe: From date of partial hepatectomy until date of first documented recurrence or date of death from any cause, assessed up to 24 months.

InterventionParticipants (Count of Participants)
Treatment1

Number of Participants With Post-operative Complications After Partial Hepatectomy After Antecedent Combination Low-dose Radiotherapy and Gemcitabine-cisplatin.

Measured post-operative complications include (but not limited to) bile leak, liver failure, ascites, infection, any organ failure or insufficiency, venous thromboembolism, and mortality. (NCT02254681)
Timeframe: up to 90 days after partial hepatectomy

InterventionParticipants (Count of Participants)
Treatment1

Percentage of Participants Who Completed ≥ 95% of the Planned Radiotherapy Treatment With Concurrent Trastuzumab Emtansine Administration Without Significant (> 5 Days) Delay

(NCT01196052)
Timeframe: From the start to the end of radiotherapy treatment (up to 51 weeks)

InterventionPercentage of participants (Number)
Trastuzumab Emtansine94.7

Percentage of Participants Who Completed the Planned Duration of Trastuzumab Emtansine Treatment

Participants were to receive up to a total of 17 cycles of trastuzumab emtansine. If trastuzumab was given concurrently with either the optional docetaxel or optional radiation, then the number of 3-week cycles of trastuzumab therapy was subtracted from the planned 17 cycles of trastuzumab emtansine therapy. (NCT01196052)
Timeframe: From the start to the end of trastuzumab emtansine treatment (up to 51 weeks)

InterventionPercentage of participants (Number)
Trastuzumab Emtansine82.4

Percentage of Participants Who Experienced at Least 1 Adverse Event During Concurrent Hormonal Therapy With Trastuzumab Emtansine Treatment

(NCT01196052)
Timeframe: From the start to the end of concurrent hormonal therapy (up to 51 weeks)

InterventionPercentage of participants (Number)
Trastuzumab Emtansine69.4

Percentage of Participants Who Experienced at Least 1 Adverse Event During Concurrent Radiotherapy With Trastuzumab Emtansine Treatment

(NCT01196052)
Timeframe: From the start to the end of concurrent radiotherapy (up to 51 weeks)

InterventionPercentage of participants (Number)
Trastuzumab Emtansine94.9

Percentage of Participants With a Cardiac Event Within 12 Weeks After the Start of Trastuzumab Emtansine Treatment

A cardiac event was defined as death from a cardiac cause or severe congestive failure (New York Heart Association [NYHA] Class III or IV) with a decrease in left ventricular ejection fraction (LVEF) of ≥ 10% from Baseline to an LVEF of < 50%. (NCT01196052)
Timeframe: Baseline to 12 weeks after the start of trastuzumab emtansine treatment

InterventionPercentage of participants (Number)
Trastuzumab Emtansine0

Percentage of Participants With a Pathological Complete Response

Pathological complete response was defined as the absence of invasive neoplastic cells at microscopic examination of the primary tumor and lymph nodes after surgery following primary systemic therapy. Pathological complete response was evaluated in participants treated with neoadjuvant therapy doxorubicin/cyclophosphamide-5-fluorouracil/epirubicin/cyclophosphamide followed by 1 or more doses of trastuzumab emtansine and who underwent surgery. (NCT01196052)
Timeframe: Day of surgery

InterventionPercentage of participants (Number)
Trastuzumab Emtansine56.0

Adverse Events, LVEF Function, and Deaths

The following percentages of participants are reported: At least 1 adverse event while receiving T-DM1; at least 1 serious adverse event while receiving T-DM1; an adverse event leading to discontinuation, dose delay, or dose reduction of trastuzumab emtansine treatment; symptomatic cardiac dysfunction; and asymptomatic decline in left ventricular ejection fraction (LVEF). An asymptomatic LVEF decline was defined as a LVEF < 50% and a maximum decrease ≥ 10% from Baseline. The percentage of participants who died is reported. (NCT01196052)
Timeframe: From the start to the end of trastuzumab emtansine treatment (up to 51 weeks)

InterventionPercentage of participants (Number)
At least 1 adverse event (AE)At least 1 serious adverse eventAn AE leading to treatment discontinuationAn AE leading to dose delayAn AE leading to dose reductionSymptomatic cardiac dysfunctionAn asymptomatic decline in LVEFDeaths
Trastuzumab Emtansine98.610.113.529.121.60.02.70

Number of Participants With Serious and Non-Serious Adverse Events

Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01479348)
Timeframe: Date treatment consent signed to date off study, approximately 20 months and 12 days.

InterventionParticipants (Count of Participants)
1/Intravenous (IV) Tetrahydrouridine (THU)2

Frequency and Severity of Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v4.0

[F-18]-5-fluoro-2'-deoxycytidine (FdCyd) was administered intravenously with administration of tetrahydrouridine (THU) and the frequency and severity of adverse events was observed. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 0 is normal, Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe or medically significant but not immediately life-threatening, Grade 4 is life-threatening consequences, and Grade 5 is death related to adverse event. (NCT01479348)
Timeframe: Within 5 days after interventions

Interventionadverse events (Number)
Day 1 Adverse EventsDay 2, Grade 2 HypoalbuminemiaDay 2, Grade 3 AnemiaDay 3 Adverse EventsDay 4 Adverse EventsDay 5 Adverse Events
1/Intravenous (IV) Tetrahydrouridine (THU)011000

Radiation Dosimetry Estimates of 5-fluoro-2'-Deoxycytidine (FdCyd) in Humans

Radiation dosimetry was determined based on the first patients. This involved making region of interest measurements on the scan for each major organ and measuring the uptake. Using standard dosimetry software this is converted into mSv/MBq, a standard measure of dosimetry. The software is known as Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA) and is commonly used to generate this kind of data. (NCT01479348)
Timeframe: 1 year

InterventionmSv/MBq (Mean)
AdrenalsBrainBreastsGallbladder wallLower large intestine wallSmall intestineStomach wallUpper large intestine wallHeart wallKidneysLiverLungsMuscleOvariesPancreasRed marrowOsteogenic cellsSkinSpleenTestesThymusThyroidUrinary bladder wallUterus
1/Intravenous (IV) Tetrahydrouridine (THU)1.838.171.034.052.522.131.902.041.105.266.021.821.161.571.631.141.718.651.691.031.128.237.961.63

Tumor to Background Ratios (TBRs) of Target Lesions at 4 Time Points After Injection

Participants were scanned by positron emission tomography (PET) and lesions were measured at 4 time points after injection. (NCT01479348)
Timeframe: 9 minutes, 32 minutes, 56 minutes and 2 hours after injection

InterventionTBR ratio (Number)
Pt 1 L. Parotid adenosquam. cell ca at 9 minPt 1 L. Parotid adenosquam. cell ca at 32 minPt 1 L. Parotid adenosquam. cell ca at 56 minPt 1 L. Parotid adenosquam. cell ca at 2 hrsPt 2 R. Parapharyngeal Spindle Cell Ca at 9 minPt 2 R. Parapharyngeal Spindle Cell Ca at 32 minPt 2 R. Parapharyngeal Spindle Cell Ca at 56 minPt 2 R. Parapharyngeal Spindle Cell Ca at 2 hrsPt 3 Non-small Cell Lung Ca at 9 minPt 3 Non-small Cell Lung Ca at 32 minPt 3 Non-small Cell Lung Ca at 56 minPt 3 Non-small Cell Lung Ca at 2 hrsPt 4 Non-small Cell Lung Ca at 9 minPt 4 Non-small Cell Lung Ca at 32 minPt 4 Non-small Cell Lung Ca at 56 minPt 4 Non-small Cell Lung Ca at 2 hrsPt 5 Hepatocellular Ca at 9 minPt 5 Hepatocellular Ca at 32 minPt 5 Hepatocellular Ca at 56 minPt 5 Hepatocellular Ca at 2 hrs
1/Intravenous (IV) Tetrahydrouridine (THU)1.41.51.51.61.91.71.71.61.41.41.51.72.42.11.62.0NANANANA

Median Progression-Free Survival (PFS)

Time in months from the start of study treatment to the date of first progression (PD) according to the RECIST criteria, or death due to any cause. PER RECIST, a PD is indicated when there is at least a 20% increase in the sum of the longest diameters from target lesions relative to the smallest sum recorded since treatment is initiated. Median PFS was estimated using a Kaplan-Meier curve, and is the time at which 50% of patients remain alive without disease progression. (NCT00447330)
Timeframe: 5 years from study start date

Interventionsurvival time in months (Median)
1- Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avastin6.97

Median Survival

Time in months from the start of study treatment to date of death due to any cause. Median survival was estimated using a Kaplan-Meier curve and is the time point at which 50% of patients remain alive. (NCT00447330)
Timeframe: 5 years after study start date

Interventionsurvival time in months (Median)
1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti10.51

Response Rate

The proportion of patients for whom the best overall response is complete response (CR) or partial response (PR). A CR occurs when all lesions disappear; whereas, a PR is indicated when there is at least a 30% decrease in the sum of the longest diameters (LD) of the target lesion. A PD (progressive disese) occurs when there is at least a 20% increase in the sum of the LD relative to the smallest sum LD recorded since treatment is initiated. Disease is considered stable if there is no response and no PD. All patients were assigned a best response for inclusion in this calculation in accordance with the protocol. (NCT00447330)
Timeframe: Every 9 weeks for up to 1 year

Interventionpercentage of participants (Number)
1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti41.7

To Assess the Safety and Tolerability of the Combination of Bevacizumab, Oxaliplatin and Capecitabine in Patients With Previously Untreated Metastatic Esophagogastric Adenocarcinoma

Number of subjects who experienced an adverse event (NCT00447330)
Timeframe: Every 21 days

Interventionparticipants (Number)
1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti56

Dose Related Toxicity

dose related toxicity is defined as follows:1. WBC damage >= grade 3; granular cell decrease >= grade 3; hemoglobin >= grade 2; platelet >= grade 2;SGPT/SGOT elevation >= grade 2; ALP >= grade 2; GGT >= grade 2; Tbil >= grade 2;renal function damage: BUN/Cr elevation >= grade 2;Non-gradular cell decreased fever >= grade 2;nausea/vomiting >= grade 2; fatigue >= grade 3; weight loss >= grade 3;gastritis >= grade 3; dairrea >= grade 3; abdominal pain >= grade 3; pancreatitis >= grade 2; upper gastrointestinal bleeding >= grade 2;other toxic reaction >= grade 3;KPS < 50 during the treatment (NCT01268943)
Timeframe: up to 9 weeks

Interventionevent (Number)
1000mg1
1200mg0
1400mg0
1500mg3

Cumulative Incidence of grade3+ Bowel Perforation, Grade 3+ Bleeding (Ocurring Withing 1 Years) and grade4+ Nonhematologic Acute Adverse Events (Limited to Within 90 Days of Treatment Start)

(NCT00685763)
Timeframe: 1 year following the completion of radiation therapy

Interventionparticipants (Number)
Proton Radiation and Chemotherapy0

Number of Participants Experienced Dose Limited Toxicity

Dose related toxicity is defined as follows:1. luecopenia > grade 2; granular cell decrease > grade 2; anemia > grade 1; platelet > grade 1;SGPT/SGOT elevation > grade 1; ALP > grade 1; GGT > grade 1; Tbil > grade 1;renal function damag > grade 2;Non-gradular cell decreased fever > grade 1;nausea/vomiting > grade 1; fatigue > grade 2; weight loss > grade 2;gastritis > grade 2; dairrea > grade 2; abdominal pain > grade 2; upper gastrointestinal bleeding > grade 1;other toxic reaction > grade 2;KPS < 50 during the treatment (NCT01584544)
Timeframe: up to 7 weeks from start of the treatment

Interventionparticipants (Number)
1000mg0
1200mg1
1350mg1
1500mg0
1650mg1

Reviews

15 reviews available for fluorouracil and Nausea

ArticleYear
The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis.
    Scientific reports, 2018, 06-06, Volume: 8, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Fatigue; Fluorouracil; Humans

2018
Small intestinal adenocarcinoma: rarely considered, often missed?
    Postgraduate medical journal, 2013, Volume: 89, Issue:1050

    Topics: Adenocarcinoma; Aged; Capsule Endoscopy; Celiac Disease; Chemotherapy, Adjuvant; Cystic Fibrosis; Do

2013
Raltitrexed-based chemotherapy for advanced colorectal cancer.
    Clinics and research in hepatology and gastroenterology, 2014, Volume: 38, Issue:2

    Topics: Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Chemical and Drug Induce

2014
Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer.
    The Cochrane database of systematic reviews, 2016, Feb-12, Volume: 2

    Topics: Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combine

2016
Oxaliplatin/fluorouracil-based adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery: a systematic review and meta-analysis of randomized controlled trials.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2016, Volume: 18, Issue:8

    Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; D

2016
Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jul-10, Volume: 29, Issue:20

    Topics: Adolescent; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemo

2011
Comparison between doublet agents versus single agent in metastatic breast cancer patients previously treated with an anthracycline and a taxane: a meta-analysis of four phase III trials.
    Breast (Edinburgh, Scotland), 2013, Volume: 22, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Anthracyclines; Antineoplastic Combined Chemotherapy Protoco

2013
Management of diabetes and pancreatic cancer.
    Oncology nursing forum, 2012, Volume: 39, Issue:5

    Topics: Adenocarcinoma; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2012
Multiorgan failure in a patient treated with the 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan regimen.
    Clinical colorectal cancer, 2013, Volume: 12, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Duodenal Neoplasms; Fe

2013
[Toxicities associated with chemotherapy in colorectal cancer].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 7

    Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Clinical Trials a

2003
[Complications of hepatic artery chemotherapy for liver metastases in colorectal cancer].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arterial Occlusive Diseases; Cholangitis, Sclerosing

2003
Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda).
    European journal of oncology nursing : the official journal of European Oncology Nursing Society, 2004, Volume: 8 Suppl 1

    Topics: Alopecia; Ambulatory Care; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic

2004
Advanced colorectal cancer: current treatment and nursing management with economic considerations.
    Clinical journal of oncology nursing, 2005, Volume: 9, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Campt

2005
Capecitabine: a new adjuvant option for colorectal cancer.
    Clinical journal of oncology nursing, 2006, Volume: 10, Issue:4

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Cause of Death; Colorectal Neop

2006
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:11

    Topics: Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Huma

1998
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:11

    Topics: Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Huma

1998
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:11

    Topics: Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Huma

1998
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:11

    Topics: Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Huma

1998

Trials

203 trials available for fluorouracil and Nausea

ArticleYear
Single Nucleotide Polymorphism Directed Antiemetic Treatment in Women With Breast Cancer Treated With Neo- or Adjuvant Chemotherapy: A Randomised Multicentre Phase II Study. (EudraCT: 2015-000658-39).
    Anticancer research, 2023, Volume: 43, Issue:6

    Topics: Antiemetics; Antineoplastic Agents; Breast Neoplasms; Female; Fluorouracil; Humans; Nausea; Polymorp

2023
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 12-01, Volume: 30, Issue:12

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2019
Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802).
    Clinical colorectal cancer, 2020, Volume: 19, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal N

2020
A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophospham
    Cancer medicine, 2020, Volume: 9, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast

2020
Daily dose to organs at risk predicts acute toxicity in pancreatic stereotactic radiotherapy.
    Acta oncologica (Stockholm, Sweden), 2020, Volume: 59, Issue:8

    Topics: Abdominal Pain; Acute Disease; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols;

2020
FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial.
    JAMA oncology, 2020, 08-01, Volume: 6, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Esophageal Ne

2020
Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial.
    JAMA network open, 2021, 04-01, Volume: 4, Issue:4

    Topics: Adult; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aprepitan

2021
A Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated With First-Line FOLFIRI Plus Bevacizumab.
    Oncology research, 2021, Sep-07, Volume: 28, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot

2021
Comparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinoma.
    Oncotarget, 2017, Jun-06, Volume: 8, Issue:23

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat

2017
Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2018, Volume: 26, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepit

2018
Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms.
    Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2017, Volume: 37, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Camptothecin; Diarrhea; Drugs, Chinese Herbal; Femal

2017
Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP).
    Clinical colorectal cancer, 2019, Volume: 18, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2019
Efficacy of nimotuzumab combined with docetaxel-cisplatin-fluorouracil regimen in treatment of advanced oral carcinoma.
    Cell biochemistry and biophysics, 2014, Volume: 68, Issue:1

    Topics: Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemot

2014
One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:14

    Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherap

2013
A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:14

    Topics: Administration, Oral; Adolescent; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protoc

2013
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:18

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca

2013
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:18

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca

2013
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:18

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca

2013
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:18

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca

2013
Optimal control of nausea and vomiting with a three-drug antiemetic regimen with aprepitant in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013, Volume: 21, Issue:11

    Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Benztropine; Camptoth

2013
[Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2013, Volume: 35, Issue:4

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabin

2013
Efficacy and tolerability of chemotherapy with modified dose-dense TCF regimen (TCF-dd) in locally advanced or metastatic gastric cancer: final results of a phase II trial.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2014, Volume: 17, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docet

2014
Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
    American journal of clinical oncology, 2016, Volume: 39, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisp

2016
Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms.
    Journal of clinical pharmacology, 2014, Volume: 54, Issue:5

    Topics: Adult; Aged; Anorexia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Proto

2014
A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:1

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Cohort Studies; De

2014
Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity?
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:17

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop

2014
DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).
    Journal of the National Cancer Institute, 2014, Volume: 106, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap

2014
A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2015, Volume: 23, Issue:6

    Topics: Administration, Cutaneous; Adult; Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Combined

2015
Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer.
    Anticancer research, 2014, Volume: 34, Issue:12

    Topics: Acetamides; Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic

2014
Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Apr-01, Volume: 33, Issue:10

    Topics: Adolescent; Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined

2015
Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial.
    European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:10

    Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Capecitabine; Colorectal Ne

2015
Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801).
    International journal of clinical oncology, 2016, Volume: 21, Issue:1

    Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Co

2016
A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma.
    Pancreas, 2016, Volume: 45, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin;

2016
Oral intake of ginger for chemotherapy-induced nausea and vomiting among women with breast cancer.
    Clinical journal of oncology nursing, 2015, Volume: 19, Issue:5

    Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide;

2015
A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors.
    Investigational new drugs, 2015, Volume: 33, Issue:6

    Topics: Administration, Oral; Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; D

2015
[Phase II clinical trial of two different modes of administration of the induction chemotherapy for locally advanced nasopharyngeal carcinoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2015, Volume: 37, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Cisplatin; Docetaxel;

2015
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.
    British journal of cancer, 2016, Mar-01, Volume: 114, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy

2016
Treatment results of alternating chemoradiotherapy with early assessment for advanced laryngeal cancer: A multi-institutional phase II study.
    Auris, nasus, larynx, 2017, Volume: 44, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C

2017
[Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2008, Volume: 30, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrah

2008
[Preliminary result of multi-center clinical trial on the docetaxel, 5-Fu and DDP in the treatment of advanced, recurrent or metastatic nasopharyngeal carcinoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2008, Volume: 30, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C

2008
Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.
    International journal of radiation oncology, biology, physics, 2009, Aug-01, Volume: 74, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial.
    BMC cancer, 2009, Apr-22, Volume: 9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplas

2009
[Oxaliplatin combined with ELF regimen in the treatment of patients with advanced gastric cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2009, Volume: 31, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pro

2009
Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:10

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2009
A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines.
    Journal of cancer research and clinical oncology, 2010, Volume: 136, Issue:1

    Topics: Adult; Aged; Anemia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasm

2010
[Efficacy of FORFIRI regimen on oxaliplatin-based chemotherapy-failed advanced colorectal cancer].
    Ai zheng = Aizheng = Chinese journal of cancer, 2009, Volume: 28, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic N

2009
Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer.
    Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetax

2010
Phase II study of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Colorectal Neoplas

2011
Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.
    Chinese journal of cancer, 2010, Volume: 29, Issue:5

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy

2010
[Comparison of the therapeutic effects of paclitaxel liposome-5-Fu versus paclitaxel-5-Fu on 67 patients with advanced gastric cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:3

    Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Pr

2010
Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer.
    Japanese journal of clinical oncology, 2010, Volume: 40, Issue:10

    Topics: Adult; Aged; Anorexia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com

2010
A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Oct-10, Volume: 28, Issue:29

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols

2010
A phase I study of docetaxel, oxaliplatin, & capecitabine (DOC) as first-line therapy of patients with locally advanced or metastatic adenocarcinoma of stomach and GE junction.
    Cancer investigation, 2010, Volume: 28, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2010
A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies.
    Acta oncologica (Stockholm, Sweden), 2011, Volume: 50, Issue:7

    Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dia

2011
[Nedaplatin or cisplatin combined with 5-fluorouracil for treatment of stage III-IVa nasopharyngeal carcinoma: a randomized controlled study].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2011, Volume: 33, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans; Lymp

2011
A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer.
    Chemotherapy, 2012, Volume: 58, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine

2012
Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer.
    Gastrointestinal endoscopy, 2012, Volume: 75, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2012
Antiemetic control with palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen in addition to either irinotecan or oxaliplatin: a retrospective study.
    Oncology, 2012, Volume: 83, Issue:3

    Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidi

2012
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Feb-20, Volume: 31, Issue:6

    Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis

2013
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Feb-20, Volume: 31, Issue:6

    Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis

2013
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Feb-20, Volume: 31, Issue:6

    Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis

2013
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Feb-20, Volume: 31, Issue:6

    Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis

2013
Optimal dose period for indisetron tablets for preventing chemotherapy-induced nausea and vomiting with modified FOLFOX6: a randomized pilot study.
    Chemotherapy, 2012, Volume: 58, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bridged

2012
Phase II trial of alternating mFOLFOX6 and FOLFIRI regimens in the first-line treatment for unresectable or metastatic colorectal cancer (KSCC0701).
    Oncology, 2013, Volume: 84, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2013
Results of adjuvant FOLFOX regimens in stage III colorectal cancer patients: retrospective analysis of 667 patients.
    Oncology, 2013, Volume: 84, Issue:4

    Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy;

2013
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases.
    Cancer, 2002, Aug-01, Volume: 95, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female;

2002
Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens.
    Cancer chemotherapy and pharmacology, 2002, Volume: 50, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression;

2002
Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study.
    Oncology, 2002, Volume: 63, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

2002
Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study.
    Oncology, 2002, Volume: 63, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2002
Reduced maintenance of complete protection from emesis for women during chemotherapy cycles.
    American journal of clinical oncology, 2003, Volume: 26, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protoc

2003
Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer.
    Journal of medical and dental sciences, 2002, Volume: 49, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cisp

2002
A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer.
    Cancer chemotherapy and pharmacology, 2004, Volume: 53, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Fatigu

2004
Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy.
    Cytokine, 2004, Feb-07, Volume: 25, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Blood;

2004
A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Mar-01, Volume: 10, Issue:5

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch

2004
Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docet

2004
Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea;

2004
Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors.
    Oncology, 2004, Volume: 66, Issue:4

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Cap

2004
Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer.
    BMC cancer, 2004, Jul-16, Volume: 4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms;

2004
Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.
    BMC cancer, 2004, Jul-20, Volume: 4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemother

2004
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:9

    Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt

2004
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:9

    Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt

2004
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:9

    Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt

2004
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:9

    Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt

2004
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:9

    Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt

2004
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:9

    Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt

2004
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:9

    Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt

2004
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:9

    Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt

2004
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:9

    Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt

2004
Phase I study of the combination of nedaplatin, adriamycin and 5-fluorouracil for treatment of advanced esophageal cancer.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2004, Volume: 17, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Diarrhea; Doxorubici

2004
Phase II clinical trial of 5-fluorouracil, trimetrexate, and leucovorin (NFL) in patients with advanced pancreatic cancer.
    International journal of gastrointestinal cancer, 2003, Volume: 34, Issue:2-3

    Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Female; Fluoro

2003
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:11

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols

2004
Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
    Japanese journal of clinical oncology, 2004, Volume: 34, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined

2004
Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
    Japanese journal of clinical oncology, 2004, Volume: 34, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined

2004
Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
    Japanese journal of clinical oncology, 2004, Volume: 34, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined

2004
Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
    Japanese journal of clinical oncology, 2004, Volume: 34, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined

2004
Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study.
    Cancer chemotherapy and pharmacology, 2005, Volume: 55, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di

2005
[Phase I study of the combination of nedaplatin (NED), adriamycin (ADM), and 5-fluorouracil (5-FU) (NAF) for treatment of unresectable advanced esophageal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Dose-Response Relati

2005
A multicenter randomized study comparing 5-fluorouracil continuous infusion (ci) plus 1-hexylcarbamoyl-5-fluorouracil and 5-FU ci alone in colorectal cancer.
    Oncology reports, 2005, Volume: 14, Issue:1

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colore

2005
Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer.
    American journal of clinical oncology, 2005, Volume: 28, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area

2005
Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma.
    The Annals of thoracic surgery, 2005, Volume: 80, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam

2005
[Clinical evaluation of chemotherapy with irinotecan (CPT-11), l-leucovorin (l-LV), 5-fluorouracil (5-FU), and UFT for metastatic or recurrent colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug A

2005
An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial.
    Oncology, 2005, Volume: 69, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia

2005
[A randomized crossover study of ramosetron plus dexamethasone for the prevention of nausea and vomiting induced by chemotherapy including cisplatin-comparison of ramosetron combined with 8 mg and 12 mg of dexamethasone].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:13

    Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma,

2005
Chronomodulated chemotherapy with oxaliplatin, 5-FU and sodium folinate in metastatic gastrointestinal cancer patients: original analysis of non-hematological toxicity and patient characteristics in a pilot investigation.
    International journal of clinical pharmacology and therapeutics, 2006, Volume: 44, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Chronotherapy; Diarrhe

2006
A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.
    Cancer chemotherapy and pharmacology, 2006, Volume: 58, Issue:5

    Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Esop

2006
A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.
    Cancer chemotherapy and pharmacology, 2006, Volume: 58, Issue:5

    Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Esop

2006
A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.
    Cancer chemotherapy and pharmacology, 2006, Volume: 58, Issue:5

    Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Esop

2006
A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.
    Cancer chemotherapy and pharmacology, 2006, Volume: 58, Issue:5

    Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Esop

2006
Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.
    Japanese journal of clinical oncology, 2006, Volume: 36, Issue:4

    Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Respo

2006
A phase I/II study of combination chemotherapy with gemcitabine and 5-fluorouracil for advanced pancreatic cancer.
    Japanese journal of clinical oncology, 2006, Volume: 36, Issue:9

    Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free S

2006
[Phase II multicenter clinical trial of nedaplatin in the treatment of malignant tumors].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2006, Volume: 28, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2006
Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma.
    Cancer, 2006, Sep-15, Volume: 107, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cape

2006
[Clinical evaluation of DLF, CLF and DFM regimens based on platinum compound plus 5-fluorouracil for treatment of advanced esophageal carcinoma].
    Ai zheng = Aizheng = Chinese journal of cancer, 2006, Volume: 25, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Ca

2006
[Phase II clinical trial of home-produced Nedaplatin in treating advanced esophageal carcinoma].
    Ai zheng = Aizheng = Chinese journal of cancer, 2006, Volume: 25, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Esophageal Ne

2006
[Phase I/II clinical trial of induction chemotherapy with nedaplatin (CDGP), docetaxel (DOC) and 5-fluorouracil (5-FU) for squamous cell carcinoma of head and neck].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:1

    Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous

2007
[Multicenter phase II study of modified FOLFIRI regimen in the advanced colorectal cancer patient refractory to fluoropyrimidine and oxaliplatin].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2006, Volume: 28, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Co

2006
[Efficacy and toxicity of FOLFOX6 regimen in treating colorectal cancer patients with liver metastasis].
    Ai zheng = Aizheng = Chinese journal of cancer, 2007, Volume: 26, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Disease-Free Surviva

2007
[Clinical comparison of GC regimen (gemcitabine and cisplatin) versus FEC regimen (fluorouracil, epirubicin, and cyclophosphamide) as neoadjuvant chemotherapy for breast cancer].
    Ai zheng = Aizheng = Chinese journal of cancer, 2007, Volume: 26, Issue:4

    Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamid

2007
Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma.
    Cancer, 2007, Jul-01, Volume: 110, Issue:1

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisp

2007
A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer.
    Japanese journal of clinical oncology, 2007, Volume: 37, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; F

2007
Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial.
    British journal of cancer, 2007, Dec-03, Volume: 97, Issue:11

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Di

2007
A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites.
    Japanese journal of clinical oncology, 2007, Volume: 37, Issue:12

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma; Disease-Fre

2007
[Study on the efficacy and safety of high dose thymopentin combined with trans-artery chemoembolization for primary liver cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2007, Volume: 29, Issue:12

    Topics: Adjuvants, Immunologic; Adult; Aged; Asthenia; CD4-Positive T-Lymphocytes; Chemoembolization, Therap

2007
Activity of sequential low-dose methotrexate and fluorouracil in advanced colorectal carcinoma: attempt at correlation with tissue and blood levels of phosphoribosylpyrophosphate.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1984, Volume: 2, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neopl

1984
A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1983, Volume: 1, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; BCG Vaccine; Breast Neoplasms;

1983
Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a "cycle active" non-cross-resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1984, Volume: 2, Issue:6

    Topics: Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials a

1984
A comparative study of oral tegafur and intravenous 5-fluorouracil in patients with metastatic colorectal cancer.
    American journal of clinical oncology, 1983, Volume: 6, Issue:2

    Topics: Administration, Oral; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Humans; Injections,

1983
Management of patients with metastatic adenocarcinoma of unknown origin: a Southwest Oncology Group study.
    Cancer treatment reports, 1983, Volume: 67, Issue:1

    Topics: Adenocarcinoma; Cyclophosphamide; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Fluoroura

1983
Randomized phase II studies in advanced colorectal carcinoma: a North Central Cancer Treatment Group study.
    Cancer treatment reports, 1983, Volume: 67, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Drug Evalu

1983
Treatment of advanced colon cancer with 5-fluorouracil (NSC19893) versus cyclophosphamide (NSC26271) plus 5-fluorouracil: prognostic aspects of the differential white blood cell count.
    Cancer, 1980, May-01, Volume: 45, Issue:9

    Topics: Adenocarcinoma; Clinical Trials as Topic; Colonic Neoplasms; Cyclophosphamide; Diarrhea; Drug Therap

1980
Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine.
    Cancer treatment reports, 1980, Volume: 64, Issue:1

    Topics: Alopecia; Antineoplastic Agents; Asparaginase; Bacterial Vaccines; Blood Cell Count; Breast Neoplasm

1980
5-Fluorouracil, methyl-CCNU, and radiotherapy with or without testolactone for localized adenocarcinoma of the exocrine pancreas: a Southwest Oncology Group Study.
    Cancer, 1980, Oct-01, Volume: 46, Issue:7

    Topics: Adenocarcinoma; Aged; Agranulocytosis; Anorexia; Antineoplastic Agents; Clinical Trials as Topic; Do

1980
Combination chemotherapy of advanced colorectal cancer with triazinate and ICRF-159 after failure of 5-Fluorouracil.
    Oncology, 1980, Volume: 37, Issue:5

    Topics: Clinical Trials as Topic; Colonic Neoplasms; Diarrhea; Drug Administration Schedule; Drug Therapy, C

1980
Combination chemotherapy of advanced colorectal cancer utilizing 5-fluorouracil, semustine, dacarbazine, vincristine, and hydroxyurea: a phase III trial by the Eastern Cooperative Oncology Group (EST: 4275).
    Cancer, 1982, Apr-15, Volume: 49, Issue:8

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; Drug Administration

1982
Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma.
    Cancer treatment reports, 1982, Volume: 66, Issue:8

    Topics: Activities of Daily Living; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neop

1982
Treatment of advanced breast carcinoma with 5-fluorouracil: a randomized comparison of two routes of delivery.
    Cancer, 1981, Oct-15, Volume: 48, Issue:8

    Topics: Administration, Oral; Breast Neoplasms; Female; Fluorouracil; Humans; Injections, Intravenous; Leuko

1981
Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.
    Cancer, 1981, Oct-15, Volume: 48, Issue:8

    Topics: Adenocarcinoma; Anemia; Carcinoembryonic Antigen; Female; Fluorouracil; Humans; Male; Middle Aged; N

1981
Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.
    Cancer, 1981, Oct-15, Volume: 48, Issue:8

    Topics: Adenocarcinoma; Anemia; Carcinoembryonic Antigen; Female; Fluorouracil; Humans; Male; Middle Aged; N

1981
Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.
    Cancer, 1981, Oct-15, Volume: 48, Issue:8

    Topics: Adenocarcinoma; Anemia; Carcinoembryonic Antigen; Female; Fluorouracil; Humans; Male; Middle Aged; N

1981
Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.
    Cancer, 1981, Oct-15, Volume: 48, Issue:8

    Topics: Adenocarcinoma; Anemia; Carcinoembryonic Antigen; Female; Fluorouracil; Humans; Male; Middle Aged; N

1981
Salvage chemotherapy with PEM and long-CF regimen in CDDP refractory advanced head and neck cancer.
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22 Suppl 3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi

1995
[Combination therapy with interferon-alpha and continuous infusion of 5-fluorouracil for advanced renal cell carcinoma].
    Hinyokika kiyo. Acta urologica Japonica, 1995, Volume: 41, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administration Sch

1995
[Comparison of granisetron alone and granisetron plus dexamethasone or hydroxyzine hydrochloride for the prevention of nausea and vomiting during chemotherapy including cisplatin].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:10

    Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female;

1995
[A late phase II trial of l-leucovorin and 5-fluorouracil in advanced colorectal cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:7

    Topics: Adult; Aged; Anorexia; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorou

1995
[Clinical effects of carmofur (Mifurol) on advanced and recurrent breast cancer in a cooperative study. Research association for re-evaluation of direct effects of Mifurol on breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:4

    Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Agents; Breast Neoplasms; Dizziness; Dru

1995
Phase I/II study of cisplatin, 5-fluorouracil and alpha-interferon for recurrent carcinoma of the head and neck.
    Investigational new drugs, 1994, Volume: 12, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Synergism; Fluorouracil

1994
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
    Lancet (London, England), 1994, May-07, Volume: 343, Issue:8906

    Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast

1994
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
    Lancet (London, England), 1994, May-07, Volume: 343, Issue:8906

    Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast

1994
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
    Lancet (London, England), 1994, May-07, Volume: 343, Issue:8906

    Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast

1994
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
    Lancet (London, England), 1994, May-07, Volume: 343, Issue:8906

    Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast

1994
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
    Lancet (London, England), 1994, May-07, Volume: 343, Issue:8906

    Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast

1994
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
    Lancet (London, England), 1994, May-07, Volume: 343, Issue:8906

    Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast

1994
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
    Lancet (London, England), 1994, May-07, Volume: 343, Issue:8906

    Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast

1994
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
    Lancet (London, England), 1994, May-07, Volume: 343, Issue:8906

    Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast

1994
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
    Lancet (London, England), 1994, May-07, Volume: 343, Issue:8906

    Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast

1994
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
    Lancet (London, England), 1994, May-07, Volume: 343, Issue:8906

    Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast

1994
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
    Lancet (London, England), 1994, May-07, Volume: 343, Issue:8906

    Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast

1994
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
    Lancet (London, England), 1994, May-07, Volume: 343, Issue:8906

    Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast

1994
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
    Lancet (London, England), 1994, May-07, Volume: 343, Issue:8906

    Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast

1994
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
    Lancet (London, England), 1994, May-07, Volume: 343, Issue:8906

    Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast

1994
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
    Lancet (London, England), 1994, May-07, Volume: 343, Issue:8906

    Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast

1994
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
    Lancet (London, England), 1994, May-07, Volume: 343, Issue:8906

    Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast

1994
Efficacy of a new 5-fluorouracil derivative, BOF-A2, in advanced non-small cell lung cancer. A multi-center phase II study.
    Acta oncologica (Stockholm, Sweden), 1994, Volume: 33, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Sm

1994
Delayed chemotherapy-induced nausea is augmented by high levels of endogenous noradrenaline.
    British journal of cancer, 1994, Volume: 70, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Circadian Rhythm; Cis

1994
[Use of dexamethasone as an antiemetic in patients with breast cancer treated with the CMF regimen].
    Przeglad lekarski, 1994, Volume: 51, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dexamethasone; F

1994
A phase I/II study of 4'-O-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose leucovorin as first-line therapy in advanced breast cancer patients.
    Cancer chemotherapy and pharmacology, 1994, Volume: 35, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Doxorubicin

1994
Control of emesis by intravenous granisetron in breast cancer patients treated with 5-FU, epirubicin and cyclophosphamide.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 1994, Volume: 2, Issue:3

    Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Constipation; Cyclophosphamide; Epirubicin; Fem

1994
[High dose cisplatin combination chemotherapy for advanced breast cancer--a report on 50 cases].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 1993, Volume: 15, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cisplatin;

1993
Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4, Issue:6

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms;

1993
[Intermittent hepatic arterial infusion of high-dose 5-FU for liver metastases from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:11

    Topics: Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intra-A

1993
Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.
    The New England journal of medicine, 1993, Apr-15, Volume: 328, Issue:15

    Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophospha

1993
Phase II evaluation of low-dose continuous 5-fluorouracil and weekly cisplatin in advanced adenocarcinoma of the stomach. A Southwest Oncology Group study.
    American journal of clinical oncology, 1995, Volume: 18, Issue:6

    Topics: Adenocarcinoma; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc

1995
Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collab
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:1

    Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemother

1996
Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
    Cancer, 1996, Jul-15, Volume: 78, Issue:2

    Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Anemia; Antidotes; Antimetabolites, Antineoplast

1996
[Comparative trial of granisetron alone and granisetron plus methylprednisolone for prevention of nausea and vomiting during cancer chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:9

    Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cross-Over Stud

1996
Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting.
    Journal of chemotherapy (Florence, Italy), 1996, Volume: 8, Issue:4

    Topics: Acute Disease; Administration, Oral; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protoc

1996
[Combination therapy with 5-fluorouracil (5-FU), cisplatin (CDDP) and interferon alpha-2B (IFN alpha-2B) for advanced renal cell carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:12

    Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Ce

1996
Phase II study of cisplatin, 5-fluorouracil, and leucovorin in inoperable squamous cell carcinoma of the esophagus. ONCOPAZ Cooperative Group, Spain.
    American journal of clinical oncology, 1996, Volume: 19, Issue:6

    Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combi

1996
[Clinical evaluation of ondansetron suppository].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:5

    Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Humans;

1997
[Clinical effect of two azasetron treatment methods against nausea and vomiting induced by anticancer drugs including CDDP].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:7

    Topics: Adult; Antiemetics; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cisplatin; Drug

1997
[Comparison of effects between single vs five-day injection of granisetron for combination chemotherapy with cisplatin and 5-fluorouracil for head and neck cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:9

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protoc

1997
Metastatic breast cancer: treatment with fluorouracil-based combinations.
    Oncology (Williston Park, N.Y.), 1997, Volume: 11, Issue:9 Suppl 10

    Topics: Adult; Aged; Anemia; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Di

1997
[Evaluation of 5-fluorouracil concentration in peripheral blood and side effects in continuous hepatic arterial infusion chemotherapy for patients with unresectable liver cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:12

    Topics: Abdominal Pain; Aged; Anorexia; Antimetabolites, Antineoplastic; Drug Administration Schedule; Femal

1997
[Efficacy of combination of ondansetron injection and tablet in CAF-induced emesis in breast cancer patients].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:3

    Topics: Administration, Oral; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neop

1998
Dacarbazine, fluorouracil, and leucovorin in patients with advanced neuroendocrine tumors: a phase II trial.
    American journal of clinical oncology, 1998, Volume: 21, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Dacarbazine; Female; F

1998
[A cooperative study on concomitant with low-dose divided administration of cisplatin (CDDP) and sustained drip infusion of 5-fluorouracil (5-FU) for unresectable advanced gastric cancer. Osaka Cisplatin Gastric Cancer Study Group].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:7

    Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administratio

1998
A crossover study of oral administration of UFT in chronic liver disease: comparison of continuous and intermittent schedules.
    Anti-cancer drugs, 1998, Volume: 9, Issue:5

    Topics: Administration, Oral; Aged; Area Under Curve; Carcinoma, Hepatocellular; Chronic Disease; Cross-Over

1998
A phase II trial of cisplatin and 5-fluorouracil in adenocarcinoma of the oesophagus.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 1998, Volume: 10, Issue:3

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combine

1998
Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy.
    Cancer chemotherapy and pharmacology, 1998, Volume: 42, Issue:4

    Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe

1998
Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1996, Volume: 2, Issue:9

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Cohor

1996
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
    Cancer, 1999, Feb-15, Volume: 85, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic;

1999
[Treatment for advanced colorectal carcinoma with 5-fluorouracil plus low-dose leucovorin].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone

1999
Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy.
    British journal of cancer, 1999, Volume: 80, Issue:3-4

    Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclopho

1999
[Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:8

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Al

1999
Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co

1999
Combination chemotherapy of continuous 5-FU infusion and low-dose cisplatin infusion for the treatment of advanced and recurrent gastric and colorectal adenocarcinomas.
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27 Suppl 2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2000
The role of low dose cisplatin plus 5-fluorouracil for treatment of recurrent and/or advanced squamous cell carcinoma of the head and neck.
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27 Suppl 2

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, S

2000
Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC).
    British journal of cancer, 2000, Volume: 83, Issue:12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuv

2000
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer.
    British journal of cancer, 2001, Apr-20, Volume: 84, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Conjunctivitis; D

2001
Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma.
    Journal of cancer research and clinical oncology, 2001, Volume: 127, Issue:5

    Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Chills; Combined Moda

2001
Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla

2001
Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
    British journal of cancer, 2001, Nov-02, Volume: 85, Issue:9

    Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols

2001
Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2002, Volume: 39, Issue:1

    Topics: Aged; Anemia; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; D

2002
Phase II study of a weekly 8-hour 5-fluorouracil and leucovorin infusion for patients with advanced colorectal cancer: dose adjusted according to its toxicity.
    Japanese journal of clinical oncology, 2001, Volume: 31, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Response Relati

2001
[Combination chemotherapy with nedaplatin (CDGP) and 5-FU for oral cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administ

2002
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Diarrhea; DNA, Antise

2002
Physical performance, toxicity, and quality of life as assessed by the physician and the patient.
    Acta oncologica (Stockholm, Sweden), 2002, Volume: 41, Issue:1

    Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols

2002
Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer.
    International journal of radiation oncology, biology, physics, 2002, May-01, Volume: 53, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female;

2002
Oral fluoropyrimidines in the treatment of advanced colorectal cancer--results of two consecutive phase II trials.
    Acta oncologica (Stockholm, Sweden), 2002, Volume: 41, Issue:2

    Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecit

2002
Treatment of advanced adenocarcinoma of the pancreas with combinations of streptozotocin plus 5-fluorouracil and streptozotocin plus cyclophosphamide.
    Cancer, 1977, Volume: 40, Issue:2

    Topics: Adenocarcinoma; Aged; Bone Marrow; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combina

1977
Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo.
    Annals of internal medicine, 1979, Volume: 91, Issue:6

    Topics: Adult; Aged; Antiemetics; Double-Blind Method; Dronabinol; Drug Evaluation; Fluorouracil; Gastrointe

1979
Combination with 5-fluorouracil, methyl-CCNU and beta-2-deoxythioguanosine in advanced colo-rectal adenocarcinoma.
    Clinical oncology, 1977, Volume: 3, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Deoxyribonucleosides; Drug Therapy, Combination; Fem

1977
Oral benzquinamide in the treatment of nausea and vomiting.
    Clinical pharmacology and therapeutics, 1975, Volume: 18, Issue:5 Pt 1

    Topics: Clinical Trials as Topic; Fluorouracil; Humans; Nausea; Prochlorperazine; Quinolizines; Vomiting

1975
Treatment of recurrent head and neck cancer with cisplatin and 5-fluorouracil vs. the same plus bleomycin and methotrexate.
    The Laryngoscope, 1992, Volume: 102, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma

1992
Methylprednisolone as antiemetic treatment in breast-cancer patients receiving cyclophosphamide, methotrexate, and 5-fluorouracil: a prospective, crossover, randomized blind study comparing two different dose schedules.
    Cancer chemotherapy and pharmacology, 1992, Volume: 30, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Double-Bl

1992
5-Fluorouracil, etoposide, and cisplatin in the management of metastatic non-small cell lung cancer.
    Cancer, 1991, Sep-01, Volume: 68, Issue:5

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung;

1991
[Clinical effects and toxicity of chemotherapy with cisplatin for head and neck cancer--the multi-institutional joint research in Tokai district].
    Nihon Gan Chiryo Gakkai shi, 1990, Oct-20, Volume: 25, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Female; Fluoroura

1990
Double-blind randomized cross-over trial comparing methylprednisolone with placebo in chemotherapy-induced nausea and vomiting: a study with special reference to efficacy parameters.
    Anti-cancer drugs, 1991, Volume: 2, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Double-Blind Method; Female;

1991
Tetracosactrin vs. methylprednisolone in the prevention of emesis in patients receiving FEC regimen for breast cancer.
    European journal of cancer (Oxford, England : 1990), 1991, Volume: 27, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cosyntropin; Cyclophosphamide; Epi

1991
A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:2

    Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neopla

1991
A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:6

    Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Brea

1990
A phase III randomised trial of cistplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group.
    British journal of cancer, 1990, Volume: 61, Issue:2

    Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; F

1990
5-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung.
    Cancer investigation, 1990, Volume: 8, Issue:3-4

    Topics: Adenocarcinoma; Adult; Aged; Allopurinol; Anorexia; Antineoplastic Combined Chemotherapy Protocols;

1990
[Randomized multicenter trial of sequential methotrexate and 5-fluorouracil versus 5-fluorouracil alone in advanced gastric cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:8 Pt 1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Administ

1989
Concurrent chemotherapy and radiation therapy for limited unresectable non-small cell carcinoma of the lung. A phase I study.
    American journal of clinical oncology, 1988, Volume: 11, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat

1988
A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1988, Volume: 6, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclopho

1988
A randomized comparison of haloperidol plus dexamethasone versus prochlorperazine plus dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1988, Volume: 6, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclopho

1988
Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF.
    European journal of cancer & clinical oncology, 1987, Volume: 23, Issue:6

    Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To

1987
A randomised cross-over trial comparing low-dose metoclopramide and chlorpromazine with high-dose metoclopramide in Chinese patients with advanced cancer receiving cisplatinum and 5-fluorouracil.
    Cancer chemotherapy and pharmacology, 1987, Volume: 20, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorpromazine; Cisplatin; Clinical Tri

1987
Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide methotrexate 5-fluorouracil: a double-blind randomized study.
    Oncology, 1988, Volume: 45, Issue:5

    Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclopho

1988
[A randomized controlled study of (2'' R)-4'-O-tetrahydropyranyladriamycin and adriamycin in combination with cyclophosphamide and 5-fluorouracil in the treatment of advanced and recurrent breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1986, Volume: 13, Issue:6

    Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxoru

1986
Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma.
    Cancer treatment reports, 1985, Volume: 69, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Do

1985
Mitoxantrone: an overview of safety and toxicity.
    Investigational new drugs, 1985, Volume: 3, Issue:2

    Topics: Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Clini

1985
A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
    Investigational new drugs, 1985, Volume: 3, Issue:2

    Topics: Adult; Aged; Alopecia; Anthraquinones; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide;

1985
A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck.
    Cancer, 1985, Dec-15, Volume: 56, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials

1985
[Preliminary report of adjuvant chemo-endocrine therapy for breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:1

    Topics: Adult; Anorexia; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Combined Modality Therapy

1985
Controlled studies of metopimazine for the treatment of nausea and vomiting.
    Journal of clinical pharmacology, 1973, Volume: 13, Issue:7

    Topics: Antiemetics; Clinical Trials as Topic; Fluorouracil; Humans; Isonipecotic Acids; Nausea; Neoplasms;

1973
Fluorouracil, imidazole carboxamide dimethyl triazeno, vincristine, and bis-chloroethyl nitrosourea in colon cancer.
    Cancer, 1974, Volume: 33, Issue:5

    Topics: Alopecia; Amides; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Colonic Neoplasms; Dr

1974
Experience with furanidyl-fluorouracil in advanced tumours of the breast.
    Neoplasma, 1974, Volume: 21, Issue:6

    Topics: Adult; Aged; Breast Neoplasms; Clinical Trials as Topic; Drug Evaluation; Feeding and Eating Disorde

1974
A clinical study of fluorouracil.
    Surgery, gynecology & obstetrics, 1968, Volume: 127, Issue:6

    Topics: Adult; Aged; Clinical Trials as Topic; Diarrhea; Female; Fluorouracil; Follow-Up Studies; Humans; Le

1968

Other Studies

149 other studies available for fluorouracil and Nausea

ArticleYear
NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri even during the COVID-19 pandemic: a real-life study.
    European review for medical and pharmacological sciences, 2021, Volume: 25, Issue:16

    Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms

2021
Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk.
    BMC cancer, 2021, Oct-16, Volume: 21, Issue:1

    Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Ph

2021
Treatment Patterns, Toxicity, and Outcomes of Older Adults With Advanced Pancreatic Cancer Receiving First-line Palliative Chemotherapy.
    American journal of clinical oncology, 2022, 02-01, Volume: 45, Issue:2

    Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil;

2022
Colorectal cancer chemotherapy: can sex-specific disparities impact on drug toxicities?
    European journal of clinical pharmacology, 2022, Volume: 78, Issue:6

    Topics: Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug-Related

2022
Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma.
    Current medical research and opinion, 2022, Volume: 38, Issue:8

    Topics: Adenocarcinoma; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atropine Derivatives;

2022
Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database.
    Journal of the National Cancer Institute, 2021, 04-06, Volume: 113, Issue:4

    Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Camptothecin; Capecit

2021
Adverse reactions and adherence to capecitabine: A prospective study in patients with gastrointestinal cancer.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2022, Volume: 28, Issue:2

    Topics: Aged; Capecitabine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Nausea; Pro

2022
Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer: Propensity Score Matching.
    Pancreas, 2021, 04-01, Volume: 50, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; De

2021
Survival and Predictive Factors of Chemotherapy With FOLFIRINOX as First-Line Therapy in Metastatic Pancreatic Cancer: A Retrospective Multicentric Analysis.
    Pancreas, 2021, 07-01, Volume: 50, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H

2021
Fluoropyrimidine-Associated Toxicity in Two Gastrointestinal Cancer Patients: Potential Role of Common DPYD Polymorphisms.
    Chemotherapy, 2017, Volume: 62, Issue:5

    Topics: Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehydrogenase (NADP); F

2017
[Determination of the Effect of Aprepitant and Fosaprepitant for Nausea in Patients with Oral Cancer Receiving Combination Chemotherapy with TPF].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2017, Volume: 44, Issue:7

    Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Docetaxel;

2017
TYMS Gene Polymorphisms in Breast Cancer Patients Receiving 5-Fluorouracil-Based Chemotherapy.
    Clinical breast cancer, 2018, Volume: 18, Issue:3

    Topics: Adult; Antimetabolites, Antineoplastic; Breast; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, B

2018
Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis.
    Cancer communications (London, England), 2018, 05-10, Volume: 38, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Chemoradiotherapy; Ci

2018
Nightmares and hallucinations with aprepitant and opium powder: a suspected drug-drug interaction.
    British journal of clinical pharmacology, 2019, Volume: 85, Issue:2

    Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Arthr

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel: A Population-Based Cohort Study.
    Pancreas, 2019, Volume: 48, Issue:7

    Topics: Aged; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Community He

2019
Single-dose palonosetron and dose-reduced regimen of dexamethasone in preventing nausea and vomiting by anthracycline-including chemotherapy in patients with early breast cancer.
    Anticancer research, 2013, Volume: 33, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast

2013
Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013, Volume: 21, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptot

2013
Safety and efficacy of modified FOLFOX6 plus high-dose bevacizumab in second-line or later treatment of patients with metastatic colorectal cancer.
    Chemotherapy, 2013, Volume: 59, Issue:2

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro

2013
Longitudinal assessments of quality of life and late toxicities before and after definitive chemoradiation for esophageal cancer.
    Japanese journal of clinical oncology, 2014, Volume: 44, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Esophageal Neoplasms

2014
Prospective study of symptom assessment among patients with cervical cancer during concurrent chemoradiotherapy with weekly cisplatin or every-3-week cisplatin and 5-fluorouracil.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2013, Volume: 23, Issue:8

    Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Anxiety; Carcinoma; Chemoradiotherapy; Cispl

2013
[Nausea, vomiting and quality of life in women with breast cancer receiving chemotherapy].
    Revista gaucha de enfermagem, 2013, Volume: 34, Issue:3

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brea

2013
Gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective cohort study.
    Chemotherapy, 2013, Volume: 59, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Biliary Tract Neoplasms; Capecitabi

2013
Second-line capecitabine and oxaliplatin combination for gemcitabine-resistant advanced pancreatic cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:17

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2014
Adherence to capecitabine treatment and contributing factors among cancer patients in Malaysia.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:21

    Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Capecitabine; Cross-Sectional Studies;

2014
Efficacy of aprepitant for nausea in patients with head and neck cancer receiving daily cisplatin therapy.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:22

    Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Drug Therapy, Combination;

2014
Pre-therapy mRNA expression of TNF is associated with regimen-related gastrointestinal toxicity in patients with esophageal cancer: a pilot study.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2015, Volume: 23, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T

2015
[Determination of the Appropriate Timing of Aprepitant Administration for Nausea in Patients with Head and Neck Cancer Receiving Combination Chemotherapy with Docetaxel, Nedaplatin(Divided Doses for 5 Days), and 5-fluorouracil].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Docetaxel; Female; Fluorouracil; H

2015
[A Case of Consciousness Disturbance Caused by Hyperammonemia during a mFOLFOX6 Regimen for Metastatic Colon Cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Colectomy; Consciousness; Fem

2015
Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.
    The oncologist, 2017, Volume: 22, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne

2017
[Predictive factors of nausea/vomiting of breast cancer patients receiving FEC and AC chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox

2008
Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer.
    Japanese journal of clinical oncology, 2009, Volume: 39, Issue:2

    Topics: Adult; Aged; Antiemetics; Benzimidazoles; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Female; F

2009
[Report of a case effectively treated by appropriate therapy for severe anticipatory nausea and vomiting due to FOLFOX or FOLFIRI].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Leucovorin; Male

2009
Severe hiccups during chemotherapy: corticosteroids the likely culprit.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2009, Volume: 15, Issue:4

    Topics: Adenocarcinoma; Adrenal Cortex Hormones; Adult; Antidotes; Antiemetics; Antimetabolites, Antineoplas

2009
[Oxaliplatin-based regimen for the treatment of advanced or metastatic gastric/esophagogastric junction cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2009, Volume: 31, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Esophagogastric Junctio

2009
Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin.
    Medical oncology (Northwood, London, England), 2011, Volume: 28, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ato

2011
Comparison of four cisplatin-based radiochemotherapy regimens for nonmetastatic stage III/IV squamous cell carcinoma of the head and neck.
    International journal of radiation oncology, biology, physics, 2011, Jul-15, Volume: 80, Issue:4

    Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp

2011
Gastroduodenal complications after concurrent chemoradiation therapy in patients with hepatocellular carcinoma: endoscopic findings and risk factors.
    International journal of radiation oncology, biology, physics, 2011, Dec-01, Volume: 81, Issue:5

    Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Chemoradiotherapy; Duodenal Ulcer

2011
Health-related quality of life after chemotherapy cycle in breast cancer in Iran.
    Medical oncology (Northwood, London, England), 2011, Volume: 28 Suppl 1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cognition Disorders;

2011
Toxicity data for preoperative concurrent chemoradiotherapy with oxaliplatin and continuous infusion 5-fluorouracil for locally advanced esophageal cancer.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2011, Volume: 24, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju

2011
[Clinical usefulness of oral aprepitant for alleviation of delayed nausea and vomiting induced by mFOLFOX6--report of a case].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:13

    Topics: Adenocarcinoma; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Female; Flu

2010
Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2012, Volume: 20, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents, Phytogenic; Colorectal Neoplasms

2012
[Weekly regimen of paclitaxel liposome combined with cisplatin and 5-fluorouracil continuous infusion in the treatment of advanced gastric carcinoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2011, Volume: 33, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo

2011
Self-reported compliance with capecitabine: findings from a prospective cohort analysis.
    Oncology, 2011, Volume: 80, Issue:1-2

    Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Fema

2011
[Efficacy and safety of aprepitant in patients with breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cyclophos

2011
[Induced nausea and vomiting induced by mFOLFOX6 and FOLFIRI with advanced colorectal cancer: a retrospective survey].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2011, Volume: 131, Issue:11

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin;

2011
Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma.
    International journal of radiation oncology, biology, physics, 2012, Jun-01, Volume: 83, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine;

2012
[Comparison of the toxicities and efficacies of the combination chemotherapy regimens in advanced gastric cancer patients who achieved complete response after chemotherapy].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2011, Volume: 58, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Ci

2011
Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations.
    International journal of medical sciences, 2012, Volume: 9, Issue:1

    Topics: Adverse Drug Reaction Reporting Systems; Capecitabine; Data Mining; Deoxycytidine; Diarrhea; Fluorou

2012
[Assessment of nausea and vomiting during FEC regimen for breast cancer after the novel antiemetic agent - introduction using MASCC antiemesis tool].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:2

    Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclopho

2012
[Antiemetic effect of palonosetron in advanced colorectal cancer patients receiving mFOLFOX6 and FOLFIRI: a retrospective survey].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptot

2012
Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity.
    Current topics in medicinal chemistry, 2012, Volume: 12, Issue:15

    Topics: Aged; Biomarkers; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Huma

2012
Is there an association between PONV and chemotherapy-induced nausea and vomiting?
    Acta anaesthesiologica Scandinavica, 2013, Volume: 57, Issue:6

    Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Betamethasone; Breast Neoplasms;

2013
Weekly hepatic arterial infusion of 5-fluorouracil and subsequent systemic chemotherapy for liver metastases from colorectal cancer.
    Japanese journal of clinical oncology, 2003, Volume: 33, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic;

2003
Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: a pilot study in Taiwan.
    Japanese journal of clinical oncology, 2003, Volume: 33, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Adminis

2003
EFFECTS OF 2'-DEOXY-5-FLUOROURIDINE (NSC-27640) AND 5-FLUOROURACIL (NSC-19893) ON CHILDHOOD LEUKEMIA.
    Cancer chemotherapy reports, 1964, Volume: 34

    Topics: Bone Marrow Examination; Child; Floxuridine; Fluorouracil; Leukemia; Leukopenia; Melena; Nausea; Tox

1964
COMPARISON OF HIGH-DOSAGE AND LOW-DOSAGE-MAINTENANCE THERAPY WITH 5-FLUOROURACIL IN SOLID TUMORS.
    Cancer, 1964, Volume: 17

    Topics: Diarrhea; Fluorouracil; Humans; Nausea; Neoplasms; Stomatitis; Toxicology; Vomiting

1964
CURRENT STATUS OF 5-FLUOROURACIL THERAPY IN FAR-ADVANCED NEOPLASTIC DISEASE.
    Geriatrics, 1964, Volume: 19

    Topics: Alopecia; Chlorpromazine; Diarrhea; Erythema; Fluorouracil; Leukopenia; Nausea; Neoplasms; Thrombocy

1964
FLUORINATED PYRIMIDINE THERAPY OF ADVANCED GASTROINTESTINAL CANCER.
    Gastroenterology, 1964, Volume: 46

    Topics: Alopecia; Colonic Neoplasms; Drug Eruptions; Esophagitis; Fluorouracil; Gallbladder Neoplasms; Human

1964
[DIGESTIVE INTOLERANCE TO DIGITALIN, CYTOSTATIC DRUGS AND VARIOUS THERAPEUTIC DRUGS. THEIR TREATMENT WITH METHOCLOPRAMIDE].
    La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1964, Oct-14, Volume: 40

    Topics: Antiemetics; Antitubercular Agents; Cobalt Isotopes; Cyclophosphamide; Cytostatic Agents; Digitalis

1964
STUDIES IN THE TOXICITY AND CLINICAL APPLICATION OF 5-FLUOROURACIL.
    The Medical journal of Australia, 1964, Oct-10, Volume: 2

    Topics: Adenocarcinoma; Agranulocytosis; Biomedical Research; Diarrhea; Diverticulitis; Drug Eruptions; Fluo

1964
Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin.
    Anti-cancer drugs, 2003, Volume: 14, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia

2003
[Preliminary evaluation of chemotherapy with docetaxel, 5-FU, CDDP for recurrent esophageal cancer--a pilot study].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Sche

2003
[Relationship of methylenetetrahydrofolate reductase C677T polymorphism and chemosensitivity to 5-fluorouracil in gastric carcinoma].
    Ai zheng = Aizheng = Chinese journal of cancer, 2004, Volume: 23, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Male; Met

2004
[Oxaliplatin plus capecitabine as a second line chemotherapy for patients with advanced gastric cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2004, Volume: 26, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Admin

2004
[Effect of steroid on antiemetic for side effect of anticancer chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dexamethasone; Drug Administration S

2005
[Relationship of serum level of dihydropyrimidine dehydrogenase and serum concentration of 5-fluorouracil to treatment response and adverse events in colorectal cancer patients].
    Ai zheng = Aizheng = Chinese journal of cancer, 2005, Volume: 24, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Dihydroura

2005
5-Fluorouracil/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome: report of a case.
    Journal of clinical pathology, 2005, Volume: 58, Issue:5

    Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineopl

2005
[Second-line chemotherapy with bi-weekly CPT-11 and cisplatin for recurrent colorectal cancer resistant to 5-FU based chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:7

    Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cispl

2005
[Clinical examination of safety and effectiveness of primary chemotherapy with CEF followed by docetaxel in preoperative breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Breas

2006
Peritoneal dissemination of hepatocellular carcinoma treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil.
    Internal medicine (Tokyo, Japan), 2007, Volume: 46, Issue:9

    Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic C

2007
[Nedaplatin (NDP)-combination therapy (NDP/5-FU,NDP/S-1) for oral cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:5

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols

2007
[The first report from Sapporo Tsukisamu Hospital--chemotherapy and chemoradiotherapy for patients with advanced pancreatic cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:7

    Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy

2007
[The second report from Sapporo Tsukisamu hospital--chemotherapy for patients with advanced colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:8

    Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplas

2007
[Efficacy of CPT-11 combined 5-FU/CF (FOLFIRI) regimen on advanced colorectal cancer].
    Ai zheng = Aizheng = Chinese journal of cancer, 2007, Volume: 26, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic N

2007
Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Japanese journal of clinical oncology, 2007, Volume: 37, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia

2007
[Dose dense chemotherapy in the postoperative adjuvant treatment for breast cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2007, Volume: 29, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan

2007
Chemotherapy-induced nausea, vomiting, and fatigue--the role of individual differences related to sensory perception and autonomic reactivity.
    Psychotherapy and psychosomatics, 2007, Volume: 76, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Arousal; Autonomic Nervous Sys

2007
Optimal schedule of methotrexate and 5-fluorouracil in human breast cancer.
    Cancer research, 1982, Volume: 42, Issue:5

    Topics: Breast Neoplasms; Cell Line; Drug Administration Schedule; Drug Evaluation; Drug Interactions; Drug

1982
Weekly large fraction radiotherapy and 5 fluorouracil as a palliative treatment for large bowel carcinoma: a pilot study.
    International journal of radiation oncology, biology, physics, 1982, Volume: 8, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Diarrhea; Fluorouracil; Humans; Intestinal Neoplasms; Intestine, Large;

1982
[The combination methyl-CCNU, vincristine, 5-fluorouracil and streptozotocin in the treatment of advanced colo-rectal adenocarcinoma].
    Schweizerische medizinische Wochenschrift, 1982, Jun-26, Volume: 112, Issue:26

    Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Combinations; Female; Fluorouracil; Humans; Leu

1982
Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio.
    Cancer, 1984, May-01, Volume: 53, Issue:9

    Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Neoplasms;

1984
Phase I evaluation of oral tegafur.
    Cancer treatment reports, 1983, Volume: 67, Issue:1

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Blood Cell Count; Diarrhea; Dose-Response Relatio

1983
[Pharmacokinetics and a phase I study of tegafur-uracil enterogranules in cancer patients].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1983, Volume: 10, Issue:12

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Pr

1983
Phase I-II studies of oral tegafur (ftorafur).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1983, Volume: 1, Issue:2

    Topics: Administration, Oral; Bone Marrow; Breast Neoplasms; Colonic Neoplasms; Dose-Response Relationship,

1983
Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1983, Volume: 1, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Doxorubicin; Drug Ev

1983
Phase II trial of streptozotocin, mitomycin C, and 5-fluorouracil in adenocarcinoma of the pancreas.
    Cancer clinical trials, 1980, Volume: 3, Issue:4

    Topics: Adenocarcinoma; Drug Evaluation; Drug Therapy, Combination; Fluorouracil; Humans; Mitomycins; Nausea

1980
Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone.
    Cancer, 1984, May-01, Volume: 53, Issue:9

    Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neopla

1984
Cyclophosphamide, methotrexate, and 5-FU (CMF)-induced nausea and vomiting: a controlled study with high-dose metoclopramide.
    Cancer treatment reports, 1984, Volume: 68, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration S

1984
Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate.
    Journal of surgical oncology, 1984, Volume: 26, Issue:3

    Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Breast Neoplasms; Cy

1984
Pharmacokinetic rationale for the interaction of 5-fluorouracil and misonidazole in humans.
    British journal of cancer, 1983, Volume: 48, Issue:5

    Topics: Adult; Aged; Drug Evaluation; Drug Synergism; Female; Fluorouracil; Gastrointestinal Neoplasms; Huma

1983
Combination chemotherapy including adriamycin for advanced transitional cell carcinoma of the urinary tract.
    Cancer chemotherapy and pharmacology, 1983, Volume: 11 Suppl

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Transitional Ce

1983
High-dose cyclophosphamide and high-dose 5-fluorouracil. A new first-line regimen for advanced breast cancer.
    Cancer, 1984, Apr-15, Volume: 53, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide;

1984
Phase I--II evaluation of combination cyclophosphamide, 5-fluorouracil, hexamethylmelamine, and prednisone in advanced breast cancer.
    Cancer clinical trials, 1981,Winter, Volume: 4, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide;

1981
Adjuvant chemotherapy (CMF) for breast carcinoma: hematological side effects.
    Journal of surgical oncology, 1982, Volume: 21, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Carcinoma; Cyclophosp

1982
Combination chemotherapy in advanced carcinoma of the cervix.
    Cancer, 1982, Nov-15, Volume: 50, Issue:10

    Topics: Alopecia; Antineoplastic Agents; Carcinoma; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Hum

1982
Prednimustine in combination with methotrexate and 5-FU (PMF): a pilot study.
    Cancer treatment reports, 1982, Volume: 66, Issue:12

    Topics: Aged; Alopecia; Breast Neoplasms; Chlorambucil; Drug Therapy, Combination; Female; Fluorouracil; Hum

1982
[Insufficient efficacy of the use of a single 8 mg tablet of ondansetron in the prevention of nausea and vomiting induced by FEC chemotherapy].
    Bulletin du cancer, 1995, Volume: 82, Issue:1

    Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms;

1995
A pilot study of concomitant radiation and chemotherapy in patients with locally advanced head and neck cancer.
    American journal of clinical oncology, 1993, Volume: 16, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S

1993
Trait anxiety and anticipatory immune reactions in women receiving adjuvant chemotherapy for breast cancer.
    Brain, behavior, and immunity, 1993, Volume: 7, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Breast Neoplasms; Chemotherapy

1993
Neoadjuvant chemotherapy in locally advanced breast cancer.
    Journal of surgical oncology, 1996, Volume: 61, Issue:1

    Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breas

1996
[CF/5-FU-DDP therapy for esophageal carcinoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 1995, Volume: 17, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Es

1995
[Antiemetic efficacy of granisetron in repeated CAF chemotherapy after breast cancer operation].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:5

    Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclopho

1997
Prolonged nausea and vomiting after high dose chemotherapy and autologous peripheral stem cell transplantation in the treatment of high risk breast carcinoma.
    Cancer, 1997, May-01, Volume: 79, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplatin; Comb

1997
A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein.
    Cancer, 1997, May-15, Volume: 79, Issue:10

    Topics: Aged; alpha-Fetoproteins; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop

1997
A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein.
    Cancer, 1997, May-15, Volume: 79, Issue:10

    Topics: Aged; alpha-Fetoproteins; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop

1997
A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein.
    Cancer, 1997, May-15, Volume: 79, Issue:10

    Topics: Aged; alpha-Fetoproteins; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop

1997
A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein.
    Cancer, 1997, May-15, Volume: 79, Issue:10

    Topics: Aged; alpha-Fetoproteins; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop

1997
Mitomycin C, cisplatin, and 5-fluorouracil for advanced and/or recurrent head and neck squamous cell carcinomas.
    American journal of clinical oncology, 1997, Volume: 20, Issue:5

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An

1997
[Usefulness of continuous venous daily chemotherapy of 5-fluorouracil and low-dose cisplatin for patients undergoing noncurative surgery].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:14

    Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Ci

1997
Biochemical modulation in the treatment of advanced cancer: a study of combined leucovorin, fluorouracil, and iododeoxyuridine.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1996, Volume: 2, Issue:9

    Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as

1996
Patients' experiences of chemotherapy: side-effects associated with 5-fluorouracil + folinic acid in the treatment of colorectal cancer.
    Journal of clinical nursing, 1998, Volume: 7, Issue:4

    Topics: Adenocarcinoma; Aged; Alopecia; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Di

1998
[Effects of intravenous and oral administration of ondansetron hydrochloride on chemotherapy-induced nausea and vomiting in patients with esophageal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:11

    Topics: Administration, Oral; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin;

1999
[5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer].
    Bulletin du cancer, 1999, Volume: 86, Issue:10

    Topics: Actuarial Analysis; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined

1999
[Chronological observation of nausea and vomiting in outpatients given oral antimetabolites as chemotherapy--two patients receiving ondansetron hydrochloride tablets].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:3

    Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antiemetics; Antimetabolites, Antineoplastic; Br

2000
Idiosyncratic reaction after oxaliplatin infusion.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chills; Fever; Fluorouracil;

2001
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
    Anti-cancer drugs, 2001, Volume: 12, Issue:4

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Com

2001
Manifest Anxiety Scale for evaluation of effects of granisetron in chemotherapy with CDDP and 5FU for head and neck cancer.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2001, Volume: 9, Issue:5

    Topics: Adult; Aged; Antiemetics; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Prot

2001
Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients.
    International journal of radiation oncology, biology, physics, 2002, Jan-01, Volume: 52, Issue:1

    Topics: Adult; Aged; Alkaline Phosphatase; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Breas

2002
[Incidence of emesis in outpatients on chemotherapy for breast cancer and the clinical efficacy of ondansetron hydrochloride tablets].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:5

    Topics: Ambulatory Care; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cycl

2002
Chemotherapy of common solid tumours in a general surgical unit.
    Clinical oncology, 1979, Volume: 5, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Interactions; Drug Syne

1979
Phase II study of adriamycin, 5-fluorouracil, levamisole, and irradiation in carcinoma of the bladder.
    Cancer treatment reports, 1979, Volume: 63, Issue:2

    Topics: Bone Marrow; Carcinoma, Transitional Cell; Doxorubicin; Drug Evaluation; Drug Therapy, Combination;

1979
Five-day continuous infusion of 5-fluorouracil for advanced colorectal, gastric, and pancreatic adenocarcinoma.
    Journal of surgical oncology, 1979, Volume: 11, Issue:3

    Topics: Adenocarcinoma; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infus

1979
Toxicity and side-effects of combination chemohormonal therapy of advanced breast cancer.
    Journal of the Indian Medical Association, 1992, Volume: 90, Issue:2

    Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therap

1992
Progressive loss of antiemetic efficacy during subsequent courses of chemotherapy.
    European journal of cancer (Oxford, England : 1990), 1992, Volume: 28, Issue:2-3

    Topics: Adult; Aged; Amitriptyline; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclophosph

1992
Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer.
    Journal of endocrinological investigation, 1991, Volume: 14, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Betamethas

1991
[Phase II study of 5'-DFUR treatment of the bladder and prostatic cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:13

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Diarrhea; Dru

1991
Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer.
    Cancer chemotherapy and pharmacology, 1991, Volume: 27, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chi-Square Distributi

1991
[Adverse reactions to carcinostatics and countermeasures].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:4 Pt 2-1

    Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carbazilquinone; Chemical and Drug Indu

1989
[Combination chemotherapy of CPM-MTX-5-FU in non-resectable and recurrent cancer patients].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:4 Pt 1

    Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Sche

1989
Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer.
    Chemioterapia : international journal of the Mediterranean Society of Chemotherapy, 1988, Volume: 7, Issue:5

    Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosph

1988
A phase II clinical trial of flutamide in the treatment of advanced breast cancer.
    Tumori, 1988, Feb-29, Volume: 74, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; Cyclophospha

1988
[The prevention of CDDP-induced emesis with a combination regimen including metoclopramide, dexamethasone, droperidol and diphenhydramine].
    Nihon Sanka Fujinka Gakkai zasshi, 1987, Volume: 39, Issue:11

    Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dex

1987
Results in the management of locally unresectable pancreatic carcinoma.
    American journal of clinical oncology, 1986, Volume: 9, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo

1986
High-dose continuous infusion folinic acid and bolus 5-fluorouracil in patients with advanced colorectal cancer: a phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Fem

1986
Stimulus control of anticipatory nausea in cancer chemotherapy.
    Journal of behavior therapy and experimental psychiatry, 1987, Volume: 18, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chlorpromazine; Combined Modality

1987
Simultaneous cisplatin and 5-fluorouracil as second-line treatment of head and neck cancer.
    Cancer treatment reports, 1987, Volume: 71, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe

1987
High-dose metoclopramide and dexamethasone as an antiemetic in outpatients receiving chemotherapy for breast cancer. Second study.
    Oncology, 1987, Volume: 44, Issue:4

    Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplati

1987
Tastes associated with parenteral chemotherapy for breast cancer.
    Cancer treatment reports, 1985, Volume: 69, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorour

1985
[Chemotherapy with FT-207 suppository (Futraful Supo) in head and neck cancer--cooperative studies by six medical schools in Kanagawa Prefecture].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:9

    Topics: Adult; Aged; Anorexia; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Fluorouracil;

1985
The effect of a susceptibility to motion sickness on the side effects of cancer chemotherapy.
    Cancer, 1985, Jun-15, Volume: 55, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Susceptibilit

1985
Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer.
    Investigational new drugs, 1985, Volume: 3, Issue:2

    Topics: Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Cycloph

1985
[590-S].
    Gan no rinsho. Japan journal of cancer clinics, 1985, Volume: 31, Issue:6 Suppl

    Topics: Administration, Oral; Adult; Animals; Anorexia; Antineoplastic Agents; Drug Administration Schedule;

1985
Phase I and pharmacologic study of 72-hour infused 5-fluorouracil in man.
    American journal of clinical oncology, 1985, Volume: 8, Issue:5

    Topics: Drug Evaluation; Female; Fluorouracil; Humans; Infusions, Parenteral; Male; Nausea; Neoplasms; Neutr

1985
Elemental diet in the management of the intestinal lesion produced by 5-fluorouracil in man.
    Canadian journal of surgery. Journal canadien de chirurgie, 1971, Volume: 14, Issue:5

    Topics: Aged; Amino Acids; Animals; Biopsy; Diarrhea; Diet Therapy; Dietary Proteins; Female; Fluorouracil;

1971
Combination chemotherapy in gastrointestinal cancer.
    Cancer research, 1970, Volume: 30, Issue:5

    Topics: Adenocarcinoma; Adult; Alopecia; Appendiceal Neoplasms; Diarrhea; Drug Eruptions; Fluorouracil; Gall

1970
Phase II evaluation of BCNU and 5-FU in gastrointestinal carcinomas.
    Oncology, 1974, Volume: 29, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Carmustine; Colonic Neoplasms; Diarrhea; Fluorouracil; Hematoc

1974
Combination chemotherapy in disseminated carcinoma of the breast.
    Oncology, 1974, Volume: 29, Issue:2

    Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Evaluation Stu

1974
Results in fifty cases of advanced squamous cell carcinoma of the head and neck treated by intravenous chemotherapy.
    British journal of cancer, 1973, Volume: 27, Issue:5

    Topics: Adult; Aged; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Combinations; Epiglottis; Female; Fluo

1973
Toxicity studies of fluorouracil used with adrenalectomy in breast cancer.
    Archives of surgery (Chicago, Ill. : 1960), 1972, Volume: 105, Issue:1

    Topics: Adrenalectomy; Adult; Aged; Alopecia; Ataxia; Blood Platelet Disorders; Breast Neoplasms; Diarrhea;

1972
5-fluorouracil intravenous infusion for 48 hours, repeated every two weeks.
    Journal of surgical oncology, 1972, Volume: 4, Issue:1

    Topics: Adult; Aged; Breast Neoplasms; Diarrhea; Evaluation Studies as Topic; Female; Fluorouracil; Gastroin

1972
Oral administration of fluorouracil. A preliminary trial.
    Archives of surgery (Chicago, Ill. : 1960), 1968, Volume: 97, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Alopecia; Bile Duct Neoplasms; Colonic Neoplasms; Diarrhea; Fluorouraci

1968